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Abstract 
The potential bio-terror threat posed by Burkholderia pseudomallei highlights the need 
for an effective vaccine.  Immunisation and challenge experiments in mice have 
demonstrated that the capsular polysaccharide (CPS-1) of B. pseudomallei, which is 
composed of β-1,3-linked 6-deoxy-D-manno-heptopyranose residues, is a promising 
candidate for vaccine development.  This thesis set out to explore routes to potential 
vaccine candidates for Burkholderia pseudomallei infection based on both bottom-up 
synthetic monosaccharide constructs and top-down CPS-1 conjugates. 
Initially this thesis focused on the development of a monosaccharide antigen based on 
the 6-deoxy-D-manno-heptose building block of CPS-1.   The antigens were conjugated 
to TetHc carrier protein via an 8-(methoxycarbonyl)octyl linker using traditional acyl 
hydrazide conjugation chemistry.  The TetHc monosaccharide conjugates were 
analysed by SDS-PAGE and MALDI-ToF mass spectrometry before undergoing 
immunisation trials in sheep. Immunological assessment of the resulting polyclonal 
antisera was conducted by ELISA, slot-blot and the Octet biosensor system.  These 
studies demonstrated the generation of antibodies that were specific for the cognate 
monosaccharide.  Preliminary investigations showed that the 6-deoxy-D-manno-
heptose-derived antibodies reacted positively with the natural CPS-1.  The linker was 
shown to be important in the specificity of the polyclonal sera, leading to cross reactivity 
with non-parent monosaccharide antigens.  A second generation of antigens was 
developed using a short linker, 3-(methyl mercaptopropionate). 
The expression and purification of the natural B. pseudomallei CPS-1 was achieved in 
an avirulent strain of Burkholderia, B. thailandensis E555.  Characterisation of the 
capsular polysaccharide highlighted the co-expression of an α-1,3-mannan 
polysaccharide.  Mild acid hydrolysis of the CPS-1 preparation, combined with capillary 
electrophoresis was trialled with a view to the generation of oligosaccharide fragments 
of CPS-1 for conjugation and immunisation studies.  While initial carbohydrate 
conjugates were prepared with a previously described tetanus toxoid Hc fragment, the 
development and in planta expression of a chemically conjugatable Hepatitis B core 
virus-like particle system was also achieved. 
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1 Introduction  
Glycobiology is the study of the structure, biosynthesis and biology of carbohydrates 
that are ever present throughout nature in a variety of glycoconjugates1.  
Polysaccharides are one of the three major classes of biopolymers, along with 
polypeptides and polynucleotides, which are responsible for the majority of information 
transfer in biological systems.  Carbohydrates  are the most abundant and structurally 
diverse organic molecules in nature2.  Part of this structural diversity can be attributed 
to the inherent variability of the structure of the monosaccharide building blocks.  
However, it is the formation of glycosidic linkages which is primarily responsible for the 
variety seen in glycan structures.  When compared to polynucleotides and polypeptides 
the number of different theoretical oligomers that can be derived from a set number of 
monomers is dramatically increased (Table 1.1)3. 
 
Oligomer Size Polynucleotide Polypeptide Polysaccharide 
1 4 20 20 
2 16 400 1,360 
3 64 8,000 126,080 
4 256 160,000 13,495,040 
5 102 3,200,000 1,569,745,920 
6 4,096 64,000,000 192,780,943,360 
Table 1.1:Table summarising the potential oligomer variations of the three major biopolymers.  Data 
taken from Werz et al
3
.  Data for polypeptides derived from the 4 nucleotide bases and polypeptide 
data derived from the 20 amino acids.  Data for polysaccharides was derived from calculations 
using the alpha and beta form of the 10 most abundant mammalian monosaccharides: D-glucose, D-
galactose, D-mannose, D-sialic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, L-fucose, D-
xylose, D-glucoronic acid and L-iduronic acid  
 
The data for the polysaccharide complexity in Table 1.1 is based on theoretical 
calculations using both the alpha and beta form of the 10 most abundant mammalian 
monosaccharides3.  The high number of theoretical polysaccharides arises from the 
fact that each monosaccharide has multiple sites for attachment.  The formation of a 
glycosidic linkage also generates a new stereocentre in the extending oligomer which 
gives rise to yet more configurations for each bond.  This is represented in Figure 1.1 
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which looks at glycosidic bond formation in its simplest form, between two D-glucose 
residues. 
 
Figure 1.1: Schematic representation of possible sites for formation of a glycosidic bond between 
two D-glucose residues highlighting the ten possible combinations between two identical 
monosaccharides. 
 
Beyond the complexity of the glycosidic linkages, carbohydrates are subject to an array 
of post-synthetic modifications, such as methylation, acetylation, phosphorylation and 
sulfation further increasing their structural diversity3,4.   It is the structural variety found 
in carbohydrates that facilitates the many roles which they play in nature.    
 
Carbohydrates are a ubiquitous energy source, as well as structural components of a 
number of natural materials such as plant tissue and the shells of many insects and 
crustaceans.  It is estimated that 4x1011 tonnes of carbohydrates are produced per 
annum by plants and photosynthesising bacteria, the majority of which are produced as 
polysaccharides1.   However, by far the most extensive role of glycans in nature is their 
presence on cell surfaces2.  The interaction of glycans with carbohydrate-binding 
proteins mediates a vast number of intra- and extra-cellular processes, for example, 
fertilisation5 in mammals, oligosaccharide signalling in plants6 and invasion and 
infection of micro-organisms7-9.  The prominence of carbohydrates in the infection and 
pathogenesis of micro-organisms results in glycans playing an integral role in the 
immune response of both mammals2, 4,10 and plants11.  The subject of Glycobiology and 
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Immunology is vast and has been studied since the identification of the ABO(H) blood 
groups over a century ago12.  The focus of this thesis is the development of a 
carbohydrate-based vaccine for the bacterial pathogen Burkholderia pseudomallei and 
as a result this introduction will only focus on the role of glycans in bacterial infection, 
and subsequent potential for development of carbohydrate vaccines. 
 
1.1 Carbohydrates and bacterial infection 
1.1.1 Bacterial adhesion 
Cell-surface carbohydrates are readily accessible and represent ideal binding sites for 
opportunistic pathogens such as viruses13, bacteria14,15,16, parasites17, 18, yeast19 and 
other fungi20.  The adhesion to mammalian cells, through adherence factors (adhesins), 
is an essential first step in the pathogenesis of many infectious diseases.  The 
attachment of bacteria facilitate the site specific colonisation and subsequent 
development of disease-states in the host21.  Attachment to cell membranes also 
prevents the removal of bacteria through normal process such as urination or vomiting.  
For example, certain strains of E. coli22 (bladder – urinary tract infection) and 
Salmonella23 (intestinal cell mucosa – infectious diarrhoea) express adhesins known as 
pili of fimbriae which protrude from the cell surface and bind to specific carbohydrate 
receptor sites on target cells24.   The role of adhesins in the bacterial colonisation 
(pathogenic, commensal and probiotic bacteria) of the gastrointestinal tract is currently 
subject of much research25, 26.  The gastrointestinal tract is covered in a mucosal layer, 
of which mucins are the major structural component25.  Mucins are highly O-
glycosylated proteins with tandem repeat domains rich in proline, threonine and 
serine26.  Although not fully understood, interference of the interaction between 
bacterial adhesins and mucins in the gastrointestinal tract is believed to offer a route to 
limit the infection by pathogenic bacteria25.  Another examples of the role of 
carbohydrates in colonisation of bacteria is the expression of surface-anchored proteins 
or afimbrial adhesins, which bind to host cell carbohydrate receptors and establish 
colonisation.  The attachment of adhesion proteins to cell surface glycans is depicted in 
Figure 1.2. 
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Figure 1.2: Schematic representation of the binding of bacterial cells to host cell glycans through a) 
pili or fimbriae and b) afimbrial adhesins.  Image reproduced from Essentials of Glycobiology with 
permissions copyright Cold Spring Harbor Laboratory Press 2008. 
 
1.1.2 Bacterial Polysaccharide Virulence Factors 
Polysaccharide virulence factors play an essential role in the survival and virulence of 
many bacteria27.   Virulence factors are molecules which are produced by pathogens 
(bacteria, viruses, fungi and protozoa) that allow them to establish and maintain 
disease states in a host28-33.   For example, it has been shown that removal of key 
carbohydrate moieties from the outer core polysaccharide of S. enterica leads to 
attenuation of the bacteria15.   
 
Toxins are a good example of bacterial virulence factors and can be divided into to two 
sub-groups: endotoxins which remain ‘within’ the cell, and exotoxins which are released 
into the host environment34.  The lipopolysaccharide (LPS) of Gram-negative bacteria is 
a typical example of an endotoxin.  LPS accounts for around 30% of the total outer cell 
membrane weight (of Gram negative bacteria) and elicits a strong immune response in 
mammals as a result of activation of the Toll-like receptor-4.  LPS (Figure 1.3) is 
comprised of a polysaccharide (O-antigen) attached to a lipid (Lipid A) through core 
oligosaccharide residues (Outer and Inner Core)35.  The O-antigen region of LPS 
consists of repeating oligosaccharide units.  Variability in the O-antigen region is 
responsible for much of the antigenic variation between different Gram-negative 
species.    The role of the O-antigen in the virulence of bacteria is elegantly 
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demonstrated by the K-12 strain of E. coli.  K-12 is a widely used laboratory strain, 
which is known to have mutations in the O-antigen gene cluster resulting in the 
abrogation of O-antigen biosynthesis.  These mutations prevent the K-12 E. coli strain 
from surviving outside of laboratory conditions, indicating that the O-antigen is essential 
for bacterial survival in the normal environment36.  The core region can be divided into 
two sections, the inner core which attaches the oligosaccharide region to Lipid A 
through an acid-labile ketosidic linkage,36 and the outer core which links the inner core 
to the O-antigen.  Lipid A anchors LPS into the cell membrane and is the bioactive 
region responsible for the over stimulation of the immune system and subsequent toxic 
effects.    As a result of this over stimulation of the immune system, septic shock 
syndrome can occur, which often requires urgent medical attention37.    
 
Figure 1.3: Schematic representation of liposaccharide structure of Gram-negative bacteria.  
Picture reproduced with permissions from Lapaque et al
35
 copyright Elsevier 2005. 
 
Other polysaccharides which play a vital role in the virulence of bacteria are 
exopolysaccharides (EPS) and capsular polysaccharides (CPS).  Dental plaque is a 
biofilm and is primarily comprised of EPS from Streptococcus mutans bacteria38.  
Glucan-mediated binding of bacteria to the EPS produced by S. mutans facilitates the  
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colonisation by bacteria in the mouth39.  Within biofilms bacteria exist in polymicrobial 
communities in which they live in a dormant state suriving on low nutrient levels.  In this 
state the bacteria are less susceptible to anti-bacterial treatments and host immune 
defence mechanisms.   
 
Capsular polysaccharides are high molecular weight polysaccharides which form a 
matrix layer around the bacterial cell encapsulating it.  Unlike EPS, capsules are 
tethered to the cell membrane, typically through a lipid moiety40.  The encapsulation of 
bacteria by capsules makes these polysaccharides ideal antigens for use in vaccines 
(Section 1.1.3).  There have been a number of functions of capsules postulated over 
the years including desiccation prevention, adherence and resistance to host 
immunity41.  The encapsulation of bacteria by polysaccharides prevents the normal 
activation of the Complement System, a major feature of innate immunity, resulting in 
the increased virulence of the bacterium40. 
 
1.1.2.1 The complement system     
The complement system consists of a number of glycoproteins which react in a series 
of cascade reactions to facilitate the destruction of a pathogen (Figure 1.4).  These 
glycoproteins (approximately 30 in total) circulate the body in the blood plasma.  The 
proteins are generally in an inactive state until they are activated by a protease, which 
in turn converts the cleaved protein into a protease in a specific sequence.  There are 
two pathways in which the complement system can contribute to the innate immunity of 
a host, the Classical pathway and the Alternative pathway42. 
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Figure 1.4: Schematic representation of the Classical and Alternative pathways of the complement 
system adapted from Austin Peay State University website, J. Thompson lecture notes
43
. 
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The Classical Pathway 
In the Classical Pathway the initial step in the complement cascade is the binding of the 
C1 protein complex to antibodies bound to antigens on the surface of a pathogen.  The 
C1 complex is activated and a serine protease cleaves the next glycoprotein in the 
cascade C4 into a small (a) and large (b) fragment.  Upon cleavage C4b binds to 
carbohydrate residues on the cell surface and C4a diffuses away from the cell.  The 
activated C4b cleaves C2, again into two fragments, C2a binds to surface bound C4b 
and C2b diffuses away.  The C4b.C2a complex, or C3 convertase, catalyses the 
cleavage of the C3 glycoprotein into two fragments a and b.  C3 is the most abundant 
of all the complement factors and is vital in the amplification of the innate immune 
response.  Numerous copies of C3b, an opsonin, bind to glycoproteins scattered on the 
cell surface and facilitate phagocytosis of the pathogen by macrophages and 
neutrophils.  C3b proteins also bind to protein C5 instigating an allosteric change 
making C5 susceptible to cleavage (again into C5a and C5b) by the C4b.C2a complex.  
C3a, C4a and C5a are classed as anaphylatoxins, which stimulate the release of 
histamine and other compounds from immune cells resulting in a localised inflammatory 
response.  C5b triggers the assembly of the membrane attack complex (MAC) on the 
surface of the cell.  The C5b.6.7.8.9 (up to 18 copies of C9) complex forms a pore in 
the surface of the cell membrane which allows the diffusion of ions, small molecules 
and water resulting in cell lysis42, 44, 45. 
 
The Alternative Pathway 
The alternative pathway does not require initial activation of the complement system by 
antibody-antigen interactions.  In normal serum, C3b exists in trace amounts and can 
be activated by polysaccharides (eg. LPS) and other endotoxins.  Activated C3b 
combines with complement factor B, a single polypeptide chain which is present in 
blood serum to form the C3b.B complex42.  Cleavage of the C3b.B complex by 
complement factor D generates the C3 convertase complex C3b.Bb.  The generation 
of a separate C3 convertase complex in the Alternative pathway, is the basis of the 
amplification of the complement system as more C3b is generated, which in turn binds 
with complement factor B to continue the cycle as shown by Figure 1.544.   
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Figure 1.5: Amplification of the complement system cascade by the Alternative Pathway.  Picture 
reproduced with permissions from Immunology A Short Course Copyright John Wiley and Sons 
2009
42
. 
 
Capsular polysaccharides interfere with the complement system by blocking the 
deposition of sub-unit C3b onto the surface of bacterial cells, thus preventing the 
opsonisation of the bacteria40.  The interference of the complement system by the 
capsular polysaccharide of B. pseudomallei, the target pathogen of this research, was 
demonstrated by a series of immunofluorescence experiments carried out by 
Reckseidler-Zenteno and co-workers (Figure 1.6)46.  Figure 1.6 demonstrates the 
prevention of C3b deposition (no red staining) on the surface of B. pseudomallei cells 
which produce the capsular polysaccharide (Figure 1.6 B and C).  The capsule masks 
the C3b binding receptors on the surface of the cell and helps the bacteria to avoid 
opsonisation and subsequent phagocytosis.  Mutant CPS negative B. pseudomallei 
strains have been shown to be 1,000 fold times less virulent than the wild-type, CPS 
positive strain, demonstrating the importance of CPS for the virulence of B. 
pseudomallei46.    
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Figure 1.6: Immunofluorescence microscopy demonstrating decreased deposition of complement 
factor C3b in 10% human serum on the surface of CPS+/-ve strains of B. pseudomallei.  B. 
pseudomallei cells were inoculated with 1) 10% human serum; 2) anti-C3b mouse monoclonal 
antibodies and 3) fluorophore labelled anti-mouse secondary antibody (red).  Cells were also pre-
stained with DAPI to identify the cell nucleus.  Blue staining indicates DAPI stained bacteria and 
red staining indicates the deposition of C3b.  Legend: A & D) cells incubated with PBS alone.  B & 
E) cells incubated with 10% human serum for 15 minutes.  C & F) cells incubated with 10% human 
serum for 60 minutes.  Image reproduced with permissions from Reckseidler-Zenteno et al.  
Copyright American Society for Microbiology 2005
46
. 
 
1.1.3 Carbohydrate-based vaccines  
Cell surface polysaccharides present an ideal candidate for use in vaccines as they are 
conserved and their presentation on the bacterial cell means they are highly accessible 
to the immune system.  Carbohydrates are by themselves, poorly immunogenic and, 
furthermore, carbohydrate specific antibodies generally have low affinity when 
compared to protein-specific antibodies 9, 47.  Traditionally, carbohydrate conjugate 
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vaccines were based on extracted polysaccharide material chemically conjugated to a 
carrier protein8.  Conjugation of polysaccharides to a carrier protein was first 
established by Avery and Goebel,48 who demonstrated that the coupling of 
Pneumococcus oligosaccharides to proteins rendered them immunogenic.   
 
The poor immunogenicity of polysaccharides is as a result of the way in which 
polysaccharides generate an immune response.  Polysaccharides are considered to be 
T-cell independent type 2 (TI-2) antigens based on their ability to stimulate B cells 
without the need for helper T-cells.  The ability of polysaccharides to directly activate B 
cells arises from the cross-linking of IgM antigen receptors on the B-cell, facilitated by 
the polyvalent nature of polysaccharides49.  T-cell independent activation of B-cells 
generally results in the production of low affinity IgM antibodies and often does not 
generate memory B-cells.  Coupling of polysaccharides to carrier proteins adds a T-cell 
dependant aspect to B-cell activation which facilitates the switching of B-cells into 
memory B-cells49.  In part it is this switching which enables glycoconjugate antigens to 
generate immunological memory for a specific antigen and thus act as vaccines8. 
 
Carbohydrate based vaccines have been developed and are licensed, for a number 
three bacterial pathogens Haemophilius influenza  type b (Figure 1.7), Neisseria 
menigitidis (Figure 1.8) and Streptococcus pneumoniae50.   
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Figure 1.7: Structure of the Pfizer (Wyeth Lederle) Haemophilius influenzae Type b CPS vaccine, 
based on the linear β-linked poly-ribosyl ribitol phosphate capsular polysaccharide.  The degree of 
polymerisation (n) is determined by the amount of periodate used in the oxidation of the native 
polysaccharide.  The oxidised polysaccharide is reductively aminated to Diptheria Toxin CRM197 
carrier protein to form the multivalent vaccine 1
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Figure 1.8: Structure of the Pfizer (Wyeth Lederle) (O-acetylated) and the Baxter Health (de-O-
acetylated) Neisseria meningitidis Group C vaccine, based on the Group C α-(2,9) linked sialic acid 
capsular polysaccharide.  Again the degree of polymerisation (n) is determined by the amount of 
periodate used in the oxidation of the native polysaccharide.  The oxidised de-O-acetylated 
polysaccharide is reductively aminated to Diptheria Toxin CRM197 carrier protein (Pfizer) (Wyeth 
Lederle) (2) and the O-acetylated polysaccharide  is reductively aminated to TetHc carrier protein 
(3)
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There are three carbohydrate based Streptococcus pneumoniae vaccines currently 
available.  Merck’s Pneumovax 23 is comprised of purified capsular polysaccharide 
from the 23 most common serotypes.  Owing to the lack of carrier protein this vaccine 
does not elicit immune memory and has low efficacy in young children51.  The second 
vaccine is Pzifer (Wyeth’s) PrevenarTM conjugate vaccine, which is comprised of 
capsular polysaccharides from a range of prevalent S. pneumoniae serotypes 
conjugated to a variety of carrier proteins52.  Glaxo Smith Kline’s Synflorix vaccine 
contains 10 CPS serotypes conjugated to carrier protein (DT and TT)53.  These 
vaccines are capable of eliciting immune memory and is effective in young infants52.   
 
There is increasing research interest in the use of purified polysaccharide material to 
synthetic oligosaccharide fragments in glycoconjugate vaccines, alongside the 
continued use of natural polysaccharide material54.  In spite of the chemically 
demanding nature of carbohydrate synthesis, synthetic oligosaccharide fragments 
present an ideal antigen for carbohydrate vaccines9.  The production, extraction and 
purification of bacterial polysaccharides can often be problematic55, in particular when 
dealing with highly infectious bacteria such as Yersinia pestis or Clostridium botulinum, 
which require extensive containment facilities.  It is also essential that all biological 
contaminants are removed from the polysaccharide extract in order to avoid adverse 
reactions, eg. septic shock syndrome56.  Extraction of polysaccharides affords a 
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polydisperse mixture of molecular masses, which upon conjugation with a protein will 
generate more diversity.  The use of synthetic fragments allows for the preparation of 
well-defined glycoconjugate vaccines. The quality control and batch to batch 
consistency of oligosaccharide fragments is a distinct advantage, particularly in the 
eyes of regulatory bodies57.   
 
Furthermore, in conjunction with the shift to synthetic oligosaccharide fragments, there 
has also been a move to the use of fully synthetic carbohydrate vaccines58-61.    Along 
with the quality control benefits described above, one of the increasing concerns 
regarding the use of glycoconjugate vaccines is carrier induced epitopic suppression 
(CIES)62.   CIES is the interference of pre-existing carrier protein antibodies on the 
development of immunity to conjugated antigens.  Such strategies include the use of 
nanoparticles63, liposomes64 or peptides65 to replace the traditional carrier proteins66.  
The coupling of synthetic oligosaccharide epitopes to nanoparticles in combination with 
immunomodulating agents has been shown to be a promising step forward in the 
development of fully synthetic carbohydrate vaccines against S. pneumoniae63, 67.   
 
1.2 Burkholderia pseudomallei 
B. pseudomallei is a Gram-negative bacteria which is the causative agent of 
melioidosis, a febrile illness with disease states such as pneumonia, septicaemia and 
chronic abscesses68.  The two main infection routes for B. pseudomallei are through 
breaks in the skin and inhalation of contaminated materials such as soil and water. 
Melioidosis is endemic to the sub-tropical regions of the globe (Figure 1.9) and as a 
result of the rise in transport of humans and animals is spreading at an ever increasing 
rate69. 
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Figure 1.9:  Global spread of melioidosis cases around the world in 2012.  Image taken from the 
Centre for Disease Control website
70
. 
 
Melioidosis has two disease states; acute, where symptoms occur with 1-9 days post-
infection, and chronic, where the infection can lay dormant for decades before 
symptoms are seen69.  There is currently no vaccine for melioidosis and treatment of 
the disease is often complicated.  Like many other environmental bacteria, B. 
pseudomallei is highly resistant to a number of antibiotics71.  As a result treatment 
involves lengthy intravenous regimens of antibiotics such as Meropenem and 
Ceftazidime71.  Even with medical attention, the mortality rates associated with 
melioidosis are high, particularly in regions where access to advanced medical facilities 
is limited (Table 1.2)68. 
Mortality Rate for Melioidosis 68 
Antibiotics – Australia 10-20% 
Antibiotics – Thailand 20-40% 
No Antibiotics >90% 
Table 1.2: Mortality rates of melioidosis depending on treatment and access to advanced medical 
facilities
68
. 
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On this basis and the relative ease at which this bacteria can be accessed the Centre 
for Disease Control (CDC) in the United States has classified B. pseudomallei as a 
category B Bio-terrorism agent72.  The need for a vaccine for melioidosis is evident and 
there has been much research to this end.   
 
1.2.1 Vaccination of B. pseudomallei 
In 1993, Kanaphun et al. demonstrated that in endemic regions, such as North East 
Thailand, large proportions of the population tested seropositive for antibodies raised 
against B. pseudomallei.  However, despite high exposure to the bacteria the incidence 
of melioidosis was relatively low73.  This demonstrated that those individuals who had 
been exposed to B. pseudomallei but not contracted melioidosis had developed 
protective immunity, indicating that vaccination against B. pseudomallei is possible.  
There have been a number of attempts to generate a vaccine for B. pseudomallei using 
different approaches.    
 
Vaccination studies using live attenuated B. pseudomallei cell based vaccines have 
been widely investigated since the late 1950’s74.  More recently, Stevens et al.75 
achieved partial immunity in mice with a B. pseudomallei mutant carrying a 
dysfunctional type-III secretion system.  The use of live attenuated strains of bacteria is 
an effective means for vaccination against bacterial pathogens.  This is based on the 
ability of the live bacteria to replicate in the host generating strong humoral and cell-
mediated immune responses76.  Despite the efficacy of live attenuated vaccines, there 
as yet has not been a B. pseudomallei vaccine which has conferred full protective 
immunity in mice77.  There are also safety concerns regarding the use of live attenuated 
vaccines, particularly in immuno-compromised individuals, due to the potential for the 
bacteria to revert to a pathogenic state leading to infection78.  The use of dead whole 
cell vaccines has also been attempted for B. pseudomallei again with limited success79-
81.  Despite providing short term protective immunity, when sacrificed, mice treated with 
dead B. pseudomallei cells were found to have very high bacterial concentration in 
major organs such as the spleen.  This indicated that the use of dead whole cell 
vaccines was not providing sufficient protection against chronic infection, a pre-
requisite for a B. pseudomallei vaccine candidate81.  
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In order to combat the safety and efficacy concerns associated with using whole cell 
(live-attenuated and whole-dead cell) vaccines, the majority of research into B. 
pseudomallei vaccines is focused on the development of sub-unit vaccines.  Sub-unit 
vaccines use purified bacterial components to elicit an immune response in the host, 
meaning that as long as the material has been separated from any possibly reactogenic 
material (LPS etc.), the vaccine should be 100% safe76.  Sub-unit vaccines have been 
licensed in humans for tetanus and diphtheria (inactivated bacterial toxin vaccine) and 
pneumococcal and meningococcal disease (polysaccharide based vaccines Section 
1.1.3)78, 82.  The recent attempts for generation of a sub-unit vaccine for B. 
pseudomallei are summarised in Table 1.3.  
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Antigen Composition Protection References 
LPS Lipopolysaccharide 80% survival at day 14 after challenge with 4,300 x MLD 41 
CPS Polysaccharide 40% survival at day 14 after challenge with 4,300 x MLD 83 
Flagellin DNA 80-90% survival at day 14 after challenge with 100 x LD50 
84-86 
Flagellin Protein 50% survival at day 7 after challenge with 100 x LD50 
84, 86 
Flagellin-CPS 
conjugate 
Protein-
Polysaccharide 
Passive transfer of sera protected 40% of diabetic rats at day 8 after 
challenge with 400x LD50 
86 
BipB, BipC, BipD Protein No survival at day 5 after challenge with 30 x LD50 
87 
Omp85 Protein 70% survival at day 15 after challenge with 10 x LD50 
88 
EF-TU Protein 
Reduced colonisation after aerosol challenge with 1 x LD50 of Burkholderia. 
thailandensis 
89 
BPSL2522 (Omp3) Protein 50% survival at day 14 after challenge with 10 x LD50 
90 
BPSL2765 Protein 75% survival at day 14 after challenge with 10 x LD50 
90 
LolC Protein 
80% survival at day 14 after challenge with 153 x MLD 
 
91 
Table 1.3: Details of sub-unit B. pseudomallei sub-unit vaccine candidates tested to date.   Median lethal dose (MLD) is broadly equivalent to lethal 
dose 50% (LD50), all experimental work was carried out in mice. Table adapted from Patel et al
77
. 
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1.2.2 Virulence factors and pathogenicity of B. pseudomallei 
A number of B. pseudomallei virulence factors have been identified and have been 
employed as potential vaccine candidates (Table 1.3).  Polysaccharide virulence 
factors play a key role in the infection mechanism of B. pseudomallei, as previously 
described, the CPS-1 of B. pseudomallei is integral in the evasion of the hosts immune 
system by B. pseudomallei (Section 1.1.2.1)46.  There a couple of models which have 
been proposed for the role of LPS in the virulence mechanism of B. pseudomallei.92  
The first focuses on the effect that LPS has on the formation of the MAC complex 
(Section 1.1.2.1).  Activation of the complement system by LPS may occur far from the 
cell, preventing the formation of the MAC on the membrane surface of the cell.  The 
second model proposes that the LPS is required for the correct presentation of the 
CPS-1 on the surface of the bacterial cell to facilitate its role as a virulence factor.92   
 
An important step in the infection mechanism of B. pseudomallei has been shown to be 
the injection of effector proteins into the host cells via the type three secretion system 
(TTSS-1) leading to the invagination of the bacteria93.  Mutations of the TTSS-1 gene 
cluster have been shown to lead to a substantial drop in virulence of the bacteria.77  
After internalisation, B. pseudomallei evades endocytic vacuoles through lysis of the 
endosome membrane93.  Pilatz et al94 demonstrated B. pseudomallei can stimulate 
actin rearrangement/polymerisation at one pole of the cell, forming a protrusion.  
Through this protrusion B. pseudomallei can infect neighbouring cells, via endocytosis 
of this protrusion, without exposure to antibodies.  A number of other putative virulence 
factors have also been identified for B. pseudomallei including; type IV pili for adhesion 
of the bacteria to host cells93, a siderophore for iron acquisition92, various degradative 
enzymes including proteases and lipases93, and quorum sensing molecules, which are 
yet to be identified95.       
 
1.2.3 Polysaccharides of B. pseudomallei  
Of all the previous attempts for generation of a sub-unit vaccine for B. pseudomallei 
those involving the use of polysaccharide conjugates, with or without the addition of 
immunogenic peptides seemed to provide the most effective protection against lethal 
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challenge77.  To date B. pseudomallei has been shown to produce six polysaccharides 
which are summarised in Table 1.4.   
Polysaccharide Structure Ref 
Capsular 
polysaccharide 
(CPS-1) 
 
46 
Lipopolysaccharide 
(O-PS II) 
 
96 
α-1,3-mannan 
 
97 
Acidic 
exopolysaccharide 
 
98 
Capsular 
polysaccharide 2 
(CP-2)  
99 
Capsular 
polysaccharide 
(CP-1a) 
 
99 
Table 1.4: Summary of the polysaccharide structures produced by B. pseudomallei 
 
Research into these polysaccharides has predominantly focused on both the capsular 
and lipo-polysaccharides.  The role of the other four polysaccharides in the virulence 
and survival of B. pseudomallei is, as yet, still unknown.  For example, the α-1,3-
mannan polysaccharide was first identified by Heiss et al.97 when it was co-extracted 
with CPS-1 (4) from B. pseudomallei and was classified as a novel CPS.  However, 
separation of the two polysaccharides was never achieved, and as yet the gene cluster 
for this polysaccharide has not been identified100.   On this basis the CPS-1 and LPS of 
B. pseudomallei present the most attractive targets for development of a carbohydrate 
vaccine for B. pseudomallei.  Previous attempts with both of these polysaccharides 
have provided some level of immunity in mice (Table 1.3)83.   
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1.2.3.1 The capsular polysaccharide of B. pseudomallei 
The capsular polysaccharide was first identified as a primary virulence factor of B. 
pseudomallei by Reckseidler et al.101  Insertional inactivation of one the 
glycosyltransferase genes for CPS-1 production resulted in a 10,000 fold reduction in 
virulence of the bacteria.  It has been shown previously, Section 1.1.2.1 how CPS-1 
acts as a virulence factor by interfering with the action of the complement system on B. 
pseudomallei, preventing opsonisation and subsequent phagocytosis  It has also been 
shown that biosynthesis of CPS-1 is up regulated during infection102.  To date, all 
clinical isolated species of B. pseudomallei  have been tested positive for the presence 
of CPS-1 giving a 100% correlation between virulence and capsule production, 
highlighting the vaccine potential of this polysaccharide103.    Sequencing of the genes 
responsible for the biosynthesis of the CPS-1 from B. pseudomallei revealed that it was 
most likely a group-III capsule, based on the presence of the kps locus.  Kps loci are 
resonpsible for the translocation through and internalisation of capsular 
polysaccharides into the outer membrane of many bacteria, including N. menigitidis and  
H. influenzae104.  The presence of a diacylglycerophosphate group at the reducing 
terminus is a recurring phenomenon of group-III capsule bacteria104.  The presence of a 
diacylglycerol capping residue on the reducing terminus has implications on potential 
conjugation routes for the polysaccharide and will be discussed further is Section  
3.2.2. 
 
As discussed previously the options for the development of carbohydrate vaccines fall 
into two main categories: the extraction, purification and use of the intact polymer or the 
use of synthetic oligosaccharide fragments.  The category III status of B. pseudomallei 
means that handling of the bacteria is restricted to labs with specialist containment 
facilities, such as those at DSTL-Porton Down.  For these reasons, the use of the 
native polysaccharide as a vaccine candidate will not be discussed at this stage.  The 
use of synthetic fragments of the CPS-1 (4) was the initial focus of this PhD project.  
The CPS-1 (4) of B. pseudomallei is a high molecular weight (ca. 200 kDa105) 
homopolymer of 1,3-linked 2-O-acetyl-6-deoxy-β-D-manno-heptopyranoside residues 
(Figure 1.10).    
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Figure 1.10: Structure of the capsular polysaccharide of B. pseudomallei. 
 
The β-1,3 linkage of CPS-1 poses an interesting challenge for carbohydrate chemists.  
A discussion of the synthetic options for the synthesis of these polysaccharides can be 
found in the next section.   However, the presence of the β-1,3 linkage also gives rise to 
questions regarding the global structure of the polysaccharide.  The tendency of β-1,3-
glucans to form helical structures (single and triple) has been well studied; lentinan 
(Sarko et al.106), curdlan (Marchessault et al.107) and schizophyllan (Fujita et al.108).  The 
propensity for β-1,3-glucans to form helical secondary structures gives some indication 
that β-1,3-mannans could adopt similar global structures.  The development of 
secondary structures in polysaccharides is known to have an effect on the function of 
the polysaccharide.  For example, heparin sulphate (HS) is a polysaccharide found on 
the surface of most cells in the form of a proteoglycan and is responsible for a variety of 
functions in the body.  HS does not have a single defined structure; rather it is 
comprised of a disaccharide building block which, depending on the specific role of the 
molecule, has a variety of different pendant groups, as shown in Figure 1.11.  A key 
role of HS in the body is the interaction of the polysaccharide with fibroblast growth 
factor (FGF) proteins, which are involved in the formation of blood clots.  The 
presentation of the pendant sulphate groups on the helical structure of HS is essential 
for the interaction with FGF proteins109.  HS is an example of how the formation of a 
helix leads to the presentation of specific components of the native polysaccharide.  
The conformation of CPS-1 will have a direct impact on the presentation of epitope 
regions to the immune system.  As such the global structure of CPS-1 must be 
considered as part of the vaccine development program. 
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Figure 1.11: The general structure of heparin sulphate 
 
Basic 3D modelling, using ChemDraw10 3DTM, indicates that the CPS-1 (4) has the 
potential to adopt an extended helical structure (Figure 1.12). 
 
 
Figure 1.12: 3D representation of a CPS-1 fragment from B. pseudomallei demonstrating the 
formation of a helical structure.  The 2-OAc groups have been highlighted in yellow for clarity.  
Images were produced using ChemDraw 3D and subjected to MM2 calculations. 
 
If the capsular polysaccharide of B. pseudomallei does adopt a helical secondary 
structure, as predicted by the 3D models, then the conformational epitope of the 
polysaccharide must be considered.  The formation of a helix by the CPS-1 (4), as 
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predicted above, leads to a number of important conformational changes.   The first is 
the apparent burying of the 2-OAc (yellow) residue within the helix core.  If this residue 
is buried within a helical structure, it implies that it may not be part of the CPS-1 (4) 
binding epitope and thus not required in synthetic mimics of the polysaccharide.  The 
models also imply that, as a result of helix formation, the O-4 to O-7 region of the 
monosaccharide building blocks would be exposed and likely dominate any binding 
events with the host immune system (Figure 1.13).  Although based on empirical 
evidence, and as such must be further investigated, these observations regarding the 
overall structure of the CPS-1 (4) provide useful insight into the requirements for 
synthetic antigens.   
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Figure 1.13: Structure of the capsular polysaccharide of B. pseudomallei with the predicted 
immuno-dominant region highlighted in red. 
 
1.3 Synthetic strategy 
There are three aspects to CPS-1 of B. pseudomallei (4) which make it an interesting 
and challenging synthetic target; i) the β-1,3-mannan configuration, ii) the unusual 6-
deoxy-D-manno-heptose configuration and  iii) the presence of the 2-O-acetyl group.  
As described above, it is our hypothesis that the acetyl group is buried within a helical 
core and as such is not a dominant factor in the immune system response to the native 
polysaccharide.  The Neisseria menigitidis Group C vaccine produced by Baxter Health 
(3) is based on the de-O-acetylated CPS-1.  This polysaccharide has proven to be as, if 
not more, immunogenic than the Wyeth Lederle (2) vaccine which is based on the 
natural O-acetylated polysaccharide50.  This suggests that the retention of O-acetyl 
groups present in natural polysaccharide is not always necessary for carbohydrate 
vaccine structures.  On this basis, the synthetic strategies for the installation of the 2 O-
acetyl group will not be discussed at this stage.  The next section will give insight into 
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previous synthetic strategies for the synthesis of β-mannosides and the 6-deoxy-D-
manno-heptose. 
 
1.3.1 Synthesis of β-mannosides 
CPS-1 of B. pseudomallei is one of many examples of β-D-mannopyranosyl residues 
which are frequently found in nature.  β-Linked mannopyranose is a common residue in 
many plant110 and microbial111-114 polysaccharides providing  biological rationale for 
their synthesis.  However, the synthesis of oligosaccharides, such as fragments of the 
CPS-1 (4) from B. pseudomallei that contain repeating β-D-mannopyranose residues is 
a complex challenge for two reasons.  Thermodynamically because the anomeric 
effect drives the formation of the α-linkage (1,2-trans) disfavouring the β-linkage (1,2-
cis) and kinetically, as a result of the steric hindrance from the axial hydroxyl at the 2 
position115.  Over the years, as synthetic carbohydrate chemistry has developed a 
number of different synthetic strategies for β-linked mannopyranose oligosaccharide 
fragments have emerged.  This next section focuses on some of the important works 
on the synthesis of β-mannosides.   
 
The majority of synthetic strategies for the synthesis of β-mannosides can be put into 
two distinct categories, direct glycosylation and glycosylation-inversion strategies. 
(Scheme 1.1).  
 
Scheme 1.1: Schematic representation of the two general approaches to β-mannoside synthesis, 
image adapted from Glycoscience, Fraser-Reid. B. O.
116
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Scheme 1.2: The effect of O-acetylation of mannosyl donors on the stereoselectivity of ‘insoluble’ 
silver salt promoted β-mannoside formation
116
 
117
.  Reagents and conditions: a) Ag silicate, DCM, rt, 
2 h. 
 
Scheme 1.3: Effect of acceptor reactivity on the stereoselective synthesis of β-mannosides from 
bromide (15) using silver silicate
116
 
118
.  Reagents and conditions: a) Ag silicate, DCM, rt, 2 h. 
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Initially β-mannosides were exclusively synthesised using α-mannosyl halides in the 
presence of a silver promoter such as silver oxide119.  Later, the use silver Zeolite and 
silver silicate based promoters was pioneered by Paulsen120 and Garegg121, 
respectively.  The use of insoluble silver promoters leads to the formation of a ‘surface-
bound’ intermediate and facilitates the SN2-like reaction between the glycosyl acceptor 
and activated donor116, giving high stereoselectivity.  van Boeckel et al.122 demonstrated 
the use of the improved silver silica-alumina system which was shown to have higher 
reactivity than the silicate/Zeolite systems.   
 
The role of protecting groups on the rate and the stereo-control of glycosylation 
reactions is widely not understood123.  The choice of protecting groups in both the donor 
and acceptor has a profound impact on the stereoselectivity of silver-promoted β-
mannosidation reactions116.  This is due to the fact that the successful synthesis of β-
mannosides requires rapid displacement of the surface-bound donor.  It is well 
established that the presence of ester-type protecting groups deactivates glycosyl 
donors.124  The use of deactivated glycosyl donors124, has been shown to result in the 
loss of stereoselectivity for the β-mannoside (Scheme 1.2 A)116.  However, van Boeckel 
et al109, demonstrated that the effect of O-acetyl groups on the stereoselectivity of the 
reaction is position dependant (Scheme 1.2 (B-C))116, 117.  The presence of an acetyl 
group in position-4 (13) was shown to be more stereoselective (α:β, 1:9) when 
compared to the 2,3,4-tri-O-benzylated donor (11) (α:β, 1:6) and the 3-O-acetlyated 
donor (8)117.  In the case of the acceptor, if the target hydroxyl group is sterically 
hindered and thus poorly reactive, the activated glycosyl donor is liberated from the 
surface into solution and the stereoselectivity of the reaction is lost as  demonstrated by 
Paulsen et al. 108,110 (Scheme 1.3).  Use of glycosyl acceptor (15) with bromide donor 
(9) showed high stereoselectivity (α:β, 1:7), in comparison the use of acceptor (17) 
which has a higher relative steric hindrance, where only the α-anomer was formed116, 
125. 
 
Since the initial work on β-mannoside synthesis using insoluble silver-salt promoters 
there have been a number of novel glycosyl donors developed for the synthesis of this 
difficult linkage.  For example, the use of 1-S-benzoxazoyl (SBox) first demonstrated by 
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De Meo et al 126 or the use of naphthylthio glycosides as shown by Tatsuta and co-
workers127.  The synthesis of β-linked manno-oligosaccharides (β-mannans) was 
originally attempted using the conventional method of glycosylation-inversion (Scheme 
1.4).   
 
There are two main routes116 for the inversion of C-2: (Scheme 1.4 (A)) two-step 
oxidation-reduction (Fraser-Reid et al.128) and (B) two-step nucleophillic displacement 
(Twaddle et al129).   
 
 
Scheme 1.4: (A) Synthesis of β-1,2-linker mannobiose using the oxidation-reduction inversion 
methodology as described by Fraser-Reid et al.  Reagents and conditions: ai) Swern oxidation; aii) 
L-Selectride;
128
 (B) Synthesis of β-1,4-linked mannobiose using the nucleophillic displacement 
method as described by Twaddle et al. 
, 129, 130
 Reagents and conditions: a) Tf2O, pyridine, DCM; b) 
Bu4NOBz, toluene. 
 
The direct synthesis of β-linked (-1,2-; -1,3- and -1,4-) mannans was demonstrated by 
Crich and co-workers131, 132 using 4,6-O-benzylidne and 4,6-O-p-methoxybenzylidene 
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acetal protected thioglycoside or sulfoxide donors in moderate yields and high β-
stereoselectivity.  Glycosyl sulfoxides, first employed by Kahne et al.133 are highly 
reactive glycosyl donors.  Crich demonstrated that pre-activation of 6,6-O-benzylidene 
acetal protected mannosyl sulfoxides with triflic anhydride (Tf2O) and 2,6-di-tert-butyl-4-
methylpyridine (DTBMP) led to the synthesis of β-mannans130.  Two mechanisms have 
been suggested for the reaction (Scheme 1.5A) via contact ion-pair (A) (kinetic isotope 
analysis) and (B) through the α-triflate (α-triflate species (B) was observed by NMR 
analysis)134 116.    
 
Scheme 1.5: Proposed mechanism for the direct glycosylation of β-mannosides: a) via contact ion 
pair (A) as predicted by kinetic isotope analysis and b) via α-triflate as predicted by detection of 
triflate (B) by NMR. 
 
Despite the complexity of the β-1,2-cis linkage, there have been great strides in the 
development of synthetic methodologies for the synthesis of these glycosides.  
However, the large-scale synthesis of β-manno-oligosaccharides is still a lengthy and 
challenging process.  This section has given a brief insight into the some of the 
developments in this area over the last 30 years.  There are many other routes which 
have not been discussed here, such as the intramolecular aglycon delivery (IAD) 
method described by Barresi and Hindsgaul135 or the use of 1,2-O-stannylene acetals 
pioneered by Srivastava et al136.  However, the synthesis of high-order β-manno-
oligosaccharide still poses a challenging synthetic task for the most experienced of 
carbohydrate chemists. 
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Scheme 1.6 Synthesis of 6-deoxy-D-manno-heptose (32) as reported by Boren et al
137
.  Reagents 
and conditions: a) NaH, BnCl, reflux, 6 h; b) 1 M HCl, acetone:H2O (4:1), rt, 6 h; ci) DCC, phosphoric 
acid, benzene:pyridine:DMSO (6:3:0.5), rt, 5 h; cii) oxalic acid, MeOH, rt, O/N, d) 
methoxymethyltriphenylphosphonium chloride, BuLi, Et2O, -10
o
C – rt, 20 min – 18 h; e) 0.125 M 
H2SO4 aq, acetone, rt, 4 h; f) NaBH4, H2O:EtOH (19:1), rt, O/N; g) 5% Pd/C, EtOH, rt, O/N; h) 0.25 M 
H2SO4 aq, 100
o
C, O/N.    
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1.3.2 Synthesis of 6-deoxy-D-manno-heptose  
Heptoses are important carbohydrates which occur in numerous structural variations in 
bacteria, such as lipo- or capsular polysaccharides138.  For example, L-glycero-D-
manno-heptose, which is commonly found in the outer core regions of LPS139 and is the 
building block of the Yersinia pestis capsular polysaccharide140.  6-Deoxy heptoses 
have been shown to be a rare component of certain bacterial polysaccharides.  The 
first 6-deoxy heptose isolated from bacteria was 6-deoxy-D-manno-heptose which was 
characterised as part of the LPS of Yersinia pseudotuberculosis group IIA141.  
Subsequently, this monosaccharide has been characterised in the polysaccharides of a 
number of different Yersinia pseudotuberculosis142 strains along with the Burkholderia96, 
97, 143 strains described previously.  Other 6-deoxy heptoses which have been 
characterised from bacterial polysaccharides include 6-deoxy-D-altro144; -D-talo145; -L-
galacto146 and L-gulo-heptose147.   
 
The synthesis of 6-deoxy-D-manno-heptose, the core building block of B. pseudomallei 
CPS-1 (4) was first reported by Boren et al.137 from methyl 6-triphenylmethyl-α-D-
mannoside (24) in 8 steps (Scheme 1.6).  Installation of a trityl ether at the 6-position 
followed by global benzylation of the 2-, 3- and 4-positions and subsequent 
deprotection of the trityl group under acidic conditions afforded alcohol (26).  Oxidation 
of the primary alcohol was carried out to generate aldehyde (27), which was converted 
to vinyl ether (28) though the use of methoxymethyltriphenylphosphonium chloride 
under Wittig conditions.  Hydrolysis of vinyl ether (28) with mild acid conditions 
furnished aldehyde (29) which was reduced using NaBH4 to afford methyl 2,3,4-tri-O-
benzyl-6-deoxy-α-D-manno-heptose (30).  The yield for the hydrolysis of the vinyl ether 
and the reduction of the corresponding aldehyde were not given in the original paper, 
but the low yield of the Wittig reaction (23%) demonstrates the need for development of 
this synthesis.                       
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Aspinall et al148 reported an improved synthesis for 6-deoxy-D-manno-heptose (32) 
again starting from methyl α-D-mannopyranose (Scheme 1.6).  Primary alcohol (26) 
was synthesised under similar conditions as previous examples using a triphenylmethyl 
(trityl) and benzyl protecting groups.  Triflate ester (33) was synthesised to facilitate the 
conversion to methyl 2,3,4-tri-O-benzyl-α-D-manno-heptopyranosidurononitrile (34) by 
cyanide displacement as described by Baer et al149. A two-stage reduction using 
DIBAL-H and NaBH4 was employed to converted nitrile (34) to the corresponding 
alcohol (30).  The combined yield of 30% for the formation of nitrile (34) and 
subsequent reduction to afford protected 6-deoxy-heptose (30) was an improvement on 
the previous synthesis of 6-deoxy-manno-heptose137. 
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Scheme 1.7: Synthesis of methyl 2,3,4-tri-O-benzyl-6-deoxy-α-D-manno-heptose (30) as reported by 
Aspinall et al
148
.  Reagents and conditions: a) triflic anhydride, 2,6-tert-butylpyridine, DCM (abs), -
10
o
C, 10 min; b) KCN, MeCN:H2O (9:1), rt, 2 h; ci) 1 M DIBAL-H, toluene (abs), -20
o
C, 45 mins, cii) 2 
M HCl , rt, 30 min, ciii) NaBH4, MeOH, rt, 1 h. 
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van der Klein et al150 demonstrated the use of cyclic sulphate intermediates for the 
synthesis of methyl α-D-manno-heptopyranose (35) (Scheme 1.8).  Methyl 2,3-O-
isopropylidene-α-D-manno-pyranose (36), was synthesised using graded, acid 
hydrolysis of 2,3:4,6-di-O-isopropylidene-α-D-manno-pyranose to generate the more 
thermodynamically stable monoacetal (36) in good yield151.  Cyclic sulphate (37) was 
synthesised by reaction of monoacetal (36) with thionyl chloride in ethyl acetate-
pyridine to form a cyclic sulphite intermediate, oxidation with sodium periodate in the 
presence of a ruthenium catalyst generated the corresponding 4,6-cyclic sulphate (38) 
in good yield 89%150.  Treatment of the cyclic 4,6-O-sulphate (38) with 
bis(methlythio)methyl-lithium, prepared by reaction of bis(methylthio)methane with 
butyl-lithium in THF/HMPA at -40oC, followed by mild acid hydrolysis afforded 
dithioacetal (40) in 87% yield.  Protected 6-deoxy-heptose (42) was synthesised by 
reaction of dithioacetal (40) with N-bromosuccinimide to liberate aldehyde (41) which 
was subsequently reduced by NaBH4 in overall yield of 53% (based on methyl α-D-
mannopyranose 35) to afford protected 6-deoxy-D-manno-heptopyranose (30)150.   
 
Scheme 1.8: Synthesis of 6-deoxy-D-manno-heptose (42) via cyclic sulfate intermediates as 
described by van der Klein et al
150
.  Reagents and conditions: ai) DMP, p-toluenesulfonic acid, 
acetone, rt, 15 min, aii) 1 M NaHCO3 aq, rt, 3 h; b) thionyl chloride, EtOAc:pyridine (16:1), rt, until 
completion TLC [3:97 acetone:DCM]; c) sodium periodate, RuCl3.H2O, rt, 1 h; d) 
bis(methylthio)methane, THF abs/HMPA, BuLi, -40
o
C, 1 h; e) H2SO4 (Conc.):H2O (3:1), 50
o
C, 2 h; f) 
NBS, triethlyammonium hydrogencarbonate, MeCN, 0
o
C, 5 min; g) NaBH4, EtOH, rt, 6 h. 
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Scheme 1.9: Synthesis of β-1,3-linked disaccharide (57), containing a 6-deoxy-manno-heptose 
residue which has the 3 position selectively deprotected for subsequent glycosylation
152
.  
Reagents and conditions: ai) NH3, MeOH, rt, aii) PhCH(OMe)2, HBF4.OEt2, 0
o
C – rt; bi) dibutyltin 
oxide, 2-naplthalene methyl bromide, benzene, reflux, bii) benzyl bromide, sodium hydride, THF, rt; 
c) DIBAL-H; di) DMSO, (COCl)2, Et3N, dii) CH3PPh3Br, BuLi; ei) OsO4, NMNO, eii) Bu2SnO, toluene, 
eiii) BnBr, CsF, DMF; f) 90% TFA, DCM; gi) 4,6-O-[1-cyano-2-(2-iodophenyl)ethylidene acetal
152
, 
CSA, DCM, gii) TMSCN, BF3.OEt2, DCM; hi) DPSO, TTBP, Tf2O, hii) acceptor (53)
152
, DCM; ji) Bu3SnH, 
AIBN, Xylene, reflux, jii) DDQ 
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Work done by Crich and Banerjee152 on the synthesis of a tetrasaccharide subunit of 
the LPS of Plesimonas shigelloides provides a direct route to β-1,3-linked 6-deoxy-D-
manno-heptosides.  Scheme 1.9 combines both the C-6 extension step required for the 
synthesis of 6-deoxy-D-manno-heptose (32) and also the stereoselective β-1,3-
mannose synthesis.    The use of diol (44) enables the selective protection of the 3-OH 
with naphthalene ether by with dibutyltinoxide and 2-napthylmethyl bromide153.  
Selective deprotection of the 6-position with DIBAL-H afforded primary alcohol (46) 
which was converted to the corresponding olefin (47) by means of Swern oxidation.  
Heptose (48) was synthesised by treatment of olefin (47) OsO4, before deprotection of 
the p-methoxyphenyl ether and installation of the 4,6-[1-cyano-2-(2-
iodophenyl)ethylidene] acetal to afford (50).  The use of 4,6-[1-cyano-2-(2-
iodophenyl)ethylidene] acetal provides the required stereo-control for the synthesis of 
β-1,4-linked disaccharide (50), whilst also facilitating the formation of the 6-deoxy-
heptose.  The subsequent reductive radical fragmentation of protected heptose (51) 
with Bu3SnH/AIBN in Xylene furnished the 6-deoxy heptose moiety (52)
154.  
Development of this route poses a viable option for the synthesis of oligosaccharide 
fragments of the CPS-1 of B. pseudomallei.  However, optimisation of this route, along 
with inclusion of synthetic strategy for the installation of the acetyl group on the 2- 
position would be a lengthy and challenging process.   
 
Prior to the start of this research project, Ancora Pharmaceuticals were contracted to 
undertake the synthesis of an octasaccharide fragment of the CPS-1 of B. 
pseudomallei (4) and, as a result, the synthesis of such compounds was not 
investigated as part of this thesis.  Currently, we have been provided with a sample of 
the hexasaccharide (54) which will be discussed later in this project.  The development 
of the synthetic procedure is still ongoing at Ancora, highlighting the complex synthetic 
challenge posed by this polysaccharide.    
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Figure 1.14: Structure of hexasaccharide fragment of CPS-1 produced by Ancora Pharmaceuticals.   
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1.4 General Aims of the Study 
As highlighted earlier in this chapter, there is a need for the development of a 
successful vaccine for the pathogenic bacteria B. pseudomallei.  The capsular 
polysaccharide of B. pseudomallei (4) has previously been shown to be a promising 
target for use in a carbohydrate vaccine (41).  Traditionally carbohydrate vaccines have 
been based on extracted polysaccharide material, or oligosaccharide fragments, 
conjugated to carrier proteins.  The synthesis of oligosaccharide fragments of CPS-1 
(4) poses a complex synthetic challenge.  As part of our research collaboration, Ancora 
Pharmaceutical were contracted to investigate the synthesis of an oligosaccharide 
CPS-1 fragment (54).   
 
Despite the widespread use of oligosaccharide fragments in vaccine development, the 
application and immunological activity of monosaccharide antigens with respect to 
vaccine generation has not been systematically investigated.  The primary aim of this 
study was to synthesise and assess the immunological activity of B. pseudomallei CPS-
1 immunogens, both synthetic monosaccharides and natural polysaccharide isolates 
(Chapter 2).  The use of a non-virulent Burkholderia strain for the production of CPS-1 
was introduced to combat the health and safety concerns with working on a category 
three pathogen for the production of the natural polysaccharide (Chapter 3).  
Conjugation of the immunogens and immunisation trials in sheep were carried out for 
the production of polyclonal sera, which were subsequently analysed for immunological 
activity (Chapter 4).  The second aim of the study was the development of a novel 
virus-like particle based carrier protein.  The use of in planta expression of a chemically 
conjugatable Hepatitis B VLP was developed and underwent initial conjugation trials 
(Chapter 5).  
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2 Chapter 2: Synthesis of monosaccharide antigens 
2.1 Introduction 
2.1.1 The monosaccharide antigens 
The capsular polysaccharide (CPS-1) of B. pseudomallei (4) is a homopolymer of 1,3-
linked 2-O-acetyl-6-deoxy-β-D-manno-heptopyranose residues, which as discussed in 
the previous chapter has been chosen as the target for this study1.  The chemical 
synthesis of this polymer provides an interesting synthetic challenge owing to the 1,2-
cis manno-pyranose configuration, which is known to be one of the most taxing linkage 
in carbohydrate synthesis2.  The chemical synthesis is further complicated by the 
presence of the 2-O-acetyl group and the 6-deoxy-manno-heptopyranose structure of 
the monosaccharide unit, requiring the need for its multistep synthesis including the C-6 
extension of D-mannose.  A review of the synthetic strategies for the chemical synthesis 
of the β-1,3-mannans and 6-deoxy-manno-heptopyranose can be found in section 1.3.  
Owing to the complex nature of the CPS-1 (4), the initial purposes of this study were to 
chemically synthesise a simplified monosaccharide component which can be derived 
from the CPS-1 of B. pseudomallei (4).   
 
Much research has gone into the use of synthetic oligosaccharide fragments for the 
generation of immunological activity towards parent polysaccharides for the purpose of 
vaccine generation,3,4,5 however, the use of monosaccharides has not been 
systematically investigated.  Sela et al.6 demonstrated that both normal and immune 
sera in animals contain carbohydrate active antibodies.  Fractionation of the sera using 
a fetuin glycoprotein functionalised column, the authors partially purified Ig fractions 
which were shown to be specific for four monosaccharides present in fetuin, D-
mannopyranose, sialic acid, D-galactopyranose and N-acetyl-D-glucosamine.  Further 
to this, it has been shown that single monosaccharide modifications to polysaccharides 
can lead to selectivity towards the monosaccharide addition.  For instance, Bromuro 
and co-workers showed that immunisation with synthetic β-glucan oligosaccharide (55) 
(Figure 2.1) containing β-1,6 branches induced immunological activity to both β-1,3 
glucan and the β-1,6 stub, where immunisation with synthetic β-glucan (56) only 
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resulted in activity towards β-1,3 glucans7.  This suggests that the presentation of 
monosaccharides to the immune system may offer a route to the generation of a 
specific antibody response. 
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Figure 2.1: Structures of synthetic β-glucan oligosaccharides (53 and 54).  Oligosaccharides were 
conjugated to diphtheria toxoid and immunological studies were carried out in mice
7
. 
 
2.1.1.1 Carrier Proteins 
The conjugation of carbohydrates to carrier proteins is essential for the development of 
a strong immune response and subsequent antibody generation (Section 1.3.3).  There 
are a number of carrier proteins that have been used for the conjugation of 
carbohydrate antigens, such as KLH, which is routinely used for glycoconjugate 
research8.  KLH is a large, heterogeneous glycoprotein with a molecular weight of 350-
390 kDa and is highly immunogenic.  It cannot be produced biochemically and is only 
obtained by purification from Megathura crenulata, the Keyhole Limpet9.  Despite its 
inherent immunogenicity, and widespread use as the carrier protein of choice, KLH has 
a number of drawbacks.  It forms large aggregates (4.5-13 MDa) and as a result is 
poorly soluble in water making it difficult to work with10.  Aggregation of the sub-units 
poses another problem with the quantification of conjugation, as it cannot be analysed 
by MS or gel electrophoresis.  The native glycosylation patterns of KLH also pose a 
significant problem for its use in this project.  The presence of any additional 
carbohydrate moieties on the protein surface may interfere with the immunological 
recognition and activity of the monosaccharide haptens11.  
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Alternatives to KLH, which have been used for conjugation of small molecule haptens 
are Bovine Serum Albumin (BSA)12, Diphtheria Toxoid (DT)13 DTCRM197 (glutamic acid 
mutant)7 and Tetanus Toxin Heavy Chain Fragment (TetHc)14.  Tetanus toxin is a 
potent neurotoxin which is produced by Clostridium tetani and consists of two 
polypeptides; the heavy chain (100,000 Da) and the light chain (50,000 Da). Mild 
enzymatic cleavage (papain) of tetanus toxin generates two major polypeptides, the 
larger of which is denoted as the TetHc fragment (50,000 Da).  The TetHc fragment 
retains both the binding activity and internalization properties that are associated with 
the intact toxin resulting in high immunogenicity, but is non-toxic15.  TetHc was an 
attractive option for this work as it can be readily expressed at high levels from E. coli14, 
has a high proportion of lysine residues for conjugation (33) and can be analysed by 
MALDI-ToF MS and SDS-PAGE16.  These attributes make TetHc a very effective 
carrier protein and a good substitute for KLH. 
 
A second set of glycoconjugates were made using BSA as the carrier protein.  These 
conjugates were used in the immunological assessment of the monosaccharide 
antigen-derived antibodies.  An alternative carrier protein is used for the immunological 
assessments to remove background activity of antibodies raised against the carrier 
protein (TetHc).  BSA was selected for this role owing to its mainstream use as a carrier 
protein in immuno-assays and as a blocking agent17.  Molecular models of both TetHc 
and BSA carrier proteins are shown in Figure 2.2, with the lysine residues, which were 
targeted for conjugation, highlighted in yellow. 
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Figure 2.2: Models of A) TetHc fragment (right image rotated 90
o
) and B) BSA (right image rotated 
90
o
).  The lysine residues, which were targeted for conjugation are highlighted in yellow TetHc (33 
residues) BSA (60 residues).  Images were produced using PyMol with the help of E. O’Neill.   
 
To investigate the potential of monosaccharide antigens, D-glucopyranose (69) and D-
mannopyranose (64) haptens were synthesied and conjugated to protein.   
Immunisation in sheep, with the D-glucopyranose TetHc protein conjugate (96) was 
carried out to determine whether monosaccharide specific antibodies could be created.  
A D-manno-pyranose BSA conjugate (93) was also made in order to test the specificity 
of the D-gluco-pyranose derived antibodies.    A CPS-1 monosaccharide, 6-deoxy-D-
manno-heptose TetHc (94) protein conjugate was prepared to investigate the activity of 
monosaccharide derived antibodies against the intact capsular polysaccharide of B. 
pseudomallei.  During this initial study into the potential of the monosaccharide antigen 
for CPS-1 (4), synthetic efforts for the 6-deoxy-D-manno-heptose hapten (91) were 
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focused on the development of the α-configured compound.  This was done to expedite 
the synthesis, avoiding the need for formation of the taxing β-1,2-cis linkage.  As 
discussed in Section 1.2.2.1, based on molecular models, it was proposed that the C-4 
to C-7 region of the monosaccharide building blocks would be the primary binding 
epitope for antibodies.  By focusing on the most basic structural component of CPS-1 
(4), the 6-deoxy-D-manno-heptopyranose monosaccharide (32), it was anticipated that 
switching from the β-configuration in the natural polysaccharide (4) to the α-configured 
monosaccharide hapten (91) would have minimal impact on antibody activity.  Section 
1.3.1 highlights some synthetic strategies which could be employed to synthesise the β-
compound.  The synthesis of 6-deoxy-D-manno-heptose (32) was made in accordance 
with literature precedence18, 19 (Section 1.3.2).  Development of the synthetic protocol to 
facilitate multi-gram synthesis of the CPS-1 monosaccharide was also attempted.   
 
2.2 Results and Discussion 
2.2.1 Synthesis of 8-methoxycarbonyl octanol (58) 
As described in Section 1.1.2, it is essential for carbohydrates to be conjugated to a 
carrier protein before they can be used as immunogens.  There are a number of 
proteins which are used in carbohydrate based vaccines (Section 2.1.2).  The 
conjugation chemistry of carrier proteins and carbohydrate antigens generally relies on 
the modification of carboxyl, hydroxyl, phenoxyl, hemiacetal, mercapto/disulphide and 
amino/imino functional groups20.  Different coupling strategies are employed depending 
on the nature of the antigen including direct activation and coupling of polysaccharides 
(reductive amination, cyanogen bromide activation) and the use of linker molecules for 
the conjugation of smaller antigens21-24.  In order to preserve the cyclic structure of 
monosaccharides, they were used in a form of glycosides attached to a linker with a 
reactive carboxyl group for conjugation to the carrier protein.  Whilst there is a variety of 
different linkers which could be employed, we decided upon the use of an aliphatic 
chain linker.  Building on the work done by Lemieux et al.23 and Inman et al.24 we used 
8-methoxycarbonyl octanol (58) as the linker.  This molecule was chosen as a result of 
its previous use in classical 1970’s studies with di- and tri-saccharide haptens, the lack 
of any immuno-dominant functional groups, such as aromatics, the ease of synthesis 
and activation for conjugation23 25.   
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Prior to conjugation, the methyl ester (58) is readily converted to the corresponding acyl 
hydrazide using hydrazine monohydrate.  Further activation of the hydrazide is required 
to facilitate the conjugation to lysine residues, which will be discussed later on in this 
chapter.  Methyl ester (58) is available at scale through the borane-THF reduction of 
inexpensive mono-methyl azelate (57) in good yield, 82%, and was produced on a 16 
gram scale (Scheme 2.1). 
 
 
Scheme 2.1: Borane-THF reduction of mono-methyl azelate (57).  Reagents and conditions: a) BH3-
THF, THF, -18
o
C – rt., 4.5 h 
 
2.2.2 Synthesis of 8-(Hydrazinocarbonyl)octyl α-D-mannopyranoside (64) 
D-Mannose (59) was per-O-acetylated using the I2/Ac2O method as described by 
Kartha and Field26.  The anomeric acetate was converted to the bromide (61) by 
treatment with 33%HBr/AcOH, in preparation for glycosylation with the linker 
compound.  Bromide (61) was glycosylated to linker (58) under Helferich conditions27, 
the yield of the glycosylation was unusually poor (39%) with the major side-product 
being the acetylated linker molecule23, indicating a high level of acetate migration 
during the reaction.  However, owing to the fact that only small amounts of the D-
mannose hapten (64) were required for the subsequent conjugation this was not 
investigated further.  It should be noted that this is the reason why benzoyl protecting 
groups were used in the synthesis of the mannoheptose hapten (Scheme 2.6).  
Deacetylation was achieved using standard Zemplén conditions to afford the 
deprotected glycoside (63).  This prospective hapten was subsequently activated for 
conjugation through the formation of the acyl hydrazide (64) using an excess of 
hydrazine monohydrate.  This reaction was monitored through the loss of the OMe 
signal in the 1H NMR spectrum and was shown to be quantitative after 4 h at 55 ºC 
(Scheme 2.2). 
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Scheme 2.2: Synthesis of hydrazide (64).  Reagents and conditions: a) I2/Ac2O, rt, 10 min; b) 33% 
w/v HBr/AcOH, DCE, 0
o
C - rt. 3 h; c) Hg(CN)2, Hg(Br)2, 8-MCO, MS 4Å, DCE, rt, ON; d) NaOMe, MeOH, 
rt, 30 min; e) NH2NH2.H2O, EtOH, 55
o
C, 4 h 
 
2.2.3 Synthesis of 8-(hydrazinocarbonyl)octyl β-D-glucopyranoside (69) 
The D-glucose hapten (69) was synthesised in the same fashion as the D-mannose 
hapten (64) above in good overall yield, (Scheme 2.3). 
 
Scheme 2.3: Synthesis of hydrazide (69).  Reagents and conditions: a) 33% w/v HBr/AcOH, DCM, 
0
o
C - rt. 3 h; b) Hg(CN)2, Hg(Br)2, 8-MCO, MS 4Å, DCE, rt, ON; c) NaOMe, MeOH, rt, 30 min; d) 
NH2NH2.H2O, EtOH, 55
o
C, 4 h 
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2.2.4 Synthesis of methyl 2,3,4-tri-O-benzyl 6-deoxy-α-D-manno-
heptopyranoside (30) 
Methyl 2,3,4-tri-O-benzyl-α-D-manno-pyranoside (26) was synthesised according to the 
procedure highlighted by Boren et al.18 (Scheme 2.4).  It was decided to adopt benzyl 
protecting groups for compatibility with the later DIBAL-H reduction step that is used for 
the C-6 extension.  The 6-position of methyl mannoside was first selectively protected 
using triphenylmethlychloride in DMF with catalytic DMAP in good yield28.  Partial 
purification was performed in order to remove unreacted starting material.  Thereafter, 
the 2-, 3- and 4-hydroxyl groups of trityl ether (24) were benzylated under Williamson 
conditions29, with initial deprotonation with NaH in DMF, followed by the dropwise 
addition of BnBr to furnish (25).  Attempts were made to carry out these two steps as a 
one-pot synthesis, but this was unsuccessful, due to complications with purification as a 
result of multiple impurities.  The trityl protecting group was removed using standard 
acid hydrolysis with 90% TFA in DCM30.  It is worth noting that trityl alcohol can be 
triturated out of the reaction mixture using cold hexane before chromatography, in order 
to simplify the purification procedure.   
 
Of the different routes for the C-6 extension step in the synthesis of 6-deoxy heptoses 
described previously, (Section 1.3.2) the work done by Aspinall et al.19 was the most 
suitable for the expedient synthesis of 6-deoxy-manno-heptose (32).  The reasonable 
yields and the use of relatively mild and cheap reagents made it an attractive option for 
potential development and scale-up.  During their work (Scheme 1.7), Aspinall and co-
workers19 used a nucleophillic substitution of triflate (33) with cyanide for installation of 
the nitrile functionality.  However, the associated yield of 50% for the two step reaction 
was lower than expected and it was felt that this could be improved upon through the 
use of iodine.  The synthesis of methyl 6-deoxy-6-iodo-α-D-manno-pyranoside (70) was 
known31 to be simple and efficient and there are many literature precedents of the 
displacement of the iodide with cyanide which is easily achieved under Finkelstein 
conditions, following a simple SN2 reaction mechanism
32-34.  The drawback of both 
iodide preparation and subsequent displacement procedure is that they required 
relatively long reaction times.  Over the last decade, the use of microwave reactors for 
accelerated reactions has become more common-place.  There has been a recent 
interest in the use of microwave conditions for carbohydrate synthesis, where it has 
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been shown to be an effective and expedient tool35, 36.  On this basis the use of 
microwave irradiation was trialled for the synthesis of the iodide (70) and nitrile (34). 
 
Iodide (70) was formed upon reflux of primary alcohol (26) with iodine, 
triphenylphosphine and imidazole in anhydrous toluene37, 38.  Initially this reaction was 
carried out under traditional reflux, but was also trialled under microwave conditions.  
The reaction time was cut down from 3 hours to 5 minutes, with an improvement in the 
yield, increasing from 73% to 81%.  The nitrile functionality was introduced under 
Finkelstein conditions, by reaction of iodide (70) with excess sodium cyanide in DMF, in 
a microwave reactor.  Due to accelerating effects of the microwave, the reaction was 
run without the use of a phase-transfer catalyst, which is usually required for this 
reaction34.  The reaction was initially optimised on a small scale to show completion in 3 
h at 70oC.   
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Scheme 2.4: Synthesis of deoxy-D-manno-heptose (30).  Reagents and conditions: a) Ph3CCl, 
DMAP, DMF, 40
o
C. 16 h; b) BnBr, NaH, DMF, rt, 4 h; c) 90% TFA (aq.), DCM, rt, 30 min; d) I2, 
imidazole, PPh3, toluene, reflux, 4 h; e) NaCN, DMF, microwave, 70
o
C, 3 h; fi) DIBAL-H, toluene, -
25
o
C, 45 min ii) 2M HCl, MeOH, rt, 45 min, iii) NaBH4, MeOH, rt, 30 min 
    
Thin layer chromatography (TLC) analysis showed the reaction to be clean, and after 
purification of the product by passing the reaction mixture through a short bed of silica 
nitrile (34) was obtained in 89% yield 9data not shown).  The reaction was performed 
on a multi-gram scale with comparable results.  The yield associated with the two steps 
(iodination and substitution with cyanide) was higher (67%) than that of the triflate ester 
 53 
 
route19 (Scheme 1.7) (59%).   For the reduction of the nitrile (34), we followed the 
procedure described by Aspinall et al.19  DIBAL-H was used to reduce the nitrile (34) to 
the imine in absolute toluene.  Following the hydrolysis of the imine using aqueous HCl, 
the corresponding aldehyde was further reduced using NaBH4 in MeOH to furnish 
protected 6-deoxy-D-manno-heptopyranose (30).  The reaction mechanism of the 
DIBAL-H reduction and subsequent imine hydrolysis is described below (Scheme 2.5). 
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Scheme 2.5: Reaction mechanism for DIBAL-H reduction of the nitrile and subsequent imine 
hydrolysis down to the corresponding aldehyde 
 
Attempts made to optimise the yield of the nitrile reduction led only to a modest 
improvement achieving 56% conversion over the three steps, compared to 50% stated 
in the literature19.  Despite the modifications to the synthetic route, due to the use of 
bulky protecting groups and moderate yields associated with the steps, it still remains 
an impractical method for the large-scale synthesis of 6-deoxy-D-manno-heptopyranose 
(32).  As a result attempts were made to employ a more efficient strategy, without the 
use of bulky protecting groups, which will be discussed in the next section. 
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2.2.5 Improvements to the synthetic route for 6-deoxy-D-manno-heptopyranose 
(32) 
Efforts were subsequently made to develop a more robust and efficient synthetic route 
for 6-deoxy-D-manno-heptopyranose (32).  The use of a synthetic oligosaccharide, for 
the generation of a carbohydrate based vaccine for B. pseudomallei would require 
multi-gram quantities for the starting monosaccharide for iterative synthesis.  The 
current synthetic route to the protected 6-deoxy-D-manno-heptose monosaccharide 
(32), summarised in Scheme 2.4 is made up of 6 steps and has an overall yield of 
approximately 20%.  Although this is a reasonable yield for a 6-step procedure, this 
chemistry was conducted only on small scale (1-3 grams of starting material).  There 
are a number of technical issues which arise upon the scale-up of this route; this 
section deals with the attempted improvement of the synthesis of 6-deoxy-D-manno-
heptopyranose (30). 
 
2.2.5.1 The use of polymer bound triphenylphosphine 
Although efficient on a small scale and an improvement on the previous syntheses by 
Boren et al.18 39 and Aspinall et al.19, the current iodination procedure is not suited for 
scale-up18, 19.    The primary issue is associated with the purification of the product from 
the reaction mixture.  During the reaction, triphenylphosine oxide is generated, which is 
difficult to remove by column chromatography.  When performed on small scale, two 
rounds of chromatography is sufficient to remove the PPh3=O by product.  However, on 
a large scale (10 – 20 grams), chromatography becomes impractical and precipitation 
of PPh3O out of solution using non-polar solvents such as hexane or ether did not 
prove successful. Therefore attempts were made to use polymer-bound 
triphenylphosphine37, 40 (Sp-PPh3) as a substitute for free triphenylphosphine, in order 
for the polymer bound PPh3=O to be filtered off prior to chromatographic purification. 
 
The reaction of I2 with protected monosaccharide (26) was carried out in the presence 
of sp-PPh3O in anhydrous toluene (Scheme 2.6) at 70
oC for 4 hours.  TLC and MALDI-
ToF (data not shown) analysis confirmed complete conversion.  The product was easily 
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separated from sp-PPh3 and washed with NaHCO3 and H2O.  TLC and MALDI-ToF 
analysis showed the reaction to be complete, chromatography purification was carried 
out and the product was isolated in a 97% yield. 
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Scheme 2.6: Iodination of protected methyl mannoside (26) using Sp-PPh3. Reagents and 
conditions: a) Sp-PPh3, Imidazole, I2, toluene, reflux, 4 h 
 
The yield of the reaction with free triphenylphosphine is 73%, with the majority of the 
losses being attributed to the chromatography steps needed for the purification of the 
product from triphenylphosphine oxide.  The use of Sp-PPh3 dramatically increases this 
yield, up to 97%, and presents an attractive replacement for triphenylphosphine.  The 
cost of Sp-PPh3 is approximately 15 times that of free PPh3 and when used on large 
scale could become expensive.  However, it is possible to reduce the Sp-PPh3=O 
generated during the reaction back to Sp-PPh3 in quantitative yield using either alane 
(AlH3) in THF
41 or trichlorosilane42.  Owing to this, and the reduction in both energy and 
materials costs associated with the purification of the PPh3=O, the use of polymer-
bound triphenylphosphine for the large-scale synthesis of 6-deoxy-6-iodo derivatives is 
an effective and green alternative to the use of triphenylphosphine itself43. 
 
2.2.5.2 Nitrile reduction 
One of the most inefficient steps of the described synthetic procedure on route to 6-D-
deoxy-manno-heptose (32) is the three-step reduction of nitrile (34) down to primary 
alcohol (30).  Over the course of the project this experiment was repeated several 
times, with the best yield being 56%, which was achieved when conducted on a 250 mg 
scale.  When the scale of the reaction was increased, the yield dropped off 
dramatically.  For example on a 1 gram scale the yield achieved was 37%, 
necessitating an alternative route.  As discussed earlier in this chapter, there are a 
number of potential routes for the single carbon extension of a monosaccharide 
(summarised in Section 1.3.2).  However, having adopted the iodide-nitrile route it was 
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decided that efforts would be focused on improving the nitrile reduction, rather than 
developing a new route using previously studied methods.  The current method of 
reduction uses DIBAL-H to reduce nitrile (34) down to the corresponding aldehyde (71), 
followed by further reduction of the aldehyde to the alcohol (30) (Scheme 2.7). 
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Scheme 2.7: Reduction of nitrile (34) to alcohol (30) using DIBAL-H  Reagents and conditions: a) 
DIBAL-H, toluene, -25
o
C, 45 min, ii) 2 M HCl, MeOH, rt,45 min; b) NaBH4, MeOH, rt, 30 min. 
 
It could be possible to improve this procedure through the use of LiAlH4 as the reducing 
agent for the aldehyde to alcohol step; however this is not desirable due to the health 
and safety issues associated with large-scale syntheses using LiAlH4.  Beyond the 
reduction of nitriles to aldehydes, the hydrolysis of nitriles presented an interesting 
option for this work.  There are a number of routes which could be employed for the 
hydrolysis of a nitrile; acid-catalysed44, base-catalysed45 and enzymatic hydrolysis46-48.  
Although intriguing and desirable, the lack of commercial availability of these enzymes 
and the enzymatic hydrolysis of nitriles with nitrilases was not investigated as part of 
this study.  Both acid- and base-catalysed reductions were trialled with no success, as 
described by Scheme 2.8. 
 
The HCl promoted hydrolysis of nitrile (34) failed completely, with no consumption of 
the starting material being observed (TLC analysis or IR analysis) after 6 h at reflux 
temperature or in microwave reactor at 120oC.  Both the reaction with H2SO4 and NaOH 
showed consumption of the starting material (TLC) analysis but both produced 
numerous degradation products.  The use of sodium methoxide was also studied for 
the formation of the imidate (2-imido-2methoxy-ethyl mannoside) (74) (Scheme 2.8), 
but again no reaction was observed after 24 hours at room temperature49, 50 or heating 
to 40 ºC for 4  
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Scheme 2.8: Attempted hydrolysis of nitrile (34) using HCl, H2SO4 and NaOH  Reagents and 
conditions: a) 4 M HCl, H2O, reflux, 6 h; b) 4M H2SO4, H2O, reflux, 2 h; c) 0.5 M NaOMe, MeOH, rt - 
40
o
C, 24 h - 4 h d) 5 M NaOH, EtOH, reflux, ON; e) 4 M HCl, H2O, rt, 30 min 
 
Recently, Barragan-Montero et al.51, demonstrated the use of 30% H2O2 and NaOH for 
the hydrolysis of methyl 6-deoxy-α-D-manno-heptopyranosylurononitrile (34) in 
quantitative yield.  The use of 30% aqueous hydrogen peroxide and sodium hydroxide 
was developed by Radziszewski et al.52 for the reduction of nitriles to amides, however 
further addition of NaOH/H2O2 upon formation of the amide, has shown to hydrolyse the 
amide down to the parent carboxylic acid45.  The use of NaOH/H2O2, in the presence of 
DMSO co-solvent, was trialled on protected nitrile (34).  Unfortunately, even with the 
further addition of excess NaOH, it was not possible to proceed beyond the amide (75) 
with the protected material (Scheme 2.9)53. 
O
BnO
BnO
OBn
OMe
CN
a
O
BnO
BnO
OBn
OMe
b
O
BnO
BnO
OBn
OMe
OHO NH2 O
727534
 
Scheme 2.9: Attempted hydrolysis of protected nitrile (34) with NaOH/H2O2.  Reagents and 
conditions: a) NaOH, 30% H2O2, DMSO, rt, 36 h 
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At this stage, owing to the lack of success with the development of this route, and the 
requirement of bulky protecting groups work on this synthetic strategy was 
discontinued. Barragan-Montero et al.51 demonstrated that the NaOH/H2O2 hydrolysis 
of the free nitrile successfully generated the carboxylic acid.  The development of 
efficient methodologies for the protecting group free synthesis of the free nitrile (78) 
were attempted next. 
 
2.2.5.3 Protecting group-free synthesis of nitrile (78) 
The synthesis of free nitrile (78) was attempted by two different methods, the first direct 
synthesis of the nitrile from benzyl-α-D-mannopyranoside (76) and secondly via the 
iodide (77) (Scheme 2.10).  
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Scheme 2.10: Proposed route for the protecting group free synthesis of nitrile (78).  Reagents and 
conditions: a) BnOH, AcCl, 50
o
C – rt, 1.5 h – 15 h, 96%; b) PPh3, DDQ, n-Bu4NCN, CH3, rt, 2 h; c) 
PPh3, Imidazole, I2, THF, reflux, 2 h, 86%; d) NaCN, KCN/H2O, rt, ON, quant. 
 
Benzyl α-D-mannopyranoside (78) was synthesised according to the protocol described 
by Zunk et al.54 in high yield (96%).  The benzyl ether was used to protect the anomeric 
position and to simplify the synthetic manipulations as a result of improved solubility in 
organic solvents, and to aid with purification.  
 
2.2.5.3.1 Direct synthesis of nitrile (78)  
Iranpoor et al.55, 56 demonstrated the conversion of alkyl alcohols to alkyl halides using 
triphenylphosphine, 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) and quaternary 
ammonium halide salts.  They further developed this work for the selective conversion 
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of primary alcohol (79) to the corresponding nitrile (80) with tetrabutylammonium 
cyanide in good yields in anhydrous acetonitrile55.   
OH
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Scheme 2.11: Direct synthesis of nitrile (80) from primary alcohol (79) as reported by Iranpoor et al. 
55
  The reaction was shown to specific for primary alcohol (79) in the presence of secondary alcohol 
(81).  Reagents and conditions: a) PPh3/DDQ/n-Bu4NCN, MeCN abs, rt, immediate. 
 
This reaction was repeated with benzyl α-D-mannopyranoside (76) in an attempt to 
furnish the desired nitrile (78) in one step (Scheme 2.10b).  Unfortunately, in our hands, 
this reaction was not successful, and no reaction was shown to have taken place after 
2 hours (TLC and MALDI-ToF MS analysis, data not shown).  It is worth noting that 
during the reaction there was no colour change from green to orange upon the addition 
of the substrate, which as described in the research paper indicates completion of the 
reaction55.  In order to assess whether the reaction conditions were correct, we 
repeated the reaction using benzyl alcohol (83) as the substrate, an example from the 
Iranpoor et al.55 paper.  This time, the indicative colour change occurred upon addition 
of the substrate and the reaction was shown to be successful by MALDI-ToF MS 
(Scheme 2.12). The fact that the reaction was successful with the benzyl alcohol and 
not with monosaccharide (76) suggested that this system was not applicable for 
carbohydrates and was abandoned at this stage.  
OH
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Scheme 2.12: Direct synthesis of benzyl cyanide (85) from benzyl alcohol (84), 100% conversion as 
shown by MALDI-ToF MS.  Reagents and conditions: a) PPh3/DDQ/n-Bu4NCN, MeCN abs, rt, 
immediate 
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2.2.5.3.2 Indirect synthesis of nitrile (78) via the iodide (77) 
Iodide (77) was synthesised in good yield (86%) using the standard conditions of 
triphenylphosphine, imidazole and I2 with anhydrous THF as the solvent.  The removal 
of the PPh3=O generated in the reactions is simplified due to the polar nature of the 
mobile phase used in the chromatography step [DCM:MeOH; 9:1].  Nitrile (78) was 
synthesised in quantitative yield using KCN in aqueous acetonitrile (Scheme 2.13).  
Therefore this route was the most efficient in transformation of mannosides into nitrile 
precursors of 6-deoxy-D-manno-heptopyranose (32) and has potential of further 
development into a scalable synthesis. 
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Scheme 2.13: Synthesis of nitrile (78) without protecting groups.  Reagents and conditions: a) 
PPh3, Imidazole, I2, THF, reflux, ON; b) KCN, MeCN:H2O (1:1); rt, 15 h 
 
2.2.6 Synthesis of 8-(hydrazinocarbonyl)octyl 6-deoxy-α-D-manno- 
heptopyranoside (91) 
To complete the synthesis of the 6-deoxy-D-manno-heptose hapten (91), the methyl 
glycoside had to be converted to the anomeric acetate via acetolysis with catalytic 
H2SO4 furnishing diacetate (85).   The free 6-deoxy-D-manno-heptose was obtained 
through successive hydrogenation of the benzyl ethers and Zemplén deprotection.  
Per-O-benzoylation of 6-deoxy-D-manno-heptose (32) was carried out in order to avoid 
the acetate migration problem experienced in the mannose series (Section 2.2.2).  
Bromide (88) was synthesised by means of HBr/AcOH, purified by flash 
chromatography and directly glycosylated to linker (58) in overall yield of 59%.  
Deprotection of (89) via Zemplén deprotection afforded methyl ester (9) in 77% yield.  
The finished 6-deoxy-D-manno-heptose hapten (91) was furnished by conversion of the 
methyl ester (90) to the corresponding acyl hydrazide (91). 
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Scheme 2.14: Completion of heptose hapten synthesis (91).  Reagents and conditions: a) H2SO4 
(cat.), Ac2O/AcOH, 0
o
C, 30 min; b) H2, Pd /C (cat.), EtOAc/EtOH, 40
o
C, 16 h; c) NaOMe, MeOH, rt, 30 
min; d) BzCl, pyridine, rt, 16 h; e) 33% w/v HBr/AcOH, DCM, 0
o
C - rt. 3 h; f) Hg(CN)2, Hg(Br)2, 8-MCO, 
MS 4Å, DCE, rt, ON; g) NaOMe, MeOH, rt, 30 min; h) NH2NH2.H2O, EtOH, 55
o
C, 4 h 
 
2.3 Conjugation of monosaccharide haptens to carrier protein 
2.3.1 Expression of His-tagged TetHc fragment in E. coli 
An E. coli BL21 strain containing the pSK1-TetHc plasmid was provided by Dr A. Scott 
of DSTL-Porton Down.  The cells were grown up in LB media (4 x 1 litre) to an optical 
density (600 nm) of 0.8, at which point the expression of TetHc protein was induced by the 
addition of isopropyl β-D-1-thio-galacto-pyranoside (IPTG).  After 16 hours incubation at 
16oC the cells were harvested, lysed by means of a cell disrupter and the resulting cell 
debris was removed by centrifugation.  The soluble protein was purified from the 
supernatant using an Äkta Xpress FPLC system (GE Healthcare) to afford pure protein 
at a yield of 55 mg/L of cell culture. 
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Figure 2.3: Chromatogram of TetHc fragment purification on Akta Xpress FPLC equipped with 1) 
Column HiTrap Ni-NTA column (5 ml, GE Healthcare); wash buffer [50 mM Tris-HCl, pH 8.0, 0.5 M 
NaCl, 30 mM imidazole]; eluent [50 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 0.5 M imidazole].  2) Superdex 
S75 XK26/60 column; eluent [50 mM HEPES, pH 7.5, 100 mM NaCl]; flow rate 3.2 ml/min. 
 
SDS-PAGE analysis (Figure 2.4) showed successful expression and purification of 
TetHc fragment, with the fractions collected containing pure protein with the gel band 
corresponding to the standard supplied by DSTL.  
 
Figure 2.4: SDS-PAGE (coomassie stained) analysis of fraction from Akta Xpress FPLC Sepharose 
S200 XK 26/60 column, flow rate 3.2 ml/min, eluent (20 mM HEPES, 150 mM NaCl, pH 7.5).  Lanes: 
A) Kaleidoscope Ladder; B) Non-expressing cells (No IPTG); C) IPTG induced expressing cells; D) 
Total cell insoluble frac.; E) Total cell soluble frac.; F) Frac. A6; G) Frac. A8; H) Purified TetHc 
standard. 
 
MALDI-ToF analysis was carried out on the intact protein as described in general 
methods section (7.1.3).  The spectrum is shown below (Figure 2.5) with the main peak 
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at ca. 53 kDa corresponding the molecular weight of TetHc and the second peak 
corresponding to the [M+2H]2+ ion. 
 
Figure 2.5: MALDI-ToF spectra of intact TetHc fragment 
 
2.3.2 Conjugation of Haptens 
In order to conjugate acyl hydrazide to the primary amines of lysine residues of the 
carrier protein, using an excess of acyl hydrazide which were initially converted to the 
corresponding acyl azides.  This was achieved through oxidation using nitrous acid, 
which is formed in situ by reaction of tert-butyl nitrite with 4M HCl in DMF at -25oC 
(Section 6.1.1.2).  The DMF solution containing the acyl azide was then added drop-
wise to a cooled solution of protein in Borax/KHCO3 buffer (pH 9.0) (Scheme 2.15)
23. 
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Scheme 2.15: General reaction Scheme of glycoconjugate synthesis.  Reagents and conditions: a) 
Hydrazine monohydrate, EtOH, 6 h, 55
o
C; bi) tert-butyl nitrite, 4M HCl, DMF, bii) TetHc, 0.08M 
Borax/0.35M KHCO3, pH 9.0, O/N, 4
o
C. 
 
The reaction between the acyl azide and lysine residues will only occur when the lysine 
side chain is in its free base form (Scheme 2.16)57 58.   
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Scheme 2.16: Reaction mechanism for amide bond formation between acyl azide and lysine 
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Figure 2.6: SDS-Page analysis and FITC-ConA staining of Man-TetHc conjugate (92).  Left Gel: 
Standard SDS-PAGE gel.  Lanes: A) Kaleidoscope ladder; B) native TetHc fragment; C) Man-TetHc 
glycoconjugate (92); D) mix native TetHc and Man-TetHc conjugate (92).  Right Gel: Western blot of 
SDS-PAGE gel. Lanes A) Kaleidoscope ladder; b) native TetHc fragment; C) Man-TetHc 
glycoconjugate (92) stained with FITC-ConA 
 
 
Figure 2.7: Overlay of MALDI-ToF spectra for native TetHc and Man-TetHc (92) glycoconjugates 
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2.3.2.1 Mannose-TetHc (Man-TetHc) Glycoconjugate (92) 
The D-mannopyranose hapten (64) was successfully conjugated to TetHc carrier 
protein on a 6 mg scale.  All protein conjugates were analysed using intact mass 
MALDI-ToF MS, SDS-PAGE and in the case of Man-TetHc, western blot analysis with 
(Fluorescein IsoThioCyanate) FITC-Concanavalin A (ConA).  Con A is a carbohydrate 
lectin originally isolated from jack-bean and is known to specifically bind to α-D-
mannose and α-D-glucose residues59.  MALDI-Tof MS is an ideal technique for the 
analysis of the glycoconjugates due to its soft ionisation with little fragmentation60, 61.  
The glycoconjugates were analysed by MS following the procedure highlighted in 
general methods section (7.1.3).  A number of matrices were trialled to generate 
spectra for these glycoconjugates.  It was shown that a saturated solution of sinapinic 
acid [70% MeCN, 0.1% TFA] was the most suitable matrix for this work.   
 
SDS-PAGE of the Man-TetHc conjugate (92) (Figure 2.6 (left)) demonstrated a band 
shift in the order of 5 – 10 kDa difference between native TetHc and the Man-TetHc 
conjugate (92).  A western blot was taken of SDS-PAGE gel and stained using FITC-
ConA, fluorescently labelled Concavalin A and imaged using a fluorescence scanner at 
495 nm (Figure 2.6 (right)). Only the Man-TetHc conjugate (92) was labelled by the 
FITC-ConA, indicating the successful conjugation and presentation of the mannose 
hapten on the surface of the TetHc carrier. 
 
MALDI-ToF analysis confirmed conjugation at an average of 23 hapten units per TetHc 
molecule, giving a conjugation efficiency of 70% considering total number of available 
lysine residues (33) (Figure 2.7). 
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Figure 2.8: SDS-PAGE analysis of Man-BSA conjugate (91). Lanes: A) Kaleidoscope ladder; B) 
Native BSA; C) Man-BSA glycoconjugate (93). 
 
 
Figure 2.9: Overlay of MALDI-ToF spectra of native BSA and Man-BSA (93) conjugates 
 
  
 68 
 
2.3.2.2 Mannose-BSA (Man-BSA) Glycoconjugate (93) 
The D-mannose hapten (64) was successfully conjugated to the BSA carrier protein on 
an 11 mg scale.  Figure 2.8 shows the SDS-PAGE analysis for the Man-BSA 
conjugate, with a corresponding band shift of approximately 7 KDa as calculated by 
MALDI-ToF MS (Figure 2.9).   MALDI-ToF analysis was carried out and gave an 
average of 20 mannose residues per BSA molecule, giving a conjugation efficiency of 
33%.  Comparing the MALDI-ToF data for the two generated glycoconjugates (Figure 
2.8 and 2.9) revealed a difference between the intensity of the molecular ions for Man-
TetHc (92) and Man-BSA (93) glycoconjugates.  The reason for the reduced intensity in 
the case of the Man-TetHc (92) conjugate is probably due to the poor solubility of the 
TetHc conjugate in the matrix solution.  The shape and distribution of the MS peaks 
collected for both the Man-TetHc (92) and Man-BSA (93) samples indicates complete 
conjugation of all chemically addressable lysine residues.  This is further backed up by 
the SDS-PAGE data, where the presence of distinct bands for the glycoconjugate 
represents complete reaction.  Due to the large excess of hapten in the reaction, it is 
conceivable to assume that all the available lysine residues in both TetHc and BSA are 
successfully conjugated.   
 
2.3.2.3 Glucose and Heptose Glyconjugates 
The conjugation of the D-glucopyranose (69) and 6-deoxy-D-manno-heptopyranose (91) 
haptens to both TetHc and BSA carrier proteins was shown to be both efficient and 
reliable, with the conjugation efficiency (based on lysine coverage (conjugated 
lysine/total lysine content)x100)) remaining consistent throughout the monosaccharide 
series.  MALDI-ToF data for all glycoconjugates is detailed in Appendix 8.1.  The Glc-
TetHc (96) and 6dHep-TetHc (94) monosaccharide antigens were used for antibody 
production by immunisation of sheep (Ig Innovations, South Wales).  The BSA antigens 
were used in the immunological assessment of the TetHc conjugates, the results of 
which are discussed in Section 4. 
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2.3.2.4 Summary of the monosaccharide hapten conjugation to TetHc and BSA 
Glycoconjugate Average Hapten per 
protein molecule 
Conjugation Efficiency 
(conjugated lysine/total 
lysine)x100 
6-Deoxy-mannoheptose-TetHc 
(6dManHep-TetHc) (94) 
23 70% 
6-Deoxy-mannoheptose-BSA 
(6dManHep-BSA) (95) 
19 32% 
Glucose-TetHc (Glc-TetHc) (96) 25 76% 
Glucose-BSA (Glc-BSA) (97) 21 35% 
Mannose-TetHc (Man-TetHc) (92) 23 70% 
Mannose-BSA (Man-BSA) (93) 20 33% 
 
Table 2.1: Monosaccharide hapten-protein conjugates prepared in the current work 
 
2.4 Conclusions 
This chapter described the initial efforts for the synthesis of three monosaccharide 
haptens, 8-(methoxycarbonyl)octyl-α-D-mannopyranoside (64);  8-(methoxycarbonyl) 
octyl-β-D-glucopyranoside (69) and 8-(methoxycarbonyl)octyl-6-deoxy-α-D-manno-
heptopyranoside (91).  The syntheses of these compounds were based on methods of 
traditional carbohydrate chemistry and produced sufficient quantities of material for 
preparation of neoglycocnjugates required for immunological studies.  The 
monosaccharide haptens were successfully conjugated to carrier proteins (TetHc and 
BSA) and used in immunisation trials.  The description of these trials, along with the 
immunological assessment of the monosaccharide antigens is presented in Chapter 4. 
 
However with the view of application of the 6-deoxy-D-manno-heptose (32) materials in 
vaccine development and oligosaccharide synthesis, large quantities (grams) of 
synthetic 6-deoxy-D-manno-heptose (32) will be required.  Therefore, upon the 
successful synthesis of the monosaccharide haptens; efforts were made to streamline 
the synthesis of 6-deoxy-mannoheptose (32) for large scale production.  Different 
strategies for the C-6 extension, along with protecting group-free synthetic routes were 
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investigated.  Some success was achieved to this end; but optimisation of this 
approach is in on-going (Scheme 2.17).   
 
Scheme 2.17: Improved synthesis of 6-deoxy-D-manno-heptose from free nitrile (79).  Reagents and 
conditions: a) NaOH/30% H2O2, rt, 36 h; b) TMSCl, pyridine; 50
o
c – rt, 1 h – 18 h; s) BH3-THF, THF, -
20
o
C – rt, 1 h – 18 h 
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3 Production and characterisation of capsular 
polysaccharide from Burkholderia thailandensis 
3.1 Burkholderia thailandensis 
Access to the CPS-1 of B. pseudomallei (4) is essential for this project, both for the 
analysis of generated antibodies and for the use of the intact polysaccharide and 
fragments thereof, in vaccination trials.  Previous attempts by collaborators to 
extract and purify the CPS-1 from native B. pseudomallei (4) have failed (Section 
3.2.1) and due to the stringent health and safety requirements for working with a 
category III pathogen, it was not possible to work with this bacterium at JIC.  
However, the availability of a non-pathogenic strain of Burkholderia which produces 
CPS-1 (4) would be a great step forward for this work.   
 
Burkholderia thailandensis is a closely related species to B. pseudomallei, but is 
essentially non-virulent1.  The lethal dose in mice for B. thailandensis (E264 strain) 
is 1000 fold greater than that of B. pseudomallei,2 with infection only occurring in 
severely immuno-compromised individuals3,4.  Originally being classified as 
pseudomallei-like, it was not until 1998 when Brett and co-workers proposed that, 
due to the several differences from B. pseudomallei, it be classified as a distinct 
species, B. thailandensis5.   B. thailandensis is usually distinguished from B. 
pseudomallei through its ability to assimilate arabinose4.  Due to its avirulent nature, 
unlike B. pseudomallei, B. thailandensis does not require category III laboratory 
facilities and is not designated as a biosecurity threat.  This makes it much easier to 
study and work with, and as a result it represents a vital tool for studying the 
pathogenesis of B. pseudomallei6.   The lack of virulence of B. thailandensis 
compared to B. pseudomallei is attributed to several genetic differences between 
the two species7, 8.  Research has shown that B. thailandensis (E264) produces a 
structurally similar LPS (100) to B. pseudomallei, but does not CPS-1(4)9.    
 
As discussed in Section 1.1.1.1, the encapsulation of B. pseudomallei with CPS-1 
(4) is essential for virulence of the bacterium.  The absence of CPS-1 (4) in B. 
thailandensis E264, as a result of the lack of the CPS-1 biosynthesis gene cluster, is 
considered to be a predominant factor in its attenuated virulence.  In an attempt to 
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understand more about the avirulent nature of B. thailandensis, Sim and co-
workers10 conducted a pan-genome array study to isolate new strains of B. 
thailandensis.  Within their study they found numerous strains of B. thailandensis 
that differed from the reference E264 strain.  However, two strains were of particular 
note; B. thailandensis E555 – isolated from soil in Indonesia and B. thailandensis 
CDC3015869 – isolated from human sera in USA.  Both of these strains appeared 
to have lost the exopolysaccharide (EPS) gene cluster present in E264 and 
replaced it with a novel genomic region (300 kb), similar to the B. pseudomallei 
CPS-1 gene cluster. Comparison between a wild type B. pseudomallei strain 
(BpK96243) CPS-1 cluster and the novel genomic region found in B. thailandensis 
highlighted a protein similarity of 96% (nucleotide similarity 93.4%)10.   
 
The presence of a B. pseudomallei-like gene cluster was further confirmed using 
immunofluorescence microscopy (Figure 3.1).  B. thailandensis E264 and E555 
were stained with 4,6-diamidino-2-phenylindole (DAPI), a blue fluorescent stain 
which binds to DNA identifying the nucleus of the cell.  Fluorescently labelled 
monoclonal antibodies specific for CPS-1 (4) were used to highlight the presence of 
CPS-1 (4) in the E555 strain, demonstrated by the red staining in Figure 3.1 B.   
 
Figure 3.1: Confirmation of CPS-1 (4) expression by B. thailandensis E555 by 
immunofluorescence analysis.  Cell nucleus stained blue (DAPI) and presence of CPS-1 (4) was 
visualised with a fluorescently labelled anti-CPS-1 antibody (red).  Image adapted from Sim and 
co-workers
10
   
 
Having identified an essentially avirulent strain of Burkholderia which produces the 
1,3-linked 2-O-acetyl-6-deoxy-β-D-manno-heptopyranoside CPS-1 (4), recent data 
from Scott and co-workers11 summarised the potential use of live B. thailandensis 
E555 bacteria as a vaccine candidate against B. pseudomallei infection.  As 
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discussed in the Section 1.2.1, there have been a number of studies looking at the 
use of attenuated B. pseudomallei cells in vaccinations, which have shown to confer 
a degree of immunity in mice12.  However, there are growing safety concerns 
regarding the use of using live-attenuated bacteria in vaccinations13.  The data 
published by Scott and co-workers11 demonstrated that immunisation with live B. 
thailandensis E555 led to the development of protective immunity in mice.  Although 
a significant step forward in this area, the use of bacteria, regardless of its avirulent 
nature, is still not desirable in the eyes of the regulatory bodies.  B. thailandensis 
E555 does however pose a viable option for large scale production of the CPS-1 
(4), which is thought to be the key for the development of a successful vaccine for 
B. pseudomallei14 (Section 1.2.1).  To date all evidence for the production of a 
similar polysaccharide by E555 is based on genomic analysis and immunoblotting 
with monoclonal antibodies raised against B. pseudomallei (K96243) whole cells.  
This chapter details the production, extraction and first full characterisation of the 
capsular polysaccharide from B. thailandensis E555.     
 
3.2 Results and discussion 
3.2.1 NMR characterisation of CPS-1 (4) from B. pseudomallei 
Prior to investigation into the use of B. thailandensis E555 for the production of 
CPS-1 (4), the extraction and purification of CPS-1 (4) from B. pseudomallei was 
attempted by our collaborators at DSTL-Porton Down.  Two samples of 
polysaccharide extract from B. pseudomallei (K96243) were provided by Dr A. Scott 
for characterisation.  One sample had been extracted from B. pseudomallei grown 
in LB-Lennox media and one was extracted from bacteria grown on solid agar as 
part of an investigation into the effects of growth conditions on CPS-1 (4) 
production.  Initial immunological studies indicated the presence of CPS-1 (4) 
through the use of a monoclonal antibody (mAb 41VH12) raised against intact B. 
pseudomallei cells.   
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Figure 3.2: 
1
H NMR (400 MHz; D2O): (A) extract from B. pseudomallei grown on solid media; (B) 
extract from B. pseudomallei grown in LB-Lennox media; (C) 
13
C NMR (100 MHz, D2O) for B. 
pseudomallei grown on solid media. 
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Figure 3.3 demonstrates that the mAb 4IVH12 antibody recognises material in both 
aqueous extractions of heat-inactivated B. pseudomallei (K96243) (cell washings) 
and on the whole bacterial cell. 
 
Figure 3.3: Slot-blot data for 1 B. pseudomallei K96243 cells indicating the presence of CPS-1 
material.   Lanes: A) cell wash; B) cell wash 1/10; C) cell wash 1/100; D) cell wash 1/1000; E) 1 
µg/ml cells; F) 0.1 µg/ml cells; G) 0.01 µg/ml cells; H) blank; I) E. coli cell wash; J) 1 µg/ml E. coli 
cells.  Rows: 1 & 2 (duplicates)) samples made using 1 mg of B. pseudomallei K96243 cells, 
grown under standard conditions.   
 
However, proton and carbon NMR (Figure 3.2) of both polysaccharide samples 
indicated no presence of 2-O-acetyl-6-deoxy-D-manno-heptopyranoside, when 
compared to the literature NMR data15, 16.   This was highlighted by the absence of 
peaks at ca. 4.9 ppm (H-1), 2 ppm (OAc) and 1.8 ppm (H-6b) as shown in the 
1H 
NMR spectrum (Figure 3.2 (A & B)).  13C NMR data (Figure 3.2 C) were collected 
for the polysaccharide extract isolated from cells grown on solid media and further 
confirmed the absence of 2-O-acetyl-6-deoxy-D-manno-heptopyranoside.  The 
absence of a peak at ca 35 ppm, corresponding to the deoxy C-6 carbon in 6-
deoxy-D-manno-heptose (32), confirms that the polysaccharide extracted from B. 
pseudomallei is not CPS-1 (4), as predicted by the antibody experiment (Figure 
3.3). 
 
B. pseudomallei produce 5 other polysaccharides (Section, 1.2.2, Table 1.4) 
alongside CPS-1 (4), many of which have been characterised by NMR.  However, 
due to the complexity of the collected NMR data, the elucidation of the structure of 
the polysaccharide(s) present in this sample would be non-trivial.  However, acid 
hydrolysis and subsequent monosaccharide analysis of the samples was carried out 
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in attempt to identify the monosaccharide components of the B. pseudomallei 
extract. 
 
3.2.1 Monosaccharide component analysis of B. pseudomallei 
polysaccharide extracts 
The B. pseudomallei (K96243) polysaccharide extract (solid media) was subjected 
to exhaustive acid hydrolysis down to monosaccharide components as described in 
experimental Section 7.1.6.  Monosaccharide component analysis was conducted 
using a Dionex ICS-5000 high-performance ion chromatography system with a 
CarboPac PA20 column.  Isocratic elution with 8 mM NaOH was shown to provide 
the best separation of 6 monosaccharide standards (Section 7.1.7.1).  
Monosaccharide analysis of the polysaccharide extract from B. pseudomallei 
(K96243) indicated the presence of at least 5 monosaccharides.  Spiking 
experiments (Figure 3.5) were carried out using both 6-deoxy-D-manno-
heptopyranose (CPS-1) and 6-deoxy-L-talopyranose (LPS) (Figure 3.4) in an 
attempt to detect the presence of either CPS-1 (4) or LPS (100) in this sample.   
O
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Figure 3.4: Structure of LPS of B. pseudomallei (100). 
 
Based on these experiments (Figure 3.5), along with the NMR data, it was possible 
to conclude that neither CPS-1 (4) nor LPS (100) were present.  The capsular 
polysaccharide of B. pseudomallei is the current focus of this study; as a result of 
the lack of this polysaccharide further work into the elucidation of the composition of 
this polysaccharide sample was not carried out.  However, based on the collected 
data it is possible to postulate the presence of multiple polysaccharides, which could 
be further investigated at a later stage if appropriate. 
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Figure 3.5: Monosaccharide component analysis of polysaccharide hydrolysate of B. 
pseudomallei cells grown on solid media. Dionex CarboPac PA 20 column (3 x 150 mm); Dionex 
CarboPac PA-100G Guard column (2 x 50 mm); flow rate 0.25 ml/min; 8 mM NaOH isocratic 
elution; 25
o
C; 10 µl (2 µg) injection; pulsed amperometric detection (Au electrode).  Trace: (A) 
10 µl (2 µg) of B. pseudomallei polysaccharide extract; (B) 10 µl (2 µg) of B. pseudomallei 
polysaccharide extract spiked with 10 µM 6-deoxy-D-manno-heptose (32); (C) 10 µl (2 µg) of B. 
pseudomallei polysaccharide extract spiked with 100 µM 6-deoxy-L-talose. 
 
Owing to the lack of success with the extraction of the capsular polysaccharide by 
collaborators, we were provided with an authentic sample of B. pseudomallei CPS-1 
(4) extracted by the Brett group in South Alabama, for use as a reference sample.  
The collected 1H and HSQC data are shown in Table 3.1 and are consistent with the 
published data17.  
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 H-1 H-2 H-3 H-4 H-5 H-6 H-7 
3)-2-O-Ac-β-D-6dHepp-(1 4.86 5.24 3.92 3.44 3.44 1.67/ 
2.11 
3.71 
 C-1 C-2 C-3 C-4 C-5 C-6 C-7 
 95.9 69.5 78.8 68.9 72.7 33.3 57.9 
 H-1 H-2 H-3 H-4 H-5 H-6 H-7 
 
Table 3.1: 
1
H NMR (400 MHz, D2O) and 
13
C NMR (100 MHz, D2O) data for CPS-1 (4) sample 
isolated from B. pseudomallei
11,13
. 
 
3.2.2 Extraction of CPS-1 from B. thailandensis 
Heiss and co-workers9 showed that the LPS (100) from B. thailandensis E264 is 
structurally identical to that of B. pseudomallei (Figure 3.4).  The multiple genome 
alignment conducted by Sim and co-workers10 demonstrated strain E555 also has 
the potential to produce a similar LPS (100) structure.  As the extraction method for 
the LPS (100) is identical to that of CPS-1 (4), an LPS-deficient mutant of B. 
thailandensis E555 was made in an attempt to simplify the extraction and 
purification procedure for CPS-1. The mutant strain of E555 was provided to us by 
our collaborator Dr A. Scott (DSTL-Porton Down) and was prepared using a 
pKNOCK plasmid18 inserted into the wbiI gene to knock out LPS biosynthesis.  The 
wbiI gene is conserved in many LPS biosynthesis gene clusters and encodes for an 
oligosaccharide dehydratase/epimerase.  Deletion of this gene has been shown to 
abrogate LPS biosynthesis is similar B. pseudomallei strains19 20.     
 
The B. thailandensis E555 ΔwbiI KmR strain was grown overnight at 37 oC in LB-
Lennox media in the presence of kanamycin.  The cells were collected by 
centrifugation and re-suspended in water, the mixture was added to hot aqueous 
phenol and the polysaccharide was extracted according to the method described by 
Burtnick and co-workers15. The crude carbohydrate material was sequentially 
treated with DNase, RNase and Proteinase K to digest DNA, RNA and proteins 
respectively before ultracentrifugation was carried out to isolate the polysaccharide.   
 
After the crude polysaccharide sample had been collected by ultra-centrifugation a 
1H NMR spectrum was acquired (Appendix 8.2) in order to confirm the presence of 
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the polysaccharide.  Despite the crude nature of the polysaccharide sample it was 
possible to see the presence of the 2-OAc peak at ca. 2.0 ppm.  The crude 
preparation was lyophilised to afford 635 mg of extract.  The next stage of the 
procedure was the acid cleavage of the lipid from the polysaccharide.  As described 
in Section 1.2.2.1 the B. pseudomallei CPS-1 is a group III capsule21 determined by 
the presence of the kps loci in the CPS-1 biosynthetic cluster22. Currently the exact 
nature of the lipid anchor of CPS-1 (4) in B. pseudomallei is unknown.  The WcbA 
and wcbO genes in the CPS-1 cluster are known homologs of the LipA and LipB 
proteins in Neisseria meningitidis23.   The LipA and LipB genes were originally 
thought to be responsible for the addition of a phospholipid-anchor onto the CPS-1 
of N. meningitidis.  However, Tzeng et al24 demonstrated that these genes 
(homologs of KpsC and KpsS in E. coli (K5 - 12) were required for the translocation 
and expression of the polysaccharide on the cell surface, but not the addition of an 
anchoring group24.  It is believed (personal communication B. Wren (LSHTM) and N. 
Harmer (Exeter)) that B. pseudomallei CPS-1 (4) is assembled on a glycosylated 
phosphatidylglycerol (101) (Scheme 3.1), similar to that of the group III capsule of S 
pneumoniae25.  Further genetic and biochemical analysis is required in order to 
validate this theory.  However, if this is the case, mild acid hydrolysis of the lipid 
moiety will furnish the glycerol capped polysaccharide (102) and not a reducing 
terminus.  The potential capping of the reducing termini has implications on the 
formation of CPS-1-glycoconjugates and will be discussed further in Chapter 4.      
 
The crude carbohydrate preparation (320 mg) was treated with 2% AcOH for 4 
hours at 100oC to remove the lipid carrier26 (Scheme 3.1) by cleavage of the 
phosphate diester bond.  After 4 hours, the solution was clarified by centrifugation 
(40 mins,  8,000 rcf) and lyophilised to afford the cleaved polysaccharide as a white 
powder (130 mg).   
  
 84 
 
 
Figure 3.6: (A) Refractive index trace of GPC purification of B. thailandensis CPS-1.  Sephadex 
G50 XK 26/40 column, flow rate 0.5 ml/min; eluent MQ-H2O, sample loaded 1.5 ml at 20 mg/ml, 
fractions (collected 40 – 290 ml) collected for 6 min (3 ml).  (B)) results from phenol:sulphuric 
acid assay. 
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Scheme 3.1: Mild acid cleavage of lipid from glycerol-CPS-1 (101).  Reagents and conditions: a) 
2% AcOH, 100 
o
C, 4 h. 
    
Purification of the CPS-1 extract from B. thailandensis E555 ΔwbiI (Bth-CPS-1 104) 
was subsequently achieved using gel permeation chromatography (GPC) to 
separate the cleaved capsular polysaccharide from the lower molecular weight 
impurities (Figure 3.6).  The collected fractions were assayed using the high 
throughput phenol-sulphuric acid assay as described by Masuko et al27 (Section 
7.1.5).  Figure 3.6 shows the refractive index trace from the GPC purification (A) 
and the corresponding phenol-sulphuric acid assay results (B). 
 
The GPC trace (Figure 3.6 (A)) shows three major peaks, with due to its size 
(predicted from western blot ca. 200 kDa)15, the Bth-CPS-1 (104) was expected to 
reside in the initial peak.  The phenol:sulphuric acid assay (Figure  3.6 (B)) 
confirmed that the first peak contained carbohydrate with the second peak 
containing no carbohydrate.  The third peak contained traces of carbohydrate, but 
due to the nature of the purification, this was believed to be low molecular weight 
impurity from the bacteria and media, and were consequently discarded.  The 
carbohydrate containing fractions were combined and lyophilised to afford Bth-CPS-
1 (104) (5 mg from 30 mg) which was characterised using NMR (3.2.4), 
monosaccharide analysis (3.2.5) and capillary electrophoresis (3.2.6).   
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Table 3.2 details the starting and resulting weight from each step of the extraction 
and purification procedure.   
Method Starting Weight (mg) Weight (mg) 
Ultra-centrifugation 4 L of bacterial culture 635 
Acid Hydrolysis 320 135 
GPC purification 30 5 
Table 3.2: Starting and resulting weight from each step of the Bth-CPS-1 (104) extraction and 
purification. 
 
Based on extrapolation of the final weight of polysaccharide it is estimated that 
approximately 100 mg of Bth-CPS-1 (104) could be purified from the 4 litres of 
starting culture.  This number is aligned with an ELISA estimate for Bth-CPS-1 (104) 
concentration on live B. thailandensis E555 ΔwbiI cells (24 µg/ml) which was 
performed by collaborators at DSTL-Porton Down, subsequent to our extraction and 
NMR analysis (Table 3.3). 
Sample Average CPS-1 
concentration (µg/ml) 
B. thailandensis E555 (live) 22 
B. thailandensis (Heat-killed) 8 
B. thailandensis E555 ΔwbiI (live) 24 
B. thailandensis E555 ΔwbiI (Heat-killed) 5 
 
Table 3.3: Concentration of Bth-CPS-1 (104) present in B. thailandensis E555 cells before and 
after heat-kill treatment as determined by ELISA.  (Personal communication, Marc Bayliss - 
DSTL). 
 
In order to determine whether the lipid cleavage step had afforded a reducing 
terminus, or as expected the Bth-CPS-1 (104) molecule is capped with glycerol the 
purified polysaccharide was reductively aminated with 8-aminopyrene-1,3,6-
trisulfonic acid (105) (APTS) (Scheme 3.2). The reaction was purified by means of a 
30% mono:bis (38:2) acrylamide gel.   
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Scheme 3.2 Reductive amination of carbohydrate and APTS (105).  Reagents and conditions: a) 
APTS, NaCNBH3, 0.2M AcOH, THF, 37
o
C 18 h. 
 
Fluorescence imaging of the gel suggested that traces of CPS-1 material had been 
successfully labelled with APTS (105) (Figure 3.7).  Unfortunately, owing to the size 
of the Bth-CPS-1 (104), further analysis of this reaction was not trivial.  This result 
demonstrates that a small population of Bth-CPS-1 (104) material may not be 
capped with glycerol and may be available for conjugation by reductive amination.  
However, it may be that the band corresponds to a small proportion of uncapped 
Bth-CPS-1 (104), or an unrelated polysaccharide (Section 3.2.3), and does not 
disprove the current hypothesis that Bth-CPS-1 (104) is capped with glycerol.           
 
Figure 3.7: Fluorescence image of APTS-labelled CPS-1 confirm the presence of a reducing 
terminus.  30% mono:bis (38:2) acrylamide Tris-borate gel [100 mM; pH 8.2]. 
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Figure 3.8: Comparison of 
1
H (400 MHz, D2O) (Red) spectrum from the authentic CPS-1 from B. 
pseudomallei (4) and (blue) the 
1
H spectrum of the polysaccharide sample extracted from B. 
thailandensis E555 ΔwbiI (104).   
 
 
Figure 3.9: NOESY spectra B. thailandensis Bth-CPS-1 (104) sample.  2-O-acetly-6-deoxy-D-
manno-heptopyranose signals (black) and D-mannopyranose signals (red) with NOE coupling 
pattern illustrated. 
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3.2.3 NMR characterisation of CPS-1 extract from B. thailandensis E555 
ΔwbiI  
Comparison of the 1H NMR spectra (Figure 3.8) for the authentic B. pseudomallei 
CPS-1 (4) sample (obtained from the Brett group15) and Bth-CPS-1 (104) indicated 
that E555 produced the same 3)-2-O-Ac-β-D-6dHepp-(1 polymer (4) as the 
native B. pseudomallei.  The two proton spectra are identical with all of the 
diagnostic peaks aligned, indicating the same structure in both compounds.  The 
other major spin system (highlighted *) present in the NMR data was attributed to an 
α-1,3-mannan polymer (106), which is known to be produced by both B. 
pseudomallei and B. mallei  strains17.  A NOESY experiment (Figure 3.9) was 
performed to confirm the identity of the mannan polymer. 
 
 
Figure 3.10: Structure of α-1,3-mannan polymer (106) that was co-purified with Bth-CPS-1 from 
B. thailandensis E555 ΔwbiI. 
 
The NOE coupling (Figure 3.9) demonstrates (M-1,2; M-1,3 and M-2,3 pattern as 
shown) that the main impurity belongs to a distinct polysaccharide which 
corresponds to the published data for the α-1,3-D-mannan (106)17.  The pattern also 
shows that there is no discernible coupling between the B. thailandensis E555 ΔwbiI  
2-O-acetyl-6-deoxy-D-manno-heptose polymer (104) and the α-1,3-D-mannan 
polymer (106).  The current hypothesis in the field is that these are two separate 
polysaccharides produced by the bacteria17 (based on NOE patterns), however, to 
date, there has been no conclusive evidence of this point.  Further work (Section 
3.3) is needed to prove whether these are in fact two separate homopolymers or a 
blockwise-assembled heteropolymer.  HSQC data (Figure 3.11) were also collected 
and the overlay of the reference B. pseudomallei CPS-1 (4) sample and the B. 
thailandensis E555 ΔwbiI Bth-CPS-1 (104) mutant (Figure 3.11) further confirms the 
structure of the CPS-1.  Corresponding 13C data were also collected and are shown 
in the appendix (Appendix 8.3). 
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Figure 3.10: HSQC (D2O) spectra for CPS-1 samples from (left): B. pseudomallei CPS-1 (4) and 
(right) B. thailandensis E555 ΔwbiI CPS-1 (104) and overlay (Bottom): Red CPS-1 (4); Blue Bth 
E555 ΔwbiI E555 CPS-1 (104).  
 
The presence of the α-1,3-D-mannan (106) polymer is unique to Burkholderia 
species, that produce 2-O-acetyl-6-deoxy-D-manno-heptopyranse CPS-1 (4) (B. 
pseudomallei) and (104) (B. thailandensis E555 ΔwbiI).  Studies on the LPS and 
OPS produced by B. thailandensis E264 by Heiss and co-workers9 clearly showed 
the lack of the α-1,3-D-mannan polymer (106) in the polysaccharide extract of this 
bacterium.  The only noticeable genomic difference between the E264 and E555 
strains (disregarding the taurine metabolism genome cluster and lipocalins present 
in E555) is the presence of the Bps-like CPS-1 cluster10.  This suggests that 
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enzymes for the production of both the mannan polymer (106) and CPS-1 (4 and 
104) are encoded on the same Bps-CPS like gene cluster.   
 
B. thailandensis (E555) represents the third species of Burkholderia which produces 
the 2-O-acetyl-6-deoxy-D-manno-heptose capsule (4) along with B. pseudomallei 
and B. mallei.  All three of these species produce both the CPS-1 (4) and α-1,3-
mannan (106) polysaccharides, but in different ratios, as shown in Table 3.4.   
Bacterial Species CPS-1 (α-1,3)-D-mannan 
B. pseudomallei 93%a (82%)b (72%)c 
7%a (18%)b 
(28%)c 
B. thailandensis E555 
(ΔwbiI) 
73%b 27%b 
B. mallei 52%a 48%a 
 
Table 3.4: Polysaccharide content of the three different Burkholderia species. A) Data taken 
from Heiss and co-workers
17
  b) NMR integration value from authentic CPS-1 sample 1 Paulr 
Brett); c) NMR integration value for authentic CPS-1 sample 2 (Paul Brett). 
 
The data displayed for B. pseudomallei were taken from Heiss and co-workers17 
compiled from both NMR data and monosaccharide composition analysis (gas 
chromatography) to determine the polysaccharide ratio of 93:7 (CPS-1:mannan).  
However, the NMR data that was collected (JIC) on two separate polysaccharide 
samples that were provided the Brett lab (in brackets) were distinctly different to the 
data shown in reference17 (Figure 3.12).  Based on integration of the H-1 signals in 
the NMR spectra the mannan (106) accounts for 18% of polysaccharide sample 1 
and 28% of polysaccharide sample 2 (proton NMR in Appendix 8.4).  This indicates 
that there may be batch to batch variability in the composition of the CPS-1 
polysaccharide(s).  The ratio of mannan:CPS-1 may depend on the production 
environment of the bacteria; media, light, temperature and oxygen levels have all 
been shown to affect the composition of different bacterial polysaccharides28 29. 
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Figure 3.12: 
1
H NMR (400 MHz, D2O) of B. pseudomallei polysaccharide extract.  (A) 
Polysaccharide extract from B. pseudomallei extracted by Brett lab and sent to JIC; (B) 
Reproduced with permissions, Copyright Elsevier from Heiss and co-workers
17
. 
  
There is also a disparity between the monosaccharide analysis and the NMR 
integration ratios in the B. thailandensis E555 ΔwbiI mutant data.  NMR integration 
estimates the mannan content to be as high as 27%, whereas monosaccharide 
analysis estimates the mannan content to only be ca. 10% (Figure 3.16).  It is not 
only the ratio of CPS-1:mannan that differs between the species, the CPS-1 (4) in B. 
pseudomallei is estimated to be ca. 200 kDa in length, where as that of B. mallei is 
estimated to be 145 kDa based on SDS-PAGE and alignment with protein 
standards.  Analysis of the B. thailandensis E555 ΔwbiI capsule (104) by Scott and 
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co-workers (Figure 3.13) showed that it was of a similar size (200 kDa) to that of B. 
pseudomallei (4) (K96243)11. 
 
Figure 3.13: Immunoblot of CPS-1 produced by (A) B. pseudomallei (4) (K96243); (B) B. 
thailandensis E555 ΔwbiI (98) and (C) B. thailandensis E263. Reproduced with permission from 
Scott and co-workers
11
.    
 
3.2.4 Monosaccharide analysis of CPS-1 extracted from B. thailandensis 
E555 (ΔwbiI pKNOCK-KmR mutant) 
Bth-CPS-1 (104) was subjected to full acid hydrolysis according to general protocol 
7.1.6.  The acid hydrolysed Bth-CPS-1 (104) extract was injected onto the Dionex 
system as before (Figure 3.14).  Of the three peaks present in the Bth-CPS-1 (104) 
sample, two have been identified as 6-deoxy-D-manno-heptopyranose (A) and D-
mannopyranose (B), both of which were elucidated using spiking experiments 
(Figures 3.15 & 3.16). 
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Figure 3.14: Chromatogram of CPS-1 extract monosaccharide analysis.  Dionex CarboPac PA 
20 column (3 x 150 mm); Dionex CarboPac PA-100G Guard column (2 x 50 mm); flow rate 0.25 
ml/min; 8 mM NaOH isocratic elution; 25
o
C; 10 µl (2 µg) injection; pulsed amperometric 
detection (Au electrode).   
 
 
Figure 3.15: Zoomed in region of the Bth-CPS-1 (98) monosaccharide analysis.  (Blue) Bth-CPS-
1 sample; (Black) Bth-CPS-1 sample spike with 25 µM 6-deoxy-D-manno-heptopyranose 
standard. Dionex CarboPac PA 20 column (3 x 150 mm); Dionex CarboPac PA-100G Guard 
column (2 x 50 mm); flow rate 0.25 ml/min; 8 mM NaOH isocratic elution; 25
o
C; 10 µl (2 µg) 
injection; pulsed amperometric detection (Au electrode).   
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The increase in relative peak height when the Bth-CPS-1 (104) sample was spiked 
with the heptose monosaccharide (25 µM) confirms the main structural component 
of this polysaccharide is 6-deoxy-D-manno-heptopyranose (32) (Figure 3.15).  The 
D-mannopyranose experiment below (Figure 3.16) shows an increase in the 
integration of the smaller peak when D-mannose is co-injected with the sample, thus 
confirming the identity of the peak as D-mannose.     
 
Figure 3.16: Monosaccharide analysis of CPS-1.  (Blue) CPS-1 sample; (Black) CPS-1 sample 
spiked with 10 µM mannose standard. Dionex CarboPac PA 20 column (3 x 150 mm); Dionex 
CarboPac PA-100G Guard column (2 x 50 mm); flow rate 0.25 ml/min; 8 mM NaOH isocratic 
elution; 25
o
C; 10 µl (2 µg) injection; pulsed amperometric detection (Au electrode).   
 
The identity of the first peak (Figure 3.14, peak C) is still unknown, experiments 
(data not shown) were run to determine whether the peak corresponded to 6-deoxy-
L-talose, one of the constituents of B. thailandensis LPS (100) or L-rhamnose, part 
of the CP-2 polysaccharide (Section 1.2.2).  Both of these experiments proved that 
neither 6-deoxy-talopyranose of rhamnopyranose were present in the Bth-CPS-1 
(104) sample, indicating the lack of LPS (100) or CP-2 in the polysaccharide extract  
The peak accounts for 3-4% of the trace and cannot be seen in NMR studies.  
Owing to this it was left unidentified for the purposes of the current study. 
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3.2.5 Partial acid hydrolysis and capillary electrophoresis experiments 
As part of the vaccine development project the use of both intact CPS-1 (4) and 
fragments of the CPS-1 are to be investigated.  After successful extraction and 
purification of Bth-CPS-1 (104) from the non-pathogenic strain B. thailandensis 
E555 ΔwbiI the partial acid hydrolysis of Bth-CPS-1 (104) backbone was attempted.  
A search of the literature found several methods for the incomplete hydrolysis of 
polysaccharides30 31.  Di and co-workers32 carried an extensive study into the effects 
of temperature, strength and volume of acid used on partial hydrolysis of 
polysaccharides from fruiting spores of Lingzhi mushrooms.  It was concluded that 1 
mL of 0.75 M H2SO4 in a sealed vial at 85
oC were the optimal conditions for partial 
hydrolysis of polysaccharides.   BaCO3 was used for the neutralisation of the acid 
due to the poor solubility of BaSO4, which is formed during the neutralisation and 
can be easily removed by centrifugation.  
 
The next stage was to label the crude oligosaccharide preparation with a fluorescent 
tag for analysis with capillary electrophoresis (CE). Previously, the Field lab has 
demonstrated the high sensitivity and resolution of CE can be implemented for the 
analysis of carbohydrates33.  CE analysis separates ions based on their 
electrophoretic mobility with the use of a strong voltage and laser-induced 
fluorescence detection (LIF)34.  In order for the neutral oligosaccharides to be 
compatible with CE analysis they must first be labelled with a charged fluorescent 
tag.   The reductive amination of carbohydrates with APTS (105) (Scheme 3.2) for 
the labelling of carbohydrates for CE has been shown to be highly efficient and 
reproducible (88% yield for maltose)35. 
 
The oligosaccharide fragments were successfully labelled with APTS (105) as 
described in experimental Section 7.3.4.  After purification by gel electrophoresis the 
APTS labelled oligosaccharides were extracted and injected onto the CE. 
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Figure 3.17: CE trace of APTS labelled CPS-1 oligosaccharides.  (Top) Glucose ladder (Bottom) 
CPS-1 oligosaccharides labelled with APTS. 
 
The CE trace above (Figure 3.17) demonstrates the successful partial hydrolysis of 
the native Bth-CPS-1 (104) using 0.75 M H2SO4, to afford CPS-1 oligosaccharides 
ranging from DP 7 to ca. 30.  In the dp 7-15 region (highlighted in red box) the 
resolution is sufficient to pick up two distinct oligosaccharides for each peak.  Due to 
the mild conditions needed for the partial hydrolysis full deacetylation of the 
polysaccharide would not occur resulting in a mixture of O-acetylated and de-O-
acetylated species, giving rise to the double peaks.  In order to verify this, the 
sample was de-O-acetylated with hydrazine monohydrate at elevated temperature 
and run on the CE again.  The contraction of the two peaks into a single peak 
confirmed the presence of both O-acetylated and de-O-acetylated residues in the 
oligosaccharide polymers (Figure 3.18).   
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Figure 3.18: CE trace for the deactylation of Bth-CPS-1 oligosaccharides. (Top) fully deactylated 
CPS-1 oligosaccharides. (Bottom) Mixed CPS-1 oligosaccharides. 
 
The CE trace of the lower bands (Sample 2, Section 7.3.4) indicated the presence 
of lower weight (dp 1-6) oligosaccharides from the mild acid hydrolysis.  There is 
currently work on-going to develop the acid hydrolysis procedure to enable tailoring 
of the hydrolysis to produce products of more defined length. 
 
3.3 Conclusions 
The lack of CPS-1 (4) in either B. pseudomallei extracts, both of which reacted 
positively with the mAb 4IVH12 raised against heat-killed B. pseudomallei cells, 
highlights issues regarding the use of antibody identification of CPS-1 (4).  During 
their work on the characterization of the B. pseudomallei (K96243) CPS-1 coding 
region, Cuccui and coworkers21 demonstrated that the 4V1H12 mAb  was a reliable 
tool for the detection of CPS-1 (4) in a range of B. pseudomallei mutants.  We have 
also shown that the antibody is reactive to purified CPS-1 extracted from both B. 
pseudomallei (4) and B. thailandensis E555 ΔwbiI (104).  However, owing to the 
results described in Section 3.2.1, the use of the mAb 4IVH12 is not sufficient for 
the confirmation of extractable quantities of material.  This is probably down to the 
inherent sensitivity of the antibody detection versus NMR and monosaccharide 
analyses.  It is assumed that there are small traces of the CPS-1 (4) material 
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present in this sample, which can be detected by the blot technique but cannot be 
purified and characterised by NMR.   
 
The fact that no CPS-1 (4) can be purified from these samples can possibly be 
attributed to the heat-kill treatment which was carried out during the culturing of the 
bacteria.  Owing to the stringent health and safety requirements of working with B. 
pseudomallei at DSTL-Porton Down, the bacteria must be heated to 80oC for 4 
hours before being sterility checked.  Subsequently to our NMR analysis 
collaborators on the growth optimisation of B. thailandensis E555 ΔwbiI has shown 
there is a dramatic reduction in the quantity of CPS-1 (4 & 104) on the bacteria post 
heat-kill treatment (Table 3.3). 
Sample Average CPS-1 
concentration (µg/ml) 
B. thailandensis E555 (live) 22 
B. thailandensis (Heat-killed) 8 
B. thailandensis E555 ΔwbiI (live) 24 
B. thailandensis E555 ΔwbiI (Heat-killed) 5 
 
Table 3.3: Concentration of Bth-CPS-1 (104) present in B. thailandensis E555 cells before and 
after heat-kill treatment as determined by ELISA.  (Personal communication, Marc Bayliss - 
DSTL). 
 
During the heat-kill procedure it is believed that CPS-1 (4) is shed into the media, as 
the cells are harvested by centrifugation, it is expected that the majority of the CPS-
1 (4) is lost at this stage in the supernatant, which was discarded.  In order for the 
successful purification of CPS-1 (4) from B. pseudomallei bacteria, the supernatant 
from the heat-kill procedure must be retained and analysed for polysaccharide 
content.   
 
This chapter has discussed the first structural characterisation of the 3)-2-O-Ac-β-
D-6dHepp-(1 capsular polysaccharide (4) of B. pseudomallei produced by a 
similar non-pathogenic strain, B. thailandensis E555 ΔwbiI (Bth-CPS-1 (104)).   
Owing to the size (ca. 200 kDa) of the capsular polysaccharide isolated from the 
Burkholderia strains, in depth characterisation and analysis of the structure of the 
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intact polysaccharide is non-trivial.  NMR data has provided some insight into the 
structural similarities between the Bth-CPS-1 (104) isolated from B. thailandensis 
E555 ΔwbiI and the CPS-1 (4) previously isolated from both B. pseudomallei and B. 
mallei.  Based on these findings it can be concluded that the main structural 
component of this polymer is based on the 6-deoxy-mannoheptopyranose (32).  
However, during the course of the NMR characterisation a number of 
inconsistencies have been observed.  The presence of an α-1,3-mannan polymer 
(106) has shown to be present in all CPS-1 samples to a varying degree.  It has 
been shown that this variation is not solely based on strain, but also as a result of 
batch to batch variability from the same strain.  Full extraction, purification and 
characterisation of the mannan polymer has, as yet not been achieved.  If, as 
currently believed in the field, these are two separate polymers, the role of the α-
1,3-mannan (106) polymer on the virulence of B. pseudomallei needs to be 
investigated.  Currently the CPS-1 ‘specific’ monoclonal antibodies used in 
Burkholderia research have been raised against whole Burkholderia cells.  These 
antibodies have been shown on numerous occasions to be reactive towards purified 
CPS-1 samples that contain a degree of mannan polymer (106), making it unclear 
which epitope the antibodies are in fact binding to.  If the mannan component is 
dominant in immune recognition, the use of synthetic oligosaccharide fragments of 
CPS-1 derived antibodies may not be sufficient to provide protective immunity 
against B. pseudomallei.   
 
With regard to the use of CPS-1 (4) conjugate vaccines, the presence of the 
mannan polymer (106) is less complex.  In fact having both the CPS-1 (4) and 
mannan (106) polysaccharides conjugated to a carrier protein may be 
advantageous for antibody generation and subsequent protection.  From a 
regulatory point of view, however, it may be essential for full characterisation of all 
constituent parts of the glycoconjugate before clinical trials are established.  To this 
end, work needs to be under-taken to gain more insight into the nature and role of 
the mannan (106) component.  As previously stated, the only discernible difference 
between B. thailandensis E264 and E555 is the presence of the B. pseudomallei 
CPS-1-like genome cluster.  This cluster is assumed to be responsible for the 
synthesis of both CPS-1 and mannan polysaccharide.  Mutation of the three 
putative glycosyltransferases (WcbB, WcbE and WcbH)21 in the CPS-1 cluster 
coupled with extraction and structural analysis of polysaccharide products could 
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help to elucidate the nature of the mannan polymer (106).  A further characterisation 
of the mAb 4IVH12 monoclonal antibody is discussed in Section 4.4.3 & 4.4.4. 
However, the successful production of CPS-1 in an avirulent strain of bacteria is a 
great step forward in the vaccine development program for B. pseudomallei.  
Through the use of B. thailandensis E555 ΔwbiI the large scale fermentation of Bth-
CPS-1 (104) is now a possibility, enabling its use in immunisation trials.  It has been 
shown that the capsule can be partially hydrolysed to produce oligosaccharide 
fragments; both O-acetylated and de-O-acetylated which are suitable for 
conjugation.  Currently there is on-going work into the optimisation of the partial acid 
hydrolysis of the polysaccharide and the conjugation of Bth-CPS-1 (104) and 
corresponding oligosaccharide fragments for immunisation trials.  The Bth-CPS-1 
(104) was then taken forward for use in the immunological assessment of the mAb 
4IVH12 monoclonal antibody and the 6dHep-TetHc (95) derived polyclonal 
antibodies.   
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4 Chapter 4: Immunological assessment of anti-
monosaccharide antibodies 
This chapter describes the preliminary immunological assessment of the anti-
monosaccharide polyclonal sheep sera.  Enzyme-linked immunosorbent assays 
(ELISAs) and slot-blot techniques were used to determine the activity and specificity 
of the polyclonal sera to the cognate monosaccharide.  Based on the results 
obtained, four more monosaccharide haptens were developed in an attempt to 
further investigate the antigenic potential of monosaccharide haptens. Analysis of 
anti-CPS-1 monoclonal antibody (mAb 4IVH12) and the 6dHep-TetHc polyclonal 
serum with the Bth-CPS-1 extract (106) was also carried out. 
  
4.1 Generation of polyclonal antibodies 
In collaboration with Ig Innovations, polyclonal antibodies to the 6dHep-TetHc (94) 
and Glc-TetHc (96) antigens were raised in sheep (2 sheep per antigen).  Sheep 
were chosen as the animal model due to previous experience of industrial 
collaborators, Mologic, who have experienced a number of antigens which have 
successfully generated antibodies in ovine systems when other systems have failed 
(eg. mice and rabbits). Mologic have demonstrated the successful generation of 
ovine antibodies against a broad range of antigens, including carbohydrates and it 
was felt that this model offered the highest chance for success for the 
monosaccharide antigens (personal communication Mark Davis, Mologic).   
 
Two sheep per antigen were immunised as described in experimental section 7.4.1; 
the schedule for the immunisations is described below (Figure 4.1).  Serum samples 
from 0, 6, 10, 14 & 18 weeks were collected and analysed for immunological 
activity. 
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Action Description Week(s) 
Pre-immune serum 
collection 
Pre-immune sample blood collected, 
serum isolated from clot via 
centrifugation 
0 
Primary immunisation 
0.5 mg of antigen for 2 sheep; emulsion 
made up with saline and Freund’s 
Complete Adjuvant (CFA) 
6 x injection sites per sheep 
0 
Re-immunisation 
0.25 mg of antigen for 2 sheep, 
emulsion made up with saline and 
Freund’s Incomplete Adjuvant (IFA) 
6 x injection sites per sheep 
4, 8, 12,16 
Bleeds 
Sample blood collected, serum isolated 
from clot via centrifugation 
6, 10, 14. 18 
 
Figure 4.1: Immunisation schedule for antibody generation at Ig-innovations. 
 
The primary immunisation included Freund’s Complete Antigen (CFA) which 
comprises a water/oil emulsion in the presence of inactivated Mycobacterial cells.  
CFA is used as an immunopotentiator and is known to enhance the reaction of a 
given antigen1.  The use of adjuvants, particularly those containing bacterial cells 
(CFA), is strictly regulated in antibody generation due to the negative effects on the 
host2 3.  For this reason, re-immunisations were performed with the addition of 
Freund’s Incomplete Adjuvant (IFA), which is based simply on a water/oil emulsion.  
Emulsion based adjuvants such as CFA/IFA act as ‘depot’ adjuvants, which protect 
the antigen from degradation and expulsion from the host system along with dilution 
effects.  In doing this the adjuvant achieves slow-release of intact antigen extending 
the period of exposure to the host’s immune system.  This results in the continual 
activation of the antibody generating cells leading to improved levels of antibody 
production1. 
 
4.1.1 Kinetics of the immune response 
Re-immunisation with an antigen is required for the development of cellular memory 
by the immune system and the generation of highly specific antibodies.  Upon initial 
immunisation (priming), the generation of antibodies is slow, with a latent period of 
up to 2 weeks, depending on the species, after which time the production of 
antibodies begins.  IgM (macroglobulin) is typically the first class of antibody 
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produced during an immune response, followed by IgG.  Even with the use of 
adjuvants, initial antibody production generally ceases entirely after 3-4 weeks4.  
However, re-immunisation with the same antigen leads to constant stimulation of 
the immune system and the development of a stronger immune response.  After the 
priming event, the latent period is much shorter with the secondary immunisation 
and the amount, type and quality of antibodies is increased.  There is also an 
increase in class switching from IgM to IgG, with IgG antibodies appearing in much 
higher concentrations (Figure 4.2)5.   
 
Figure 4.2: Kinetics of an immune response.  The latent period is the time taken for B-cells to 
come into contact with antigen and start producing antibodies.  The length of the latent period 
is dependent on the species, antigen and adjuvant used.  Figure reproduced with permissions 
from Immunology: a Short Course Copyright John Wiley and Sons 2009
5
. 
 
Affinity maturation of the antibodies6 occurs as a result of a B-cell selection process.  
The differentiation of B-cells into antibody producing plasma cells is triggered by the 
binding of B-cells to the antigen.  As the concentration of antibody increases in the 
blood there is greater competition between the B-cells and antibody for the free 
antigen.  As a result only the B-cells with high-affinity receptors located on their 
surface will be able to bind to the antigen and thus differentiate into plasma cells.  
This preferential selection of B-cells leads to the development of antibodies with 
high antigen affinity5, 7. 
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Figure 4.3: ELISA of Glc-TetHc sera (0, 6, 10, 14 & 18 W) activity against Glc-BSA (50 µg/ml) 
unless specified, on the plate.  Legend: (blue) 0 week Glc-TetHc sera; (red) 6 week Glc-TetHc 
sera; (green) 10 week Glc-TetHc sera; (purple) 14 week Glc-TetHc sera; (black) 18 week Glc-
TetHc sera and (orange) 10 week Glc-TetHc sera against BSA (50 µg/ml) on plate.  Data were 
recorded in triplicate using standard ELISA protocol 7.4.2.1. 
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4.2 Results and discusion 
4.2.1 ELISA analysis of glucose derived antibodies  
ELISA analysis was carried out on the glucose antigen (96) derived sera (Figure 
4.4) in order to determine the activity and specificity of the generated antibodies. 
O
OH
HO
HO
OH
O N
H
O
TetHc
96 25  
Figure 4.4: Structure of Glc-TetHc antigen 
 
Figure 4.3 demonstrates that the Glc-TetHc derived sera have activity towards the 
Glc-BSA glycoconjugate immobilised on the surface of the ELISA plate.  Both 
negative controls [pre-immune (blue) and 10 W – BSA (orange)] showed some 
activity towards the Glc-BSA antigen.  The activity of the pre-immune samples 
(blue) demonstrates the native background binding of the sheep sera to the Glc-
BSA conjugate, prior to immunisation with target antigen.  The 10 week-BSA activity 
(orange) demonstrates the background binding of the sheep sera to the carrier 
protein (BSA) used during the ELISA analysis.  The activity of the 10 W serum 
against the BSA control was comparable to that of the pre-immune serum towards 
the Glc-BSA conjugate.  This demonstrates that polyclonal sheep sera do not have 
pre-existing activity towards the BSA carrier or the Glc-BSA conjugate. As a result, 
any observed activity of the immune sera (6, 10, 14, 18 weeks) above this baseline 
activity (blue and orange) represents specific activity of the polyclonal sera towards 
the target hapten (69).  All of the immune sera (6, 10, 14,18 weeks) were shown to 
have activity which was significantly higher than the baseline activities (blue and 
orange), demonstrating the specific binding to the D-glucose hapten (69).  At high 
sera concentrations (dilution factor 1 in 100 – 1 in 800) there is a distinct difference 
in response between the 6 (red) week sample and the later bleeds (10 (green), 14 
(purple) & 18 (black) weeks).  This increase in response is a result of a longer time 
period between immunisation and bleed and is consistent with antibody affinity 
maturation.  After 10 W the antibody response appears to indicate that antibody 
maturation is complete.  Figure 4.3 shows data for the response of combined 
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Figure 4.5: ELISA of Glc-TetHc sera (0 & 10 weeks) activity against Glc-BSA (50 μg/ml) or Man-
BSA (50 μg/ml) on the plate.  Legend: (blue) 0 weeks Glc-TetHc sera against Glc-BSA on plate; 
(green) 0 weeks Glc-TetHc sera against Man BSA on plate; (red) 10 weeks Glc-TetHc sera 
against Glc-BSA on plate; (black) 10 weeks Glc-TetHc sera against Man-BSA on plate.  Data 
was recorded in triplicate using standard ELISA protocol 7.4.2.1.  
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Glc-TetHc sera from two sheep (CF1497 and CF1498); ELISA experiments were 
also carried out on the individual serum samples and the results were shown to be 
analogous to the combined data (Appendix 8.5)  and as a result all subsequent 
ELISA were carried out using combined sera from both animals.   
 
In order to determine whether there was any antibody specificity for the 
monosaccharide motif, the combined 10 week Glc-TetHc serum was analysed 
against both the Glc-BSA and Man-BSA conjugates (Figure 4.5).  The pre-immune 
serum was again shown to have low background activity towards the Glc-BSA 
(blue) and Man-BSA (green) conjugates, indicating that any observed activity of the 
sample sera (10 weeks) was as a result of the polyclonal sera binding to the target 
hapten.  The 10 week sera were selected at this stage as it gave the strongest 
response against the Glc-BSA in previous ELISA experiments (Figure 4.3).  The 10 
week serum was shown to have a slightly reduced activity towards the Man-BSA 
conjugate (black) when compared to the Glc-BSA activity (red), at high sera 
concentration (1 in 100 – 1 in 3200 dilution factor).  This indicated that the Glc-
TetHc polyclonal antibodies have limited selectivity towards the D-glucose hapten 
(69) over D–mannose hapten (64).   
 
Competition ELISA experiments were designed in order to further investigate the 
activity and specificity of the polyclonal sera.  
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Figure 4.6: Competition ELISA results from Glc-TetHc (0/10 Week; 1 in 1600 dilution) sera against Glc-BSA (50 µg/ml) on plate pre-incubated with serial 
dilutions of: A) octyl β-D-glucopyranoside; B) D-glucopyranose and C) methyl β-D-glucopyranoside.  Legend: (Red) 10 Weeks sample 1 in 1600 dilution; 
(Blue) 0 Weeks sample 1 in 1600 dilution.  Experiment was run according to standard competition ELISA protocol 7.4.2.1.  
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4.2.1.1 Competition ELISAs with Glc-TetHc polyclonal sera 
Glc-TetHc sera (0 (blue) & 10 (red) weeks, 1 in 1,600 dilution) were pre-incubated 
with serial dilutions of a) octyl β-D-glucopyranoside; b) D-glucopyranose and c) 
methyl β-D-glucopyranoside (Figure 4.6 (A-C)).  The competition ELISA 
experiments with D-glucopyranose and methyl β-D-glucopyranoside suggest that the 
antibodies are unable to bind to the free monosaccharides in solution (Figure 4.6 
(B-C)).  Octyl β-D-glucopyranoside (4.6 A) shows good competition for binding with 
the 10 week (red) Glc-TetHc serum.  There is also inhibition of the pre-immune 
serum (blue) in the presence of octyl β-D-glucopyranoside at high concentration.  
This may indicate that the octyl β-D-glucoside has a general inhibition effect on 
antibody binding as a result of its surfactant properties.  However, octyl β-D-
glucoside is routinely used as a detergent in immunofluorescence assays at 
concentrations of 0.5% - 0.1% (17- 3 mM) to remove background antibody binding 8.  
As such, it is not expected that the presence of octyl β-D-glucoside as a surfactant is 
sufficient to impact on specific antibody binding, indicating that the combined 
monosaccharide-linker motif is required for binding of the polyclonal antibodies to 
the target D-glucose hapten (69).  The fact that the generated antibodies are shown 
to bind to octyl β-D-glucopyranoside could explain the activity of the Glc-TetHc sera 
towards the Man-BSA glycoconjugate (93) (Figure 4.5).  Polyclonal serum contains 
multiple antibodies with different specificities and binding epitopes, and as such, 
antibodies raised against the linker may be present.  This would lead to positive 
binding of the serum to the Man-BSA glycoconjugate, thus masking any 
monosaccharide specific antibodies.  
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Figure 4.7:  Man-BSA and Glc-BSA competition ELISA results from Glc-TetHc (0/18 week; 1 in 
1600 dilution) sera against A) Glc-BSA (50 µg/ml) and B) Man-BSA (50 µg/ml) on plate pre-
incubated with serial dilutions of Man-BSA (0 W – green and 18 W – purple) and Glc-BSA (0W – 
blue and 18 W – red).  Legend: (blue) 0 weeks 1 in 1600 dilution Glc-TetHc sera pre incubated 
with Glc-BSA; (red) 18 weeks 1 in 1600 dilution Glc-TetHc sera pre incubated with Glc-BSA: 
(green) 0 weeks 1 in 1600 dilution Glc-TetHc sera pre incubated with Man-BSA; (purple) 18 
weeks 1 in 1600 dilution Glc-TetHc sera pre incubated with Man-BSA.  Experiment was run 
according to standard competition ELISA protocol 7.4.2.1 and results were recorded in 
triplicate. 
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0.800
250502552.50.50.250.050.0250
A
4
0
5
 
[Glc/Man-BSA] µg/ml 
A) Glc/Man-BSA Competition (Glc-BSA on Plate) 
0 W (Glc-BSA) 18 W (Glc-BSA) 0 W (Man-BSA) 18 W (Man-BSA)
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0.800
250502552.50.50.250.050.0250
A
4
0
5
 
[Glc/Man-BSA] µg/ml 
B) Glc/Man-BSA Competition (Man-BSA on Plate) 
0 W (Glc-BSA) 18 W (Glc-BSA) 0 W (Man-BSA) 18 W (Man-BSA)
 115 
 
Competition experiments with Glc-BSA (97) and Man-BSA (93) (Figure 4.7A and B) 
demonstrate that the Glc-TetHc derived sera possess some degree of specificity 
towards the D-glucose hapten (69).  Both the competition experiments with the 18 
week Glc-TetHc serum and Glc-BSA glycoconjugate (red) show positive binding to 
the Glc-BSA in solution.  However, the competition experiments with the Man-BSA 
(purple) indicate that the polyclonal antibodies do not bind to the Man-BSA in 
solution.  The observation that the Glc-TetHc serum reacts positively with the Man-
BSA glycoconjugate when it is bound on the surface of the ELISA plate, but not 
when in solution indicates that the binding event to Man-BSA may be concentration 
dependent.  When bound to the plate the Man-BSA will be at a much higher 
localised concentration than in solution.  This effect may facilitate the binding of the 
antibodies to the non-cognate antigen when it is surface bound, however further 
investigation is required to verify this observation.  It is known from previous 
competition experiments (Figure 4.7 A) that the monosaccharide-linker motif is 
required for antigen binding.  The fact that the linker molecule is the same in both 
the Man-BSA and Glc-BSA conjugates further implies that the background binding 
may be as a result of the alkyl linker.  Attempts were made to further deconvolute 
the activity of the polyclonal antibodies and are described in Section 4.3.   
 
The evidence presented so far suggests that there is some degree of 
monosaccharide specificity present in the Glc-TetHc derived antibodies.  This 
monosaccharide specificity is further demonstrated in the slot-blot analysis, which is 
described in Section 4.2.3. 
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Figure 4.8: ELISA of 6dHep-TetHc sera (0, 6, 10, 14 & 18 W) activity against Hep-BSA (50 µg/ml) 
unless specified, on the plate.  Legend: (blue) 0 week 6dHep-TetHc sera; (red) 6 week 6dHep-
TetHc sera; (green) 10 week 6dHep-TetHc sera; (purple) 14 week 6dHep-TetHc sera; (black) 18 
week 6dHep-TetHc sera and (orange) 10 week 6dHep-TetHc sera against BSA (50 µg/ml) on 
plate.  Data was recorded in triplicate using standard ELISA protocol 7.4.2.1. 
   
 
Figure 4.9: ELISA of 6dHep-TetHc sera (10 W – black) and Glc-TetHc sera (10 W – red) activity 
against Glc-BSA (50 μg/ml) and Hep-BSA (50 µg/ml) on the plate.  Legend: 0 W Glc-BSA (black) 
18 weeks 6dHep-TetHc sera against Glc-BSA on plate; (red) 10 weeks Glc-TetHc sera against 
Glc-BSA on plate; (blue) 18 weeks 6dHep-TetHc sera against Hep-BSA on plate.   Data was 
recorded in triplicate using standard ELISA protocol 7.4.2.1. 
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4.2.2 ELISA analysis of heptose derived antibodies 
The 6-deoxy-D-mannoheptose TetHc antigen (94) derived sera were analysed by 
ELISA in order to determine the activity of the antibodies towards the target 6-
deoxy-D-manno-heptose hapten (91). 
O
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94  
Figure 4.10: Structure of the 6-deoxy-D-mannoheptose TetHc antigen (94). 
 
Figure 4.8 again shows the time-dependent maturation of antibody affinity towards 
the target hapten (91).  The maturation of antibody activity towards the antigen is 
slower than that of the glucose antigen (Figure 4.3) with the response developing 
until week 14.  There are a number of potential reasons behind this phenomenon 
including differences in the immunisation formulations or a delayed/poor immune 
response to the 6-deoxy-D-manno-heptopyranose antigen by the sheep as a result 
of the increased complexity of the antigen.  However this result clearly shows the 
development of an antibody response to the 6dHep-TetHc antigen (94). 
 
The 6dHep-TetHc serum (18 weeks) was analysed against the Glc-BSA 
glycoconjugate, in parallel with the Glc-TetHc serum (18 weeks) (Figure 4.9).  The 
result shows a reduced response of the 6dHep-TetHc sera (black) against Glc-BSA 
when compared to the Glc-TetHc sera (red).  The result is even more obvious when 
the response of the 6dHep-TetHc sera against Glc-BSA (black) is compared to that 
of the 6dHep-TetHc sera against 6dHep-BSA (blue) when performed under the 
same conditions.  The much higher activity of the 6dHep-TetHc sera against the 
6dHep-BSA, compared to that against Glc-BSA, again demonstrates the potential 
monosaccharide specificity of the generated antibodies.  This result is further 
confirmed by the slot-blot analysis of the polyclonal antibodies Section 4.2.3.   
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Figure 4.11: Slot blot analysis of A) Glc-TetHc serum (18 W; 1 in 1600 dilution) and B) 6dHep-
TetHc serum (18 W; 1 in 1600 dilution) against 1) Glc-BSA (50 µg/ml); 2) Man-BSA (50 µg/ml); 3) 
Hep-BSA (50 µg/ml) and CPS-1 (50 µg/ml).  Data was recorded in sextuplicate using slot-blot  
protocol 7.4.3. 
 
Figure 4.12: Colourimetric density analysis of the blot images using Image-J.  Legend: (blue) 
6dHep-TetHc serum (18 W; 1 in 1600 dilution); (red) Glc-TetHc serum (18 W; 1 in 1600 dilution).  
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4.2.3 Slot-blot analysis of monosaccharide derived antibodies 
Slot-blot analysis of both sets of polyclonal sera (Glc-/Hep-TetHc; 18 W; 1 in 1600 
dilution) further demonstrated the monosaccharide specificity of both sets of 
antibodies.  Figure 4.11 shows the blot membranes from both experiments; it is 
evident that there is some degree of background binding of the antibodies to all of 
the antigens, as shown in the ELISA experiments (Figures 4.5 and 4.9).  However, 
the positive signal is markedly stronger with the Glc-TetHc serum and Glc-BSA and 
the 6dHep-TetHc serum and Hep-BSA.  Colourimetric analysis of the blots was 
carried out using Image-J gel analysis software.  The black rectangles (Figure 4.11) 
represent the sample areas selected for the analysis.   Image-J9 is used to compare 
the colourimetric density (intensity) of bands on gels/western blots and can be used 
to quantify the antibody response to the chosen antigen. The relative density of 
bands, with the background colour (BSA control) subtracted, was calculated and the 
average for each antigen was plotted on a column graph (Figure 4.12).   
 
Figure 4.12 shows that both sets of antigens are specific towards the cognate 
antigen, confirming the conclusions of the ELISA analysis.  Again, background 
binding of the antibodies to the non-cognate antigens was observed.  In both cases, 
the antibodies are more reactive towards the Man-BSA glycoconjugate when 
compared to the other non-cognate antigen.  This result is not surprising as D-
manno-pyranose is structurally more similar to both antigens than 6-deoxy-D-
manno-heptose and D-gluco-pyranose (Figure 4.13). 
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Figure 4.13: Structural differences between the three monosaccharide motifs 
 
This result demonstrates that the background binding is not solely dependent on the 
presence of the linker molecule, as there is differentiation between the three 
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antigens by both the Glc-TetHc sera and the 6dHep-TetHc sera.  This highlights the 
different specificities of the polyclonal sera and the need for affinity purification of 
the antibodies followed by further analysis.  The lack of binding of the 6dHep-TetHc 
sera to the CPS-1 on the blot indicates that monosaccharide derived antibodies are 
not sufficient for the recognition of CPS-1 of B. pseudomallei; see section 4.4.3 for 
further analysis. 
 
4.3 Enhancement of the antigenicity of the monosaccharide 
antigens 
The ELISA and slot-blot analyses suggest that the immune system is capable of 
distinguishing between monosaccharide structures such as D-manno-pyranose, D-
gluco-pyranose and 6-deoxy-D-manno-heptose.   However, it is apparent that the 
linker molecule is playing an important role in the binding of the antibodies to the 
antigens as demonstrated by the background binding seen throughout the analyses.  
In an attempt to increase the antigenicity of the monosaccharide antigens and to 
remove the binding effect of the linker motif, a two sided strategy was employed. 
 
The first strategy involved the use of fluorine to boost the immunogenicity of the 
glucose antigen.  Fluorine has been widely applied in medicinal chemistry 
(Flurithromycin10 and Efavirenz11) for decades.  Currently 20-25% of the drugs 
currently in the production pipeline contain at least one fluorine atom in their 
structure12.  Recently there has been an interest in using fluorine to increase the 
activity of carbohydrate based antigens, with particular focus on anti-cancer 
vaccines.  A key process in the evolution and malignancy of many cancers is the 
development of abnormal glycosylation patterns known as, tumour associated 
carbohydrate antigens (TACA), on tumour cells surfaces13.  It has been shown that 
TACAs can be used to not only distinguish between cancer types but also help to 
understand the developmental stage of the cancer14.  As a result, there has been a 
concerted effort into the development of TACA derived cancer treatments and 
preventative vaccines.  However, despite initial promise, vaccines based on natural 
TACA structures are not sufficient for the development of IgG antibodies and 
subsequent T-cell dependent immunity15.  This is based on the fact that a number of 
TACAs are also presented by ‘normal’ cells at reduced levels, and as such are 
regarded as ‘self’ by the immune system16.  There is also an issue with metabolic 
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stability of the natural carbohydrate antigens as a result of degradation by 
carbohydrate active enzymes, which can severely impact on efficacy15. The 
inclusion of fluorine molecules into the structures of TACAs is one method in which 
these problems can be avoided.  It has been shown that the fluorination of 
carbohydrate based antigens (STn antigen17 MUC1 glycopeptide18) can lead to 
increased immunogenicity and specificity of antibodies to the natural antigen, along 
with increased metabolic stability.  On this basis, a 6-deoxy-6-fluoro-D-
glucopyranose hapten (111) was synthesised and again sheep were immunised, in 
collaboration with Ig Innovations, for antibody generation in an attempt to generate a 
more specific immune response to the cognate glucose hapten. 
 
The second strategy involved the synthesis of a second set of monosaccharide 
antigens (section 4.3.2) based on the same conjugation chemistry but with a thiol-
linked three-carbon linker (3-methyl mercapropionate). The second generation of 
antigens will be conjugated to BSA carrier protein and used for the further 
evaluation of the specificity of the monosaccharide antibodies.  It was anticipated 
that by using BSA conjugates of the monosaccharide antigens with shortened linker 
in ELISA and blot analysis any activity and resulting specificity would be focused 
upon the monosaccharide motifs and not the carrier protein or linker molecule.   
 
4.3.1 Synthesis of 6-deoxy-6-fluoro-D-glucose TetHc antigen (112) 
8-(Methoxycarbonyl)octyl 6-deoxy-6-fluoro-D-glucopyranoside (107) was 
synthesised in one step from 8-(methoxycarbonyl)octyl-β-D-glucopyranoside (68) 
using diethylaminosulfur trifluoride in moderate yield of 36% (Scheme 4.1)19 20.  
Purification of the reaction by flash chromatography afforded a second, less polar 
compound, which was isolated, per-O-acetylated in-order to facilitate NMR 
charecterisation and identified by NMR (1H, 13C and 19F).  The acetylated byproduct 
was shown to be 8-(methylcarbony)octyl 2,4-di-O-acetyl-3,6-di-deoxy-3,6-di-fluoro-
β-D-allo-pyranoside (109), identified by the characteristic coupling constants in the 
1H NMR data; [H-4 J3,4 = 3.5 Hz and J4,5 = 10.0 Hz]
21.  The splitting patterns in both 
the 1H and 13 C NMR spectra place the second fluorine atom in an axial 
configuration at the C-3 position.  13C NMR spectra for (107) and (109) are displayed 
in Appendix 8.6.   
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Scheme 4.1: Synthesis of 8-(methoxycarbonyl) 6-deoxy-6-fluoro-β-D-gluco-pyranoside (108) and 
8-(methoxycarbonyl)-2,4-di-O-acetyl-3,6-dideoxy-3,6-difluoro-β-D-allo-pyranose (109).  Reagents 
and conditions: a) DAST, DCM (abs), -40
o
C – rt, 1 h; b) Ac2O, pyridine, rt, O/N. 
 
Owing to the D-allose configuration of this compound, further investigation into this 
compound was not carried out; however, it does pose an interesting observation 
from a mechanistic point of view.  It has been shown previously by 
Somawardhana22 and Card19 that treatment of methyl α-D-glucopyranoside with 
DAST under the same conditions described here leads to the formation of methyl 
4,6-dideoxy-4,6-difluoro-α-D-galactopyranoside (Scheme 4.2).  It is known that 
anomeric configuration has an effect on the reactivity of the endo-cyclic hydroxyls of 
monosaccharides, as first described by a series of tosylation experiments of α/β-D-
gluco-pyranoside conducted by Compton23.  However, the SN2 mechanism of 
fluorination results in an inversion of stereochemistry.  Owing to this, formation of 
the 3-deoxy-3-fluoro-α-glucopyranose will be sterically hindered due to predominant 
1,3-diaxial interactions leading to the formation of the 4-deoxy-4-fluoro product 
(Scheme 4.2). 
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Scheme 4.2: Synthesis of methyl 4,6-dideoxy-4,6-difluoro-α-D-galacto-pyranoside (110) from 
methyl α-D-gluco-pyranoside with DAST.  Reagents and conditions: a) DAST, DCM (abs), -40
o
C 
– rt, 1 h 
 
The 6-deoxy-6-fluoro-β-D-glucopyranoside derivative (107) was converted to the 
acyl hydrazide (111) by reaction with hydrazine monohydrate at 50oC.  The TetHc 6-
deoxy-6-fluoro conjugate (6D6FGlc-TetHc) (112) was synthesised by the standard 
conjugation protocol as described in Section 2.3.2 (Scheme 4.3).  The MALDI-ToF 
and SDS-Page analysis of the 6D6FGlc-TetHc glycoconjugate indicated an average 
of 23 haptens per protein, giving a conjugation efficiency of 70% (MALDI-Tof data 
shown in Appendix 8.7).  The 6D6FGlc-TetHc conjugate was submitted to Ig 
Innovations for antibody generation. 
 
Scheme 4.3: Conjugation of 8-(methoxycarbonyl)octyl-6-deoxy-6-fluoro-β-D-glucopyranoside 
(107) to TetHc carrier protein.  Reagents and conditions: a) NH2NH2, EtOH, 4 h, 55
o
C; bi) tert-
butyl nitrite, 4 M HCl, DMF, bii) TetHc, 0.08M Borax/0.35M KHCO3, pH 9.0, O/N, 4
o
C. 
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Figure 4.14: ELISA assessment of 6D6FGlc-Sera against Glc-BSA (50 µg/ml) and Man-BSA (50 
µg/ml) on plate.  Legend: (purple) 0 W 6D6FGlc-TetHc sera against Glc-BSA (50 µg/ml); (blue) 18 
W 6D6FGlc-TetHc sera against Man-BSA (50 µg/ml); (green) 18 W 6D6FGlc-TetHc sera against 
Glc-BSA (50 µg/ml); (black) 18 W Glc-TetHc sera against Glc-BSA (50 µg/ml); (red) 18 W Glc-
TetHc sera against Man-BSA (50 µg/ml).  
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4.3.1.1 Immunological assessment of the 6D6FGlc-TetHc sera 
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Figure 4.15:  Structure of the 6d6FGlc-TetHc antigen (112) 
 
The activity profile of the 6d6FGlc-TetHc (112) derived antibodies (Figure 4.14) 
(pre-immune (purple) and 18 weeks against Glc-BSA (green) and Man-BSA (blue) 
conjugates is similar to the Glc-TetHc sera (Figure 4.14 (Glc-BSA (red) and Man-
BSA (black)).  The activity of the 6d6FGlc-TetHc sera indicated that antibodies 
raised against the 6-fluorinated D-glucose antigen recognise the native unfluorinated 
D-glucose hapten (69).  Due to the variable nature of polyclonal sera, and the effect 
of the alkyl linker on specificity (Section 4.2) at this stage, it was not possible to 
make direct comparisons regarding the relative activities of the Glc-TetHc and 
6d6FGlc-TetHc derived sera.  In order to determine the impact of fluorination on 
activity and specificity of the derived antibodies, a much more detailed analysis of 
the antibodies is required.  Ideally, generation of monoclonal antibodies specific for 
the fluorinated (111) and native D-glucose hapten (69) would be produced.  This 
would allow for the binding kinetics of both antibodies to be determined and provide 
insight into the immunological impact of fluorination.  This work was not conducted 
as part of this study, but the preliminary activity result is encouraging and indicates 
that further development and investigation of the fluorinated haptens would be 
warranted.   
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Scheme 4.4: Synthesis of the short linker haptens.  Reagents and conditions: a) BF3.OEt2, DCM, 
0
o
C – r.t., O/N; b) NaOMe, MeOH, rt, 30 min; c) NH2NH2.H2O; EtOH, 55
o
C, 4 h.   
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4.3.2 Synthesis of short linker haptens 
A second generation of monosaccharide haptens was developed through the use of 
3-methylmercaptopropionate in an attempt to further investigate the specificity of the 
anti-monosaccharide antibodies.  In order to simplify the synthesis of the short linker 
haptens, methyl 3-mercaptopropionate was selected as the new linker.  The use of 
thiol based linker in these conjugates will further differentiate the linker moiety from 
the original 8-methoxycarbonyl octanol linker.  It also allows for the direct synthesis 
of the conjugates from the per-O-acetylated monosaccharides24.  These haptens will 
help to establish whether the apparent specificity of the sheep sera raised against 
the monosaccharide antigens is conferred by the carbohydrate motifs or as part of a 
combined monosaccharide-linker epitope.   
 
The short linker haptens were all synthesised in three steps from the per-O-
acetylated monosaccharides (Scheme 4.4).  Boron trifluoride diethyl etherate-
promoted glycosylation was achieved in moderate yield for all three conjugates, 
followed by global deactylation under Zemplén conditions.  The per-O-acetylated 6-
deoxy-D-manno-heptopyranoside (120) was provided by Giulia Pergolizzi (Field 
Lab).  Acyl hydrazides were formed upon reaction of the methyl ester with hydrazine 
monohydrate at elevated temperature as described earlier for (64, 69 and 91, 
Section 2.2).  Conjugation to carrier protein and use of the second-generation 
antigens is ongoing in the Field group. 
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4.4 Immunological assessment of anti-CPS-1 monoclonal 
antibody 
4.4.1 Conjugation of CPS-1 to cBSA carrier protein 
The use of the native capsular polysaccharide for the immunological assessment of 
the potential vaccine candidates is an important part of the larger vaccine 
development project.  The direct loading of polysaccharides on to polystyrene 
ELISA plates has been shown to be inconsistent, even at high loading 
concentrations25.  There are a number of methods which can be employed to 
improve binding of polysaccharides to ELISA plates, such as covalent attachment25, 
conjugation to a carrier protein,26 or antibody capture ELISA27.  As previously 
described the mAb 4IVH12 antibody, raised against intact K96243 B. pseudomallei 
cells was available to us28.  However, use of this monoclonal antibody in capture 
ELISA assays was unexpectedly not possible due to cross-reactivity between the 
secondary antibody (anti-sheep) used for the detection of sheep sera and the 
mouse monoclonal.  To overcome this problem the conjugation of CPS-1 to 
catonised BSA was attempted.  The conjugation of B. pseudomallei CPS-1 (4) to 
cBSA has previously been described by Burtnick et al29.   
 
cBSA was chosen as the carrier protein in this instance in order to follow the 
protocol established by Burtnick et al29.  cBSA is native BSA which has been treated 
with an excess of ethylenediamine, essentially capping all negatively charged 
residues with primary amines (Scheme 4.5).  This increases the number of 
conjugation sites, whilst also making the carrier more immunogenic than the native 
protein30. 
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Scheme 4.5: Schematic representation of the synthesis of cBSA from native BSA with 
ethylenediamine. 
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Burtnick et al29  used periodate oxidation of CPS-1 to afford non-reducing terminal 
aldehydes. Two vicinal diols (axial-equatorial or equatorial-equatorial) are required 
for formation of the intermediate oxidation complex31.  As a result of the β-1,3-
linkage of the Bth-CPS-1 (104) periodate oxidation can only occur at the non-
reducing terminus where the 3-OH and 4-OH are correctly orientated for periodate 
oxidation.  This method provides a simple route to the selective installation of 
aldehydes at the non-reducing terminus of the Bth-CPS-1 (104) which can be 
exploited for the chemical modification of the polysaccharide.   
 
In section 3.3.2 the successful reductive amination of CPS-1 to aminopyrene 
trisulfonic acid (APTS) (105) is described.  However, as the efficiency of this 
reaction was not fully investigated it was decided to proceed with the periodate 
oxidation to ensure sucessful coupling of the cBSA to the carrier protein.   The 
native Bth-CPS-1 (104) (5 mg) was successfully conjugated to the carrier protein on 
a 1:1 ratio with the carrier protein as described by Burtnick and co-workers (Scheme 
4.6).  After the periodate oxidation step the sample was purified using a PD-10 
column before reductive amination with cBSA.  The reaction was terminated with 
the addition of NaBH4 and extensively dialysed against MQ-H2O and lyophilized to 
afford CPS-1-cBSA glycoconjugates (6 mg). 
 
Scheme 4.6: Schematic representation of CPS-1 conjugation to carrier protein.  Reagents and 
conditions: a) NaIO4, PBS, rt, 40 mins; b) 1M NaBH3CN in 10 mM NaOH, PBS, rt, 4d; c) 1M 
NaBH4 in 10 mM NaOH. 
 
An initial SDS-PAGE gel was run on the glycoconjugates sample (Figure 4.16) 
using cBSA as the standard.  Coomassie staining of the initial gel revealed bands at 
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70, 150 and 250 kDa corresponding to cross-linked cBSA as a result of 
catonization.  The presence of a protein band at +250 kDa (red box) indicated the 
successful conjugation of the oxidised CPS-1 to cBSA.  In contrast to the data 
published by Burtnick et al.32 a large proportion of the cBSA remained unmodified.  
This may be as a result of difference between the Bth-CPS-1 (104) and the B. 
pseudomallei CPS-1 (4) polysaccharides that was used in the two experiments.  
Currently studies are under way in the Field lab regarding the use of both 
polysaccharides for conjugation in order to determine the cause of this observation. 
 
Size exclusion chromatography (S200 column) was performed to remove unreacted 
cBSA and isolate the high molecular weight material (red box) (Figure 4.17). 
 
Figure 4.16: SDS-PAGE gel of cBSA conjugation reaction. Lanes: A) Kaleidoscope ladder; B) 
cBSA (2 mg/ml); C) cBSA (0.5 mg/ml); D) Glycoconjugate (2 mg/ml); E) Glycoconjugate (0.5 
mg/ml) 
 
Isocratic elution (50 mM HEPES; pH 7.5, 150 mM NaCl) of the glycoconjugates 
sample was done on an S200 HR (Superdex) column XK26/60 and fractions (1 ml) 
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were collected and analysed using the high-throughput phenol-sulphuric acid assay 
to determine the carbohydrate content (Figure 4.17). 
 
Figure 4.17: Size exclusion chromatography of CPS-1-cBSA glycoconjugate.  XK26/60 S200 HR 
column (Superdex); flow rate 1 ml/min; eluent 50 mM HEPES, pH 7.5, 150 mM NaCl; sample 
loaded 500 µl and 12 mg/ml; fractions (40 – 150 ml) 1 ml.  Series (Blue) UV trace (A280) protein 
content; (Green) Phenol:sulphuric acid assay (A490) carbohydrate content.  Fractions taken for 
SDS highlighted in red. 
 
A selection of fractions were taken from the peaks of interest (UV and carbohydrate 
active) and run on SDS-PAGE gel and western blot using the ant-CPS-1 
monoclonal antibody (mAb 4IVH12) (Figure 4.18). 
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Figure 4.18: 1) Coomassie stained SDS-PAGE gel of fractions taken from SEC of CPS-1-cBSA 
glycoconjugate; 2) Western blot of SDS-PAGE gel.  Lanes: K) Kaleidoscope ladder; I) Initial 
sample; A1) Fraction A1; A2) Fraction A4; A8) Fraction A8; A12) Fraction A12); A15) Fraction 
A15; B12) Fraction B12; B8) Fraction B8; B4) Fraction B4); C7) cBSA; P) CPS-1 sample (0.5 
mg/ml) 
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The western blot analysis indicates the conjugation of Bth-CPS-1 (104) to the carrier 
protein and subsequent purification from excess cBSA.  The SEC elution pattern, 
SDS-PAGE and western blot analyses suggests a series of glycoconjugates with 
varying molecular weights were produced (highlighted in red box Figure 4.18).  
Using a set of protein standards it is possible to estimate the molecular weight of the 
different conjugates from the SEC elution pattern.   
 
 
Figure 4.19: Calibration curve for molecular weight prediction using the S200 SEC column.  
Standards (black diamonds left to right): blue dextran – 2000 kDa; β-amylase – 200 kDa; ADH – 
150 kDa; BSA – 66 kDa; carbonic anhydrase - 29 kDa; cytochrome C – 12.4 kDa. Fractions (red 
crosses): A8 – 1000 kDa; A15 – 500 kDa; B8 – 250 kDa; C7 – 70 kDa. Ve – elution volume of 
sample; Vo – void volume of column (43.22 ml). 
 
The molecular weight estimation (Figure 4.19) confirms the data from the SDS-
PAGE gel and western blot indicating the successful purification of the Bth-CPS-1-
cBSA conjugates from the native cBSA (fraction C7 – predicted MW of 70 kDa).  
Molecular weight estimations of the three sets of bands in the western blot predict 
conjugates of 1000 kDa (fraction A8); 500 kDa (fraction A15) and 250 kDa (fraction 
B8).  It is important to note that owing to the fact that CPS-1 will behave differently 
to the globular protein standards the molecular weight estimations can only act as 
rough guides.   
 
However, it does indicate the generation of glycoconjugates with different Bth-CPS-
1 loadings, which can be isolated using chromatography.  The isolation and 
extraction of Bth-CPS-1 (104) will afford a polydisperse population of different 
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polysaccharide chain lengths.  Our collaborators (DSTL-Porton Down) have 
demonstrated using SDS-PAGE, that the Bth-CPS-1 (104) is approximately 200 
kDa in size (Figure 3.12).  However, an accurate determination of the molecular 
weight of the Bth-CPS-1 (104) population is not possible.  The distribution of the 
Bth-CPS-1-cBSA glycoconjugates could arise from the conjugation of different 
polymer lengths to the cBSA.  This highlights one of the issues of using isolated 
polysaccharide material for the purposes of vaccine generation.   One other 
explanation for series of conjugates is the possibility of the cross-linking of cBSA 
molecules with CPS-1.  The use of the periodate oxidation step for the generation of 
aldehyde moieties means that there is potential for reductive amination to occur at 
both ends of the polysaccharide.  As described previously (Section 3.2.2), it is 
believed that CPS-1 is capped with a glycerol glycoside, if this is the case periodate 
oxidation of the glycerol moiety will occur, forming aldehydes available for reductive 
amination with the carrier protein.  Owing to the complex and heterogeneous nature 
of the conjugation products another route for the loading of CPS-1 on 96-well plates 
for ELISA analysis was required.  However, the conjugation of intact CPS-1 is part 
of the larger vaccine development program and development of this conjugation 
protocol is currently on going in the Field group. 
 
4.4.2 Biotinylation of CPS-1       
The use of biotinylated CPS-1 in conjunction with streptavidin labelled plates offered 
a simple and efficient method of attaching CPS-1 to an ELISA plate.  As shown in 
the previous section, the periodate oxidation of CPS-1 is an effective route for the 
generation of aldehyde groups which can be used to functionalise the CPS-1 
polymer.  The oxidised Bth-CPS-1 (2 mg) was reacted with EZ-link Hydrazide-
PEG4-biotin
33 (125) (Pierce Biotechnology, Thermo Fischer) and purified using a 
PD-10 desalting column to afford biotinylated CPS-1 (125) (2 mg) for use in ELISA 
analysis (Scheme 4.7).   
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Scheme 4.7: reaction fof oxidised CPS-1 (123) with EZ-link Hydrazide-PEG4-Biotin PEG 4.  
Reagents and conditions: a) 0.1 M NaPO4, 0.15 M NaCl, pH 7.2, rt, 2 h. 
 
In order to confirm the successful biotinylation of the Bth-CPS-1 (104) an 
immunofluorescence experiment was employed using streptavidin coated 
microscope slides.  A pattern was drawn on the microscope slide using the 
biotinylated CPS-1.  After incubation with mAb 4IVH12 (K69243) antibody and a 
fluorescent secondary antibody (Alexa 566-anti-mouse, Invitrogen) fluorescence 
imaging was done.  Figure 4.20 shows the detection of biotinylated CPS-1 on the 
surface of the microscope slide, confirming the successful attachment of biotinylated 
CPS-1 to a streptavidin surface. 
 
Figure 4.20: Left) Schematic representation of pattern drawn on streptavidin coated microscope 
slide with biotinylated CPS-1.  Right) Fluorescence image of microscope slide demonstrating 
the successful biotinylation of CPS-1 and subsequent attachment to a streptavidin coated 
surface. 
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Figure 4.21: ELISA of anti-B. pseudomallei (K69243) mAb 4IVH12 activity against biotin-CPS-1 
(2 μg/ml) on streptavidin coated plate.  Data was collected in duplicate following CPS-1 ELISA 
protocol 7.4.2.3 
 
Figure 4.22: Competition ELISA of anti-B. pseudomallei (K69243) mAb 4IVH12 (2.19 µg/ml) with 
purified CPS-1 and Ancora hexasaccharide at varying concentrations (25 – 0.5 µg/ml) against 
biotin-CPS-1 on the plate (2 µg/ml).  Legend: Red) Response of anti-B. pseudomallei (K69243) 
4IVH12 mAb antibody (2.19 µg/ml) against biotin-CPS-1 under normal conditions; blue 
diamond) response of anti-B. pseudomallei (K69243) monoclonal antibody (2.19 µg/ml) against 
biotin-CPS-1 with CPS-1 (25 – 0.5 µg/ml) in competition; black triangle) response of anti-B. 
pseudomallei (K69243) mAb 4IVH12 (2.19 µg/ml) against biotin-CPS-1 with Ancora 
hexasaccharide (25 – 0.5 µg/ml) in competition.  Data was collected in triplicate following ELISA 
protocol 7.4.2.3 
0.250
0.350
0.450
0.550
0.650
0.750
0.850
35.0017.508.754.382.191.090.550.270.140.07
A
4
0
5
 
[Antibody] µg  
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0.800
0.01 0.1 1 10 100
A
4
0
5
 
 
Log10[CPS-1] µg 
Monoclonal CPS Competition
Monoclonal 2.19 µg/ml
Monoclonal Hexasaccharide Competition
 137 
 
4.4.3 ELISA assessment of monoclonal antibody against CPS-1 
In order to determine that the biotinylated CPS-1 (124) was suitable for ELISA 
based assays, the binding of the monoclonal antibody was assessed using a 
streptavidin-coated ELISA plate.  The concentration dependent response of the anti-
B. pseudomallei (K69243) monoclonal antibody demonstrates that the use of biotin-
CPS-1 (124) and streptavidin coated plates was suitable for the ELISA analysis of 
the monoclonal antibody (Figure  4.21).  In an attempt to investigate the validity of a 
synthetic oligosaccharide fragment of CPS-1 for use in a potential B. pseudomallei 
vaccine a competition ELISA with the synthetic Ancora hexasaccharide (54) and 
CPS-1 was carried out (Figure 4.22).   
 
Anti-B. pseudomallei (K69243) mAb 4IVH12 (4.38 µg/ml in PBST) was incubated 
with equal volumes of CPS-1 and equal volumes of hexasaccharide (50 µg/ml – 0.1 
µg/ml in PBST) for 30 minutes at 37
oC.  Antibody concentration of 4.38 µg/ml was 
chosen, as upon incubation with equal volumes of antigen would give a final volume 
of 2.19 µg/ml  At 2.19 µg/ml, mAb 4IVH12 demonstrates 60% of maximum activity 
under the conditions of the ELISA assay.  Using this concentration ensures that 
saturated binding of the antibody solution is not achieved and that any competition 
is clearly visible during the experiment.  
 
The result from the competition ELISA experiment with the Ancora hexasaccharide 
and the MAb 4IVH12 antibody indicates that there is no recognition of the synthetic 
hexasaccharide by the monoclonal antibody.  This result raises questions about the 
validity of either the use of synthetic oligosaccharide fragments of CPS-1 as vaccine 
candidates, or the use of the anti-B. pseudomallei (K69243) monoclonal.  The 
4IVH12 monoclonal (anti-CPS-1) antibody used in this research was raised against 
heat-inactivated B. pseudomallei cells28.  As a result of the nature of the mAb, it is 
not possible for conclusions to be made at this stage.  Immunisation trials with the 
synthetic hexasaccharide are planned for the future and should provide further 
insight into the potential of synthetic antigens.  It has also been shown that heat 
inactivation of B. pseudomallei dramatically decreases the CPS-1 content around 
the cells, which may have a negative impact of anti-CPS-1 antibody generation (M. 
Bayliss, personal communication, Table 3.3).  The MAb 4IVH12 antibody was 
characterised by the authors using western blot and immunofluorescence 
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techniques.  It was shown that the antibody was reactive and specific to; a high-
molecular weight polysaccharide component, which was not LPS and was located 
on the surface of the bacterial cell.  Based on these observations, it was concluded 
that the 4IVH12 mAb was specific for the capsular polysaccharide of B. 
pseudomallei28.  Subsequently, AuCoin and co-workers raised another monoclonal 
antibody (mAb 3C5) specific for B. pseudomallei CPS-1 in a similar fashion34.  Both 
monoclonal antibodies have been shown to be highly reactive to all CPS-1-
producing strains of B. pseudomallei and B. mallei 28, 34.  The monoclonal antibody 
was also shown not to react towards CPS-1 deficient strains of Burkholderia (B. 
thailandensis E264) 15, 18.  In the case of the mAb 4IVH12 we have shown (section 
3.2.1) that the antibody is reactive towards CPS-1 positive B. thailandensis E555 
(ΔwbiI) strain.  However, extraction and characterisation of CPS-1 material from B. 
pseudomallei 35, B. mallei28, 35 and B. thailandensis  (E555) ΔwbiI (this thesis) has 
shown high levels of an α-1,3-mannan polysaccharide (106) contaminant (Section 
3.2.3).  We have shown that the level of mannan content is variable not only 
between Burkholderia species, but also between different polysaccharide 
extractions (Table 3.4).  The presence of the mannan polymer is thought to be 
linked to the CPS-1-genome cluster and thus it can be expected that all CPS-1 
positive strains of Burkholderia will also produce the mannan polysaccharide.  
These observations, along with the lack of specificity of the mAb 4IVH12 antibody 
towards the Ancora hexasaccharide indicate that the epitope of the monoclonal may 
not be the -3)-2-O-acetyl-6-deoxy-β-D-manno-heptose-(1- polysaccharide as 
previously assumed, but could possibly be associated with an alternative 
Burkholderia polysaccharide, such as the α-1,3-mannan28.   
 
The lack of activity of the 4IVH12 antibody against the hexasaccharide (54) could 
also be associated with the global presentation of the polysaccharide.  As discussed 
in Section 1.2.2.1 basic 3D modelling of the CPS-1 suggest that it may form a 
helical structure.  The conformation of the polymer may be radically different from 
an oligosaccharide fragment and as such the hexasaccharide may not be sufficient 
for recognition by the antibody at these concentrations (25 - 0.05 µg/ml).     
 
At this stage the detailed immunological assessment of the 6dHep-TetHc derived 
antibodies against the purified Bth-CPS-1 (104) material was not possible due to 
time constraints.  ELISA analysis using the biotinylated CPS-1 (124) was attempted 
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but all experiments failed as a result of activity of sheep derived sera against the 
streptavidin plates.  An experiment was run with just the commercial streptavidin 
plates and the sheep sera (0 & 18 W) and both were shown to be equally reactive to 
the plate.  However, the slot-blot analysis of the 6dHep-TetHc sera (section 4.2.3) 
indicates that the sera are not active towards the native polysaccharide.  
Investigations into the monoclonal antibody activity towards the Ancora 
hexasaccharide (54) have highlighted the possibility that the global structure of the 
CPS-1 may play an important role in the recognition of this polysaccharide and as a 
result antibodies raised using mono-/oligo-saccharide fragments of the CPS-1 may 
not be sufficient.  Further analysis of the 6dHep-TetHc sera was performed using an 
Octet 96Red biosensor system (ForteBio) and is described in Section 4.5. 
 
 
4.5 Octet analysis 
The Octet 96Red biosensor system (FortéBio) was used to further investigate the 
binding of the mAb 4IVH12 and the 6dHep-TetHc derived sera to CPS-1 extracted 
from B. thailandensis E555 ΔwbiI.  The Octet system uses biolayer interferometry to 
detect binding onto the surface of a functionalised disposable biosensor.  The dip 
and read format of the Octet systems negates the need for microfluidics giving it a 
distinct advantage over other techniques, such as SPR (Biacore)36.   
 
Initial attempts were made to use anti-mouse IgG (Fc Capture (AMC)) functionalised 
biosensors to immobilise mAb 4IVH12 anti-CPS-1 antibody on the surface of the 
biosensor.  Detection of binding of the immobilised antibody and the CPS-1 in 
solution was difficult with only a low response being observed.  In order to assess 
both the binding of mAb 4IVH12 and the Hept-TetHc sera to CPS-1, streptavidin 
biosensors were used to immobilise biotinylated CPS-1 (124).  
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Figure 4.23: Octet analysis of mAb 4IVH12 binding to biotin-CPS-1 immobilised (10 µg/ml) on 
the surface of streptavidin biosensors.  Legend: (blue) 6.66 nM mAb 4IVH12; (red) 3.33 nM mAb 
4IVH12; (green) 1.67 nM mAb 4IVH12.  Work flow: A) Initial baseline for biosensor stabilisation 
(60 seconds); B) loading of biotinylated CPS-1 (400 Seconds); C) baseline stabilisation (60 
seconds); D) binding of antibodies to immobilised CPS-1 (900 Seconds); E) dissociation of 
antibodies (1200 seconds).   
 
Figure 4.24;  Schematic representation of the octet experiment for mAb 4IVH12.  Workflow: A) 
Initial baseline for biosensor stabilisation (60 seconds); B) loading of biotinylated CPS-1 (400 
Seconds); C) baseline stabilisation (60 seconds); D) binding of antibodies to immobilised CPS-
1 (900 Seconds); E) dissociation of antibodies (1200 seconds).  Image adapted from ForteBio 
Octet Brochure
37
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Figure 4.23 shows the binding curves of three different concentrations (6.66 nM, 
3.33 nM and 1.67 nM) of mAb 4IVH12 with biotinylated CPS-1 immobilised on 
streptavidin biosensors.  The binding curves for mAb 4IVH12 indicates strong 
binding of the antibody to the biotinylated CPS-1 (124), with a slow dissociation rate 
[kd 2.27x10
-5 1/s.  The equilibrium dissociation constant (kon/koff) of mAb 4IVH12 to 
the biotinylated CPS-1 was calculated, (using ForteBio Octet analysis software) to 
be 2.66x10-11 M (R2 = 0.99) demonstrating the low nanomolar affinity of the 
monoclonal antibody for the biotinylated Bth-CPS-1 preparation (124). 
 
Next the binding of the combined heptose sera to the immobilised biotinylated CPS-
1 (10 µg/ml) was assessed using the Octet instrument.  Previously, assessment of 
the binding was attempted using ELISA and slot blot analysis, however due to high 
background binding this was not possible.  It was believed that due to the sensitivity 
of the Octet system it would be possible to deconvolute specific binding from 
background binding.  Serial dilutions of the pre-immune sera were analysed as 
reference samples and the data were subtracted from the corresponding 18 week 
sera data.  This normalised the data removing the non-specific binding element of 
the pre-immune sera leaving only binding of the immune sera.  The data were 
corrected to the baseline and the 25-point moving average response was plotted 
against time (Figure 4.25).         
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Figure 4.25: The normalised binding curves for the 18 W heptose sera. Legend: (blue) 18 W 1 in 
100 dilution; (red) 18 W 1 in 200 dilution; (green) 18 W 1 in 400 dilution and (purple) 18 W 1 in 
800 dilution.  (A) association step (1500 sec); (B) dissociation step (1000 sec).  Data was 
normalised by subtraction of pre-immune binding from 18 week binding and corrected to the 
baseline.  25-piont moving average of the data was plotted.  
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Figure 4.24 demonstrates that when the background binding of the pre-immune 
sera is removed, there is some binding of the 6dHep-TetHc polyclonal sera to the 
immobilised capsular polysaccharide.  The binding only occurs at very high sera 
concentration, with no binding observed below the 1 in 400 dilution factor.  
However, the binding profile observed in the high sera concentrations (1 in 100 
(blue); 1 in 200 (red); and 1 in 400 (green)) resemble a typical antibody-antigen 
binding curve.  This result indicates that there is potential binding of the 
monosaccharide derived antibodies to the cognate polysaccharide CPS-1  
 
4.6 Conclusions and future directions 
This chapter has detailed the preliminary immunological assessment of anti-
monosaccharide raised antibodies.  Monosaccharide specificity was observed in 
both the D-glucose and 6-deoxy-D-manno-heptose derived antibodies.  However 
there were high levels of background binding to the non-cognate haptens 
throughout.  The initial immunological assessment of the D-glucose derived 
polyclonal sera (Glc-TetHc) has demonstrated that antibodies with specificity for 
different monosaccharides can be produced.  ELISA and slot-blot analysis has 
shown that the Glc-TetHc sera have higher binding towards the Glc-BSA 
glycoconjugate when compared to the Man-BSA and 6dHep-BSA (Section 4.2.1).  
Further analysis of the polyclonal antibodies, including the use of the second 
generation antigens (short-linker), is required to further understand the binding 
specificity of the polyclonal antibodies.  By using a shortened/different linker it may 
be possible to determine the role of the linker molecule on antibody binding affinity 
to the target monosaccharide.  Immunisation with monosaccharide conjugates 
employing a series of linker molecules could help elucidate the ideal linker for the 
presentation of monosaccharides to the immune system 
 
Polyclonal antibodies raised against the 6-deoxy-6-fluoro-D-glucose hapten (117) 
(Section 4.3.2) were shown to bind to the native D-glucose BSA conjugate (97).  
Affinity purification of the polyclonal sera using immobilised D-glucose hapten (69) 
would remove some background binding which would facilitate the further 
characterisation of the antibodies.  The Octet Red96 biosensor system provides a 
high-throughput platform for the kinetic analysis of antibody binding.  After 
purification of the Glc-TetHc and 6d6FGlc-TetHc sera, binding kinetics analysis 
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using the Octet system should help to elucidate the specificities of the antibodies 
and determine the effects of fluorination of the monosaccharide antigen. 
 
Analysis of the 6dHep-TetHc derived sera activity towards the biotinylated Bth-CPS-
1 (124) using ELISA was not possible due to the high background activity of the 
polyclonal sera against the streptavidin coated plates.  However, octet analysis of 
the 6-deoxy-D-heptose monosaccharide-derived antibodies suggested that some 
binding to the cognate CPS-1 occurred.  In order to confirm this, the Octet analysis 
(Section 4.5) needs to be repeated using all of the available immune sera samples 
(6, 10, 14 & 18 weeks).  If the observed binding is a result of specificity towards the 
cognate polysaccharide, maturation of the binding profile would be observed.  If 
successful, purification of the antibodies and characterisation of the binding of the 
antibodies to native CPS-1 on the surface of the B. thailandensis E555 ΔwbiI mutant 
will be required.  Immunofluorescence and ELISA analysis will provide some 
information regarding the potential application of the monosaccharide antigen in 
vaccination studies. 
 
Further investigation of the mAb 4IVH12 anti-CPS-1 monoclonal antibody using 
biotinylated CPS-1 showed it to have low nanomolar affinity.  However, detection of 
binding to the synthetic Ancora hexasaccharide (54) was not observed.  It was 
concluded that either CPS-1 forms a global structure, thus presenting a 
conformational epitope which is required for recognition by the monoclonal antibody.  
As such, the synthetic hexasaccharide will not present the same conformational 
epitope and mAb 4IVH12 will not bind.  Alternatively, the monoclonal antibody, 
which was raised against heat-inactivated B. pseudomallei cells, is specific for 
another epitope such as the α-1,3-mannan polymer also produced by B. 
pseudomallei and B. thailandensis E555 ΔwbiI (Section 3.2.1 & 3.2.2).  
Understanding the role of the α-1,3-mannan in the virulence of B. pseudomallei and 
its potential as a vaccine candidate is important to this project.  Currently CPS-1 
extracts from three strains of Burkholderia (B. pseudomallei, B. mallei and B. 
thailandensis E555) have been shown to contain the mannan polysaccharide to 
varying degrees (Section 3.2.2).  Access to the purified polysaccharides will enable 
further investigation and understanding of the role of these two polysaccharides and 
inform decisions regarding their use as vaccine candidates.  
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5 Hepatitis B core Antigen Virus-like Particle carrier protein 
5.1  Introduction 
The role of carrier proteins has been pivotal in the development of polysaccharide 
conjugate vaccines for diseases caused by Haemophilius influenza, Neisseria 
menigitidis and Streptococcus pneumonia.  However, it has become apparent that 
as the use of these vaccines becomes more widespread, the potential for 
immunological interference caused by the carrier protein increases.   This 
interference is described as carrier-induced-epitopic suppression (CIES).  CIES 
describes how pre-existing antibodies to the carrier protein can reduce the 
immunological efficacy of the conjugated hapten.  Figure 5.1 highlights the three 
possible mechanisms by which CIES can affect the immunogenicity of haptens 
conjugated to carrier proteins1. 
 
Figure 5.1 A shows the normal interaction of a conjugate vaccine with the immune 
system, the carrier protein enables the T-cell dependant recognition of the 
conjugate antigen.  This is the basis of the cooperative effect which is the driving 
force behind the use of carrier proteins such as                                                                                                                                                                                                                                                                                                                                                                                                
Diphtheria Toxoid (DTCRM197).  Figure 5.1 B highlights how the presence of anti-
carrier protein antibodies can lead to steric hindrance, effectively blocking the 
hapten molecule from the immune system (B-cells) leading to a poor response and 
thus fewer antibodies.  Figure 5.1 C shows how the recognition of the carrier protein 
can dominate the T-helper cell response through competitive mechanisms and lead 
to low yield of anti-hapten antibodies.  In Figure 5.1 D the presence of T-regulatory 
cells specific for the carrier proteins can negatively affect anti-hapten responses.   
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Figure 5.1: Schematic representation of mechanisms for CIES, reproduced with permissions 
from Dagan
1
 et al.; Copyright Elsevier 2010. 
 
Research has also shown that when compared to other carrier proteins such as 
diphtheria toxin, the use of Tet-Hc in conjugate vaccines results in increased CIES 
effects, necessitating higher vaccine doses1.  As a result there has been movement 
towards the use of novel carrier protein in glycoconjugate vaccines to combat this 
problem, with the use of virus-like particles (VLPs) as vaccine carriers becoming an 
attractive option2. 
 
Since the idea of using VLPs in vaccinations was first introduced in the 1980’s by 
Maupas3 et al. and Krugman4 5 et al. during their work on Hepatitis B vaccines, there 
has been significant interest in the area6.  VLPs are multiprotein structures which 
mimic the structure of the native virus, but do not have the viral genomic information 
and as a result are non-replicative2.  Owing to this, VLPs avoid the need for 
attenuation or inactivation highlighting their potential as safe vaccine carriers2.  The 
repetitive, organised structure of VLPs leads to cross-linking of B-cell receptors 
making VLPs capable of inducing strong B-cell responses without the need for 
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adjuvants or high vaccine doses2, 7, 8.    As a result of these factors VLPs are a safe, 
potent and cost effective means of vaccine generation. 
 
There are currently a small number of commercially available VLP-based vaccines 
in use around the globe (Table 4.1), with a great many more undergoing clinical 
trials2, 9. 
Vaccine Vaccination Target Manufacturer 
Engerix® Hepatitis B (HBV) GSK 
Ceravix® Human papillomavirus (HPV) GSK 
Recombivac HB® Hepatitis B (HBV) Merck 
Gardasil® Human papillomavirus (HPV) Merck 
Table 5.1: Table listing commercially available VLP based vaccines in use as of 2013
2
.  
 
Currently the available VLP-based vaccines are used for vaccinating against the 
virus from which the VLP is derived (i.e. Ceravix is a HPV based VLP vaccine for 
HPV infection).  These vaccines use the structural mimicry of the VLPs towards the 
native virus to elicit an immune response and generate protective immunity2.  
However, due to their highly repetitive and immunogenic structure there has been 
recent interest in using VLPs as antigen carriers for other bacterial (tuberculosis)10, 
viral (dengue)11 and protozoan (malaria)12 infections.  Much of this research has 
focused on the use of hepatitis B derived VLP carrier proteins13.     
 
5.1.1 Hepatitis B virus 
Hepatitis B Virus (HBV) is a DNA virus which infects the liver causing both acute 
and chronic liver infections.  It is widespread throughout the globe, with sub-
Saharan Africa and East Asia being most affected, where up to 10% of the adult 
population are infected.  Annually hepatitis B infects 2 billion people and accounts 
for 600,000 deaths (WHO Hepatitis B Fact Sheet NO204, 2013).  The HBV particle 
(Figure 5.2) consists of an exterior lipid envelope, the surface antigen (HBs-Ag) and 
an interior nucleocapsid, the core antigen (HBcAg)13, 14.  HBeAg is an extracellular 
form of HBcAg and plays an important role in the identification of chronic Hepatitis B 
patients15.  The nucleocapsid encapsulates the HBV genome and the polymerase 
required for viral replication16.  The surface antigen consists of a lipid envelope 
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embedded with three different glycoproteins (large, middle and small surface 
antigens), which are required for the adhesion and infection of host cells13.  The 
particles were first identified by Dane et al. in 1970, using electron microscopy, and 
are now referred to as Dane particles17.   
 
 
Figure 5.2: Structure of the hepatitis B virus (picture taken from Johns Hopkins Bloomberg 
School of Public Health Website)
18
. 
 
The current hepatitis B vaccine program is VLP-based (Engerix and Recombivac 
HB) and uses the HBsAg of the hepatitis B viron19.  However, owing to the highly 
immunogenic nature of the core antigen (HBcAg) there has been increased 
research in using this VLP as a novel protein carrier for vaccines.  HBcAg has been 
previously shown to be an excellent antigen carrier platform20 with strong 
immunogenicity and adjuvanting properties.  The strong self-adjuvanting properties 
of HBcAg are as a result of the fact that HBcAg can act as both a T-cell dependent 
and T-cell independent antigen21, 22.  HBcAg is a 21.5 kDa protein (Figure 5.3), with 
two HBcAg monomers forming a dimer through disulphide bridges (Figure 5.3 
yellow), which acts as the building block for the capsid shell.  The capsid shell has 
an icosahedral shape (Figure 5.4) and either consists of 180 (30 nm; T=3 particle) 
or 240 (34 nm T=4 particle) copies of the HBcAg protein14.  
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Figure 5.3: Structure of HBcAg dimer (monomer in purple).  Image reproduced from Wynne et 
al. Copyright Elsevier 1999
23
. 
 
The HBcAg dimer has three primary sites for insertion of an antigenic epitope 
(hapten) for presentation, the C-terminus, N-terminus and the major 
immunodominant region (MIR) (Figure 5.3).  The N-terminal domain is necessary for 
the assembly of the HBc monomers into the global VLP structure2,14.  Owing to its 
requirement for particle assembly, hapten attachment/insertion at this site is 
problematic.  The C-terminus is arginine-rich and is responsible for nucleic acid-
binding and not necessary for particle assembly24.  The MIR region (amino acids 74-
89) at the top of the ‘spike’ (E1 loop) that is formed by the arrangement of two α-
helices, is highly immunogenic.  The MIR has been shown to be the main region of 
shared antigenicity between the two forms of this protein (HBcAg and HBeAg), 
indicating that it is the primary immunogenic site in both assembled VLPs and free 
core protein monomers25.  Modification and insertion of epitopes into this region has 
been the most successful for the generation of highly reactive recombinant VLPs2, 
26.  There have been a number of efforts focused on the insertion of peptide 
sequences into the MIR of HBcAg, which are detailed in the following references2, 13, 
27, 28. 
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Figure 5.4: Image of the HBcAg VLP (T=3 particle) PDB code: IQGT, model produced using 
PyMol.. 
 
Figure 5.4 shows the global structure of the HBcAg VLP, with the E1 loops 
protruding from the particle surface offering the ideal site for antigen attachment13. 
 
5.1.2 HBcAg tandem core 
The development of HBcAg based vaccines is dependent on the successful 
insertion of the antigen of choice into the MIR region of the E1 loop29.  The location 
of the MIR and the proximity of the two loops in the dimer (Figure 5.3) mean that the 
presence of large peptides or highly charged inserts, can lead to stereo/electronic 
effects which can adversely affect particle assembly.  In order for the successful 
insertion of large peptides into the MIR, the N- and C- terminus of the peptide insert 
must naturally be in close proximity to avoid steric constraint on the insert or be 
attached by long flexible linkers30.  The inclusion of large proteins in the MIR of the 
HBcAg monomer can also lead to steric interference on the assembly of the dimer 
building block  In an attempt to combat this, groups in Leeds (Rowlands) and Oxford 
(Stuart) developed tandem core technology, which is currently licensed by our 
collaborators, iQur21.  Utilising computational analysis, gene constructs were 
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produced in order to fuse two HBcAg core monomers together through a flexible 
peptide linker (Figure 5.5)21.   
  
 
Figure 5.5: Schematic of the tandem HBcAg core with two HBcAg monomers fused together 
with a flexible peptide linker highlighted in yellow (adapted from Gehin et al
21
.  
 
The fusion of two HBcAg monomers to form a single peptide increases the 
versatility of the HBcAg as a vaccine carrier in two ways.  Through the inclusion of 
distinct restriction sites in the two E1 loops  each loop can be addressed 
independently to either produce a bivalent platform (Figure 5.6a) or a system where 
the antigen is only inserted a single E1 loop (Figure 5.6b) removing the potential for 
steric hindrance associated with double insertion (Figure 5.6c). 
 
Figure 5.6: Schematic representation illustrating (a) the development of a bivalent platform 
using tandem technology, (b) the insertion of antigen into a single E1 loop with tandem 
technology and (c) the steric hindrance that is associated with the use of wild-type HBcAg core. 
 
 
154 
 
In comparison to the current studies using the tandem-core technology, our 
research efforts were focused on the development of a chemically addressable 
HBc-Ag carrier protein.  Instead of engineering genetic constructs for the insertion of 
a single protein epitope into the MIR of the HBc-Ag protein, we designed a short 
peptide insert which would allow chemical conjugation of synthetic antigens to the 
E1-loop. 
 
5.1.2.1 The peptide insert 
As described earlier in this thesis, the development of a carbohydrate vaccine for B. 
pseudomallei has involved the chemical conjugation of haptens (69 and 91) to 
surface lysine residues present in TetHc.  In order to make use of the existing 
haptens we decided to focus on the insertion of lysine residues into the MIR of the 
HBcAg protein (in both the wild type monomer and the tandem core), in an attempt 
to furnish a chemically addressable HBcAg VLP.  In 200231, Jegerlehner et al. 
demonstrated the insertion of a single lysine into the MIR sequence and used a 
hetero-bifunctional linker to conjugate a series of antigens to the VLP.  During this 
work the authors attempted coupling of antigens to both the wt-HBcAg and their 
lysine-modified variant.  The coupling efficiency of the unmodified wild-type VLP 
was shown to be less than 5%31.  There are only two native lysines in each HBcAg 
monomer, both of which are buried in the VLP shell upon assembly, masking them 
from chemical modification.  This highlights the need for the insertion of chemically 
addressable groups, such as lysine, for the development of a platform carrier 
protein. 
 
We wanted to build on the positive results of the multivalent display of the heptose 
antigen (91), discussed in Chapters 2 and 4, through the use of an oligo-lysine 
insert.  It was hoped that through the use of an oligo-lysine insert at the tip of the 
MIR region, the organised and repetitive structure of the VLP could be exploited.  
The repetitive presentation by the VLP would result in B-cell cross-linking, 
mimicking a natural polysaccharide immune response, whilst still having T-cell 
dependant activation as a result of the protein carrier.   
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However, it was thought that the insertion of an oligo-lysine insert would lead to a 
large charge imbalance in the particle, making the tips of the E1-loop positively 
charged.  This could not only affect the assembly of the dimers into viable VLPs, but 
also the immunogenic properties of the assembled VLP.  In order to combat this it 
was decided to flank the poly-lysine insert with aspartate residues and thus balance 
the positive charge.  Glycine spacers were also used at each end of the insert to 
separate the sequence from the native peptide.  Inserted in the DNA sequence that 
codes for the E1 loop are two restriction sites (AseI and SalI) which are used in the 
development of new VLP constructs.  The section between the two restriction sites 
codes for a 10 amino acid sequence.  It has been shown previously that it is 
possible to insert entire proteins into the MIR of the HBcAg protein32.  However, 
these studies involved extensive optimisation of the expression and purification 
techniques to afford valid recombinant VLPs30.   In order to reduce the likelihood of 
preventing particle assembly, a small peptide insert of similar size (14 amino acids) 
to the original sequence was designed.  The peptide insert was comprised of 
Glycine-(Aspartate)3-(Lysine)6-(Aspartate)3-Glycine (D3K6D3), in an attempt to 
maximise the number of lysine residues, without dramatically increasing the size of 
the insert  It was anticipated that the inclusion of four extra amino acids would not 
have a negative effect on particle assembly; however this could only be determined 
experimentally.  A model of the new HBcAg monomer was produced using PyMol 
(Figure 5.7) with the inserted peptide sequence highlighted in yellow (lysine) and 
blue (aspartate). 
 
Figure 5.7: Structure of wt-HBcAg dimer with new protein insert (Lys - yellow, Asp - blue).  
Structure modelled using PyMol and PDB structure 1QGT. 
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5.1.3 VLP production 
VLPs have been produced for approximately 40 different viruses using at least 5 
different expression system 2 [Baculovirus and insect cells27, 33; mammalian cells34;   
bacteria (E. coli)34; yeast (S. cerevisiae) 35 and plants28 (tobacco36, potato2, tomato2 
and soybean2].  Previously, our collaborators (iQur) attempted the production of a 
similar tandem core HBcAg in yeast (S. cerevisiae) with limited success. There is 
anecdotal evidence to suggest that plants offer a more suitable platform for the 
folding of the complex VLP structures than other expression systems, such as yeast 
(personal communication, M. Whelan, iQur Ltd; G. Lomonossoff, JIC).  Both the 
quality and yield of VLPs produced in plants have been shown to be higher when 
compared to expression in yeast32.   
 
In 1998, Tsuda et al.37achieved the first expression of HBcAg in transgenic tobacco 
plants.  Using full length viral vectors from Cowpea Mosiac Virus (CPMV) and 
Potato Virus X, the Lomonossoff group first achieved transient expression of HBcAg 
in 2006, with comparable yields (10 mg/kg fresh weigh tissue) to that achieved 
using stable transgenic lines38.  In 2008, through the use of the patented pEAQ-HT 
expression system developed by the Lomonossoff group, the transient expression 
of HBcAg was achieved with much improved yields (1 g/kg FWT).  Owing to this and 
due to the expertise and previous success of HBcAg production in planta by the 
Lomonossoff group (JIC), efforts were focused on expression of the D3K6D3 VLP in 
Nicotiana benthamiana using the pEAQ-HT expression system developed by the 
Lomonossoff group. 
 
5.1.3.1 The pEAQ-HT expression system 
The pEAQ-HT (easy and quick) expression system is a transient expression system 
specifically designed to give high-level expression of proteins in plants39-41.  pEAQ-
HT is based on the cloning of the desired gene between a modified 5’-untranslated 
region (5’-UTR) and 3’-UTR of Cowpea mosaic virus (CPMV) RNA-239, 40.  The map 
for the tandem-core HBcAg plasmid is detailed in Appendix 8.8.  
 
Through the use of the pEAQ-HT expression system, it is possible to generate 
proteins in extremely high yield, without the need for viral replication in the host, 
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removing the need for plant pathogen regulations.  It has been shown that the yields 
associated with the pEAQ-HT systems are equivalent to the highest reported yields 
for systems which rely on viral replication39.  Expression of VLP proteins by means 
of the pEAQ-HT system has shown to be an effective and efficient method for 
producing fully assembled particles in planta28,40.  Agroinfilitration of plants utilises 
the delivery of Agrobacteria into viable plant leaf tissue by vacuum infiltration42 
(large scale) or by direct pressure infiltration into the abaxial air space of leaves43 
(small scale).  Once located into the plant cells, the Agrobacterium uses horizontal 
gene transfer to transfer the desired genetic information from the bacteria to the 
plant. 
 
5.2 Results and Discussion 
5.2.1 Production of the D3K6D3 pEAQ-HT wt/t-HBcAg plasmids 
In order to produce both the wild type and tandem core (D3K6D3 VLPs in planta, 
new pEAQ-HT plasmids first had to be generated, with the assistance of H. Peyret 
(Lomonossoff group).  Wild type and tandem pEAQ-HT-t-HBcAg-EL (tandem) and 
pEAQ-HT-wt-HBcAg-EL (wild type) expression plasmids were kindly donated by the 
Lomonossoff group (JIC).   
 
Restriction digests (AseI & SalI) of both plasmids was carried out using standard 
conditions and the samples were run on a 0.8% agarose gel.  The corresponding 
bands were excised from the gel and the plasmids were extracted using Qiaquick 
gel extraction kit (Qiagen).  The forward and reverse primers were annealed and the 
ligation reactions were carried out using a 3:1 ratio of insert to plasmid backbone.  
After overnight incubation at 16 oC, Top10 chemically competent E. coli cells 
(Invitrogen) were transformed with the plasmids.  Colony PCR and sequencing was 
used to confirm the successful cloning of the wt/t-HBcAg D3K6D3 plasmids.  Once 
the plasmids (wt-D3K6D3HBcAg and tandem-D3K6D3HBcAg) had been 
successfully cloned, Agrobacterium tumifaciens LBA4404 cells were transformed by 
electroporation.  After recovery on ice, the cells were plated out on to agar 
supplemented with kanamycin and rifamycin.  After incubation for 3 days at 27oC, 
colony PCR was performed and the reactions were analysed by ethidium bromide-
stained agarose gel electrophoresis (Figure 5.11). 
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Figure 5.8: Agarose gel of colony PCR of A. tumifaciens transformation.  Lanes: A) Ladder 
(Hyperladder 1; Bioline; B) pEAQ-HT-wt-HBcAg D3K6D3; C) pEAQ-HT-t-HBcAg D3K6D3; D) PCR 
positive control.  D3K6D3 insert size is 1.59 kDa, recombinant D3K6D3 wt-HBcAg vector is 1288 
bp (B); recombinant D3K6D3 t-HBcAg (C) vector is 1835 bp. 
 
Figure 5.8 highlights the successful cloning, expression and amplification of the 
D3K6D3 HBcAg plasmids in agrobacterium.  The bands at approximately 1800 and 
1200 bp correspond to the monomeric and tandem recombinant plasmids 
respectively.   
 
5.2.2 In planta expression of the VLPs 
A trial in planta expression was conducted using three A. tumifaciens clones 
carrying the D3K6D3 wt/t-HBcAg plasmids, as judged by colony PCR.  Infiltration 
solutions of the cells containing pEAQ-HT-wt/t-HBcAg D3K6D3 plasmids were 
made up in MMA [10 mM MES, 10 mM MgCl2, 100 µM acetosyringone, pH 5.7] 
buffer supplemented with acetosyringone and used to infiltrate the youngest leaves 
of two plants.  Acetosyringone is a phenolic plant compound which is secreted 
during infection and has been shown to up-regulate Agrobacterium infiltration44,45.  
Pre-incubation of Agrobacterium with acetosyringone in MMA buffer, which is 
designed to mimic the environment of the cell leaf activates the cells and leads to 
improved expression levels44.  Six days post infiltration (dpi) the leaves were 
harvested and a single disc (10 mm diameter) was cut from each infiltrated leaf.  
The six discs from each plant were collected and extracted in both HBV extraction 
buffer (HBex) and phosphate buffer in order to determine the best extraction buffer.  
After extraction, the plant material was removed via centrifugation and the crude 
VLP extracts were loaded onto a LDS-PAGE gel for western blot analysis.  
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A western blot of the LDS-PAGE gel was taken and detected using mouse anti-
hepatitis B virus core antigen antibody [10E11] (AbCam), which recognises the first 
10 amino acids of the N-terminus.  Enhanced chemiluminescence techniques were 
used for visualization and the blot was scanned using an Imagequant LAS 500 
scanner (Figure 5.9). 
 
Figure 5.9:  Western blot of trial expression for D3K6D3 wt-HBcAg and D3K6D3 t-HBcAg VLPs 
extracted in PBS and HBex buffer systems.  Lanes: D3K6D3 wild type monomer (Wt 1-3); 
D3K6D3 tandem core (t 1-3); positive control C
+
 wt-HBcAg (200 ng).  Primary antibody: mouse 
anti-Hepatitis B core antigen (10E11 AbCam) (1 in 1000); secondary antibody: goat anti-mouse 
IgG HRP labelled (1 in 3000); detection method enhanced chemiluminescence.   
 
Figure 5.9 demonstrates the successful in planta expression of the t-HBcAg 
D3K6D3 VLP. There was no expression of the wt-HBcAg D3K6D3 with any of the 
plasmid preparations.  This result ratifies the use of the tandem core particle over 
the monomeric core as discussed in the introduction section of this chapter.  It is 
assumed that the inclusion of the highly charged D3K6D3 insert in the E1 loop of 
the monomer prevents the assembly of the dimer building blocks, halting VLP 
assembly.  Based on the results of these blots, the modified D3K6D3 tandem core 
VLP presents a viable option for the generation of a chemically addressable VLP 
carrier.  A larger scale preparation of the D3K6D3 tandem core VLPs was carried 
out using 13 plants, the leaves of which were again harvested 6 dpi.  
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Figure 5.10: (Left) Nicotiana benthamiana leaf being infiltrated with agrobacterium solution.  
(Right) Infiltrated plants. 
 
Once harvested the protein was extracted from the plant material, again using 
phosphate and HBex buffer.  The crude material was isolated on a sucrose gradient 
(20 – 60%) via ultracentrifugation and the fractions were analysed by LDS-PAGE 
(Figure 5.11). 
 
Figure 5.11: Coomassie stained LDS-PAGE gel of VLP purification sucrose gradients.    Lanes: 
A) Supernatant; B) 20% sucrose; C) 30% sucrose; D) 40% sucrose; E) 50% sucrose; F) 60% 
sucrose 
 
The 30-50% sucrose fractions were collected and extensively dialysed against 200 
mM AmBic buffer. An estimation of the expression levels, based on standards, was 
made and shown to be in the region of 0.4 mg of protein per gram of plant tissue.  
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Once dialysed the samples were concentrated by speed vac and submitted for TEM 
analysis (Figure 5.12). 
 
Figure 5.12: Negatively stained TEM image of D3K6D3 tandem core VLP (14,500x).  
 
Figures 5.12 and 5.13 confirm the successful production of fully assembled D3K6D3 
tandem core VLPs.  The image shows that the virus like particles have a tendency 
for self-aggregation, which has been seen before with modified tandem core 
particles.  However, the problem may be accentuated by electrostatic interactions 
generated by the highly charged insert.  The aggregation may impact on the 
availability of the lysine residues for conjugation, but this could only be assessed 
through experimental analysis.  The assembled VLPs are approximately 30 nm in 
diameter as shown below.   
 
Figure 5.13: Zoomed in TEM image of D3K6D3 tandem core VLP (50,000x). 
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5.2.3 Conjugation with FITC 
In order to assess the availability of the inserted lysine residues for conjugation, the 
fluorophore, fluorescein isothiocyanate (FITC) was used.  MALDI-ToF MS has been 
instrumental in the analysis of the TetHc glycoconjugates (Chapter 2) but was not 
successful for the VLP monomer. MALDI-ToF MS was conducted on the pure VLP 
sample but no peak was detected at 42.6 KDa, the mass of the tandem core 
monomer.  On this basis, FITC was selected to aid with the identification and 
characterisation of the VLP conjugates.  The reaction between the isothiocyanate 
group and the lysine residue is similar to that of the acyl azide reaction used 
previously in this study.  Approximately 500 µg of crude VLP was reacted with a 
large excess of FITC in conjugation buffer [0.08M Na2B4O7.10H2O; 0.35m KHCO3; 
pH 9.0] overnight.  After extensive dialysis the crude conjugation was concentrated 
and run on SDS-PAGE and agarose gels. 
 
 
Figure 5.14: Coomassie stained SDS-PAGE gel of FITC conjugated VLP.  Lanes: A) 
kaleidoscope ladder; B) D3K6D3 VLP standard; C) FITC Conjugated D3K6D3 VLP. 
 
Figure 5.14 above shows a small band shift from the unmodified VLP sample to the 
FITC conjugation reaction, indicating that the conjugation of FITC to the D3K6D3 
VLP had been successful.  A second SDS-PAGE gel was visualised using a 
fluorescence scanner and image of which is shown in Figure 5.15. 
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Figure 5.15:  Fluorescence image of SDS-PAGE gel of FITC conjugated VLP. Lanes: A) 
kaleidoscope ladder; B) unmodified D3K6D3 VLP; C) FITC conjugated D3K6D3 VLP. 
 
Despite the high levels of background fluorescence as a result of residual FITC, it is 
possible to see two distinct bands in the gel above. The band labelled above is 
proposed to be FITC labelled D3K6D3 VLP, with the second band corresponding to 
FITC labelled RuBisCo, a major impurity of plant derived proteins. At this stage the 
SDS-PAGE gel data suggested that the lysine residues present in the insert had 
been successfully labelled with FITC, but due to low loading and high background 
the data were inconclusive.  As a result of this agarose gels (Figure 5.16) were also 
run in an attempt to confirm success of the conjugation reaction.  Agarose gels were 
stained using both coomassie and ethidium bromide (EtBr).  EtBr staining detects 
VLPs as the assembly of the VLP in planta encapsulates random nucleic acid into 
the particle, providing an alternative stain to coomassie.  
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Figure 5.16: Agarose gels of FITC conjugated D3K6D3 VLP.  (Left) coomassie stained gel; 
(Right) ethidium stained gel. Lanes: A) unmodified D3K6D3 VLP; B) FITC conjugated D3K6D3 
VLP.  Fluorescence imaging of the agarose gel was not possible due to low loading on the 
agarose gels. 
 
The agarose gels provide further proof that the FITC conjugation of the VLPs was 
successful.  The large band shift between the two samples is indicative of a change 
in mass and charge of the particles.  At pH 8.0 (TBE Buffer) (the charge at the top of 
the E1) the overall charge of the insert at the top of the E1 loop should theoretically 
be balanced.  Upon conjugation the positive charges of the lysine residues would 
effectively be neutralised generating an overall negative charge at the top of the E1 
loop.   
Residue pKa 
Aspartic Acid 3.7 
Lysine 10.5 
FITC 6.4 46 
Table 5.2: Table showing the pKa values for aspartate, lysine and FITC. 
 
This effect would be further enhanced by the presence of the carboxylic acid group 
in the conjugated FITC.  The increase in overall negative charge of the particle will 
cause the large band shift seen in the agarose gels.  Positive staining with ethidium 
bromide was proof for the presence of nucleic acid indicating that the bands 
corresponded to VLPs.   All the evidence collected at this stage suggested that 
FITC of the VLPs was successful and that the lysine residues remained chemically 
accessible upon assembly  
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5.2.4 Purification of VLPs by size exclusion chromatography 
The conjugation of VLPs with FITC raised a number of issues regarding the purity of 
the plant produced VLPs.  The sucrose gradient purification is not sufficient to 
remove all contaminants such as the RuBisCO and other plant material.  In order to 
improve the purity of the VLPs, a second batch of material was produced in plants.  
After extraction and purification (in phosphate buffer) using two sucrose gradients, 
the particles were taken to our collaborators iQur for further purification using size 
exclusion chromatography.  The sample was loaded onto a sepharose CL4B XK 
26/40 column and eluted using PBS (Figure 5.17). 
 
 
Figure 5.17: Trace from Sepharose CL4B column purification of the D3K6D3 VLPs.  Sepharose 
CL4B XK46/40 column flow rate 2 ml/min; eluent PBS; sample loaded 6 ml of plant prep.; 
fractions collected (56 ml – 182 ml) volume collected (1-18) 2 ml; (19-27) 10 ml.  (Blue) UV trace 
A280; (red) conductivity.  
 
Fractions of interest (1-18) were taken and analysed on a Tris-glycine SDS-PAGE 
gel (pH 6.8, Bio-Rad).  The gel was run under standard conditions (Section 7.1.5) 
and stained using a silver staining kit as per manufacturer’s instructions (Pierce), a 
western blot of the gel was also taken and imaged using enhanced 
chemiluminescence detection (Section 7.1.5.6) (Figure 5.18), showing the presence 
of assembled VLP. 
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Figure 5.18: (Left) Silver stained tris-glycine gel of D3K6D3 t-HBcAg VLP purification 
(Sepharose CL4B).  (Right) Western blot of tris-glycine gel.  Lanes: A) wt-HBcAg (50 ng); B) 
loaded sample; C) precision plus dual colour ladder; D) fraction 2 E) fraction 3; F) fraction 4 G) 
fraction 5; H) fraction 6; I) fraction 7; J) fraction 9; K) fraction 11) fraction 15.  Primary antibody: 
mouse anti-Hepatitis B core antigen (10E11 AbCam) (1 in 1000); secondary antibody: goat anti-
mouse IgG HRP labelled (1 in 3000); detection method enhanced chemiluminescence. 
 
MS analysis was done on the highlighted bands of the gel in order to confirm the 
identity of the higher order bands along with the lower molecular weight impurities.  
The high-order structures were shown to be VLP by MS analysis, confirming the 
positive response to the monoclonal antibody in the western blot.  This indicated 
that the VLP was not breaking apart under the reducing conditions of the gel 
demonstrating the robustness of the particles.  The lower weight impurity (band 5) 
was shown to be an unidentified N. benthamiana protein.  In order to determine 
whether the protein (bands 1, 2 and 3) in the above gel and blot corresponds to 
assembled VLP, as opposed to free t-HBcAg D3K6D3 protein, further agarose gels 
were run.  Agarose gels stained for both protein and nucleic acid give a better 
indication of the presence of VLP (Figure 5.19).  Fractions were run without 
concentration on a 1.2% agarose gel with TBE buffer and stained with SYPRO 
Ruby (protein) and ethidium bromide (nucleic acid). 
 
 
167 
 
 
Figure 5.19: Agarose gels (1.2%) of SEC fractions. (Left) SYPRO Ruby stain; (Right) ethidium 
bromide stain.  Lanes: A) Purified D3K6D3 VLP (4.5 µg); B) SEC Input; C) frac 2; D) frac 8; E) 
frac 15; F) frac 19; G) frac 22; H) frac 23; I) frac 24). 
 
Although the bands are weak the gels give a good indication that the assembled 
VLP is eluted off the column after the initial void volume as expected.  The fractions 
were concentrated and run again on agarose gel (Figure 5.20) and studied by TEM. 
 
Figure 5.20: Agarose gels (1.2%) of concentrated SEC fractions stained silver nitrate.  Lanes: A) 
Purified D3K6D3 VLP (4.5 µg); B) SEC Input; C – T) fractions 9 – 26. 
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Figure 5.21: Negatively stained TEM of pooled fractions (9 – 23) from size exclusion 
chromatography of D3K6D3 VLPs.  80,000x magnification shows the presence of T=3 (30 nm) 
particles denoted * and T=4 (34 nm) particles denoted ^. 
 
The agarose gel (Figure 5.20) showed VLPs in fractions 9-23, which were pooled 
and further concentrated to a total volume of 2 ml.  This was then analysed by TEM 
(Figure 5.21) to prove the presence of VLPs in the sample.  The TEM images 
indicated the presence of both 30 nm particles (T=3 particles 90 copies of dimer) 
and 34 nm particles (T=4 120 copies of dimer) particles.  The particles were then 
extensively dialysed (Pierce Float-A-Lyzer, 1000 KD MWCO) into Borax [0.08 mM 
Na2B2O7.10H2O, pH = 9.0] buffer.  The dialysed VLPs (3 ml) were then conjugated 
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again to FITC in an attempt to further confirm the availability of the inserted lysines 
for conjugation.  KHCO3 was added to the VLPs (500 µl) in Borax to give 
conjugation buffer [0.08 m Borax, 0.35 M KHCO3, pH = 9.0] and FITC was added 
and the conjugation was left at 4 oC overnight.  The excess FITC was removed by 
spin filtration (Sartorius Vivaspin 10,000 MWCO) and the VLPs were isolated by 
sucrose gradient.   The UV visualisation of the FITC-VLP sucrose gradient (Figure 
5.22) clearly demonstrates the successful conjugation of FITC to the VLP.  Free 
FITC in solution (from spin filtration wash) demonstrates that due to its small size 
free FITC does not enter the sucrose gradient and remains in the supernatant layer 
(Figure 5.22 B).  Only FITC which is conjugated to VLP will be able to enter the 
sucrose gradient.  It was shown in Section 5.2.2, during the purification of the VLPs 
that the particles are purified primarily from the 30-50% sucrose gradient.  The 
fluorescent band (ca. 40 – 50% sucrose) in Figure 5.22 C corresponds to FITC 
which has been covalently bound to the VLP.   
 
 
Figure 5.22:  UV visualisation of the FITC labelled VLP sucrose gradient. A) schematic 
representation of the sucrose gradients (not to scale); B) free FITC in the supernatant (S/N); C) 
FITC-VLP in the S/N. 
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This result confirms the successful production of, and conjugation of FITC to the t-
HBcAg D3K6D3 VLPs.  The fluorescent VLPs were collected and analysed by SDS-
PAGE and agarose gel electrophoresis for completion (Figure 5.23 & 5.24) and 
confirm that the conjugated material is FITC-labelled D3K6D3 t-HBc-Ag VLP.  The 
characteristic band shift in the agarose gels (Figure 5.24) further demonstrates the 
successful conjugation of the D3K6D3 t-HBC-Ag VLPs with FITC. 
 
Figure 5.23: SDS-PAGE gel of the isolated sucrose gradient fraction visualised using different 
techniques: 1) Coomassie stained; 2) fluorescence image (495 nm) and 3) visualised under blue 
light (470 nm).  Lanes: A) Kaleidoscope ladder containing fluorescent proteins at 25 and 75 
kDa; B) native D3K6D3 HBc-Ag VLP; c) FITC conjugated D3K6D3 HBc-Ag VLP.  
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Figure 5.24: Agarose gel of the isolated sucrose gradient fraction visualised using different 
techniques: 1) Coomassie stained; 2) ethidium-bromide stained and 3) fluorescence image (495 
nm).  Lanes: A) unmodified D3K6D3 HBc-Ag VLP; B) FITC conjugated D3K6D3 HBc-Ag VLP. 
 
5.3 Conclusions 
The initial work described in this chapter demonstrated the development and in 
planta expression of a novel tandem hepatitis B core antigen (t-HBcAg D3K6D3).  A 
peptide consisting of six chemically addressable lysine residues flanked with three 
aspartate residues on each side was designed.  The insert was cloned into both the 
wild-type and tandem constructs; however, trial expression with the wild-type variant 
failed but succeeded with the tandem core construct.  Tandem particles were 
initially purified and a trial conjugation with fluorescein isothiocyanate was 
attempted.  Analysis of the conjugate demonstrated the successful conjugation of 
the VLP material, but also highlighted some issues of purity.  More extensive 
purification methods were developed utilising size exclusion chromatography.  In 
collaboration with iQur Ltd the VLP material was shown to high purity, ca. >90%.  
The VLPs will be conjugated to existing and future antigens (monosaccharide and 
CPS) for use in immunisation trials.  The generated antibodies will then be used for 
comparison with the more traditional TetHc glycoconjugates to assess the potential 
of the t-HBcAg D3K6D3 as a carrier protein; this work is currently on-going in the 
lab.  
 
5.3.1 Future Directions 
The in planta production of the D3K6D3 t-HBcAg VLPs described in this chapter has 
been shown to be an improvement compared to the current alternative expression 
systems (yeast, E. coli and Baculovirus) (personal communication, M. Whelan,  iQur 
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Ltd.).  However, if the VLPs are shown to be a good carrier protein further work will 
be needed to establish large scale production of the VLPs as the current method of 
sucrose gradient purification does not lend itself to scale up.  Optimisation of either 
the purification methodology of the plant derived material, or of a more suitable 
expression system must be carried out before this material can be developed 
further.  If the production and purification of the D3K6D3 VLPs can be improved, 
given that the inclusion of antigens is based solely on chemical modification rather 
than the development of individual constructs, the development of a series of VLP 
based immunogens is possible.  
 
Owing to the nature of the D3K6D3 tandem core it is possible to utilise the second 
E1 loop to include a second antigen such as an immunogenic peptide sequence.  
As discussed in the introduction one of the vaccination strategies for B. 
pseudomallei involves the use of immunogenic peptides (i.e. LolC).  The D3K6D3 
tandem core provides the ideal platform for the expression of a peptide containing 
carrier protein (1st E1 loop) followed by the chemical conjugation of a carbohydrate 
vaccine to the 2nd E1 loop to give a multi-component vaccine.  iQur and DSTL-
Porton Down are currently developing B. pseudomallei LolC t-HBcAg constructs 
which could be used in combination with the D3K6D3 insert to develop a bivalent B. 
pseudomallei vaccine candidate.   
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6 Conclusions and outlook 
Immunisation and lethal challenge studies in mice using the capsular 
polysaccharide of B. pseudomallei (CPS) (4) have shown it to be a potential 
candidate for the development of a carbohydrate vaccine for B. pseudomallei1,2.  As 
discussed in the introduction to this thesis, the full chemical synthesis of 
oligosaccharide fragments of the CPS (4) is a challenging endeavour.  This thesis 
has focused on two strategies for the development of carbohydrate antigens of the 
CPS (4).  The first involved the synthesis and conjugation of monosaccharide 
haptens (64, 69 & 91), and the second, the purification and extraction of the 
polysaccharide from an avirulent strain of Burkholderia (Figure 6.1).   
 
Figure 6.1: Schematic representation of the two methods for the development of CPS antigen 
glycoconjugates. 
 
This final section will summarise the progress made during this research project, 
whilst putting the results into the context of the vaccine development program. 
 
6.1 Monosaccharide antigens 
In an attempt to explore the potential of multivalent monosaccharide antigens for the 
purpose of antibody generation two monosaccharide haptens were developed; 8-
(methoxycarbonyl)octyl β-D-glucopyranoside (69) and 8-(methoxycarbonyl)octyl 6-
deoxy-6-fluoro-β-D-glucopyranoside (111).  The monosaccharide haptens were 
conjugated to TetHc carrier protein and underwent immunisation trials in sheep.  
Immunological assessment by ELISA and slot-blot analysis, of the polyclonal sera 
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demonstrated activity towards the cognate monosaccharide hapten-BSA 
conjugates.  It was shown that the 8-carbon alkyl linker (58) had a strong influence 
on antibody development, resulting in cross-reactivity with the non-cognate 
monosaccharide haptens, D-mannose (64) and 6-deoxy-D-manno-heptose (91).  
However, competition experiments using the D-mannose hapten-BSA conjugate 
(93) established that the polyclonal Glc-TetHc sera had a degree of specificity for  
D-glucose.  A second set of short linker haptens using 3-methyl mercaptopropionate 
were developed and will be used to assess the effect of a shorter linker on antibody 
development and specificity (Figure 6.2).   
 
S OMe
OOHO
 
Figure 6.2: General structure of the second generation short-linker haptens.  3-methyl 
mercaptopropionate was used as the linker in place of 8-methoxycarbonyl octanol (58). 
 
The 6-deoxy-6-fluoro-D-glucose antigen (112) was developed in order to assess the 
potential of using fluorine for the development of improved antigens, as seen with 
other fluorinated carbohydrate antigens3.   Preliminary ELISA experiments with the 
6-deoxy-6-fluoro-D-glucopyranose hapten derived sera showed activity towards the 
native D-glucose hapten-BSA conjugate (97).  Further investigations, including the 
purification of antibodies using immobilised antigen will be required to assess the 
potential for the monosaccharide hapten derived antibodies.  If purification of these 
antibodies and further immunological analysis (ELISA and Octet Red 96) are shown 
to confirm the presence of monosaccharide specific antibodies, then the production 
of monosaccharide specific monoclonal antibodies should be investigated. 
 
In the context of the development of a vaccine for B. pseudomallei, a 
monosaccharide antigen based on the 6-deoxy-D-manno-heptopyranose building 
block of the B. pseudomallei capsular polysaccharide was produced.  The 
monosaccharide hapten, 8-(methoxycarbonyl)octyl 6-deoxy-D-manno-
heptopyranose (91) was again conjugated to TetHc fragment and submitted for 
immunisation trials in sheep.  Preliminary immunological assessment (ELISA and 
slot-blot) of the polyclonal antibodies demonstrated specificity for the 6-deoxy-
heptose monosaccharide.  Further investigations with the Octet Red96 biosensor 
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system suggested activity of the anti-monosaccharide antibodies towards the intact 
CPS.  Purification of the antibodies and further characterisation will be required in 
order to confirm this activity as outlined in section 4.5.  If this activity is confirmed, 
the use of this monosaccharide antigens will be investigated further.  As part of this 
research project, efforts were made to simplify the synthesis of 6-deoxy-D-manno-
heptopyranose using protecting-group free strategies.  Continuation of this work in 
the lab should look at streamlining this process further in order to facilitate further 
research into synthetic CPS antigens.     
 
Development of the monosaccharide antigens is ongoing, focusing on the use of a 
synthetic dendrimer for the presentation of the monosaccharide hapten (Figure 6.3).   
 
Figure 6.3: Schematic representation of the development of an octameric dendrimer for the 
multi-valent presentation of the monosaccharide CPS hapten. 
 
The aim of this work is to develop a multivalent scaffold of the monosaccharide 
which could be conjugated to a carrier protein such as TetHc, or the D3K6D3 t-
HBcAg virus-like particle carrier developed in this thesis.  Alternatively the 
dendrimer scaffold could be linked to an immunomodulating peptide or 
polysaccharide, directing the antigen to antigen-presenting cells resulting in a strong 
immune response4, 5.  The use of an immunomodulating sequence removes the 
need for reliance on carrier proteins.  This work could provide a route for the 
development of a fully synthetic polysaccharide vaccine for B. pseudomallei. 
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6.2 Natural polysaccharide 
The extraction and purification of B. pseudomallei CPS in the avirulent B. 
thailandensis E555 ΔwbiI strain offers a scalable route for the production of CPS.  
The characterisation of this polysaccharide, confirmed the observation made by 
Heiss et al.6 regarding the presence of an α-1,3-mannan polysaccharide (106) in 
Burkholderia CPS extracts.  It was anticipated, based on the fact that the native B. 
thailandensis E264 strain does not produce the mannan polysaccharide, that the 
biosynthesis of the α-1,3-mannan (106) is associated with the CPS biosynthetic 
cluster. To date the separation of the two polysaccharides has not been successful 
and it is not known whether they are two distinct polysaccharides or part of a hetero-
polysaccharide.  Manipulation of the CPS-biosynthetic cluster in the B. thailandensis 
E555 ΔWbiI may prove to be useful in deciphering the relationship of these two 
polysaccharides. 
 
The conjugation of isolated Bth-CPS (104) to a carrier protein was successful, but 
led to the formation of a heterogeneous mix of glycoconjugates.  Mild acid 
hydrolysis of the polysaccharide was carried out resulting in a mixed population of 
2-O-acetylated and 2-de-O-acetylated oligosaccharide fragments. Method 
development is required to establish the optimum conditions to provide 
oligosaccharide fragments for conjugation.  Further immunological experiments 
using the 2-O-acetlyated and 2-de-O-acetylated forms of the polysaccharide must 
also be employed in order to confirm the validity of the assumption regarding the 
lack of importance of this group on the immune system recognition of the 
polysaccharide. 
 
Based on ELISA and Octet 96Red analysis of the Ancora hexasaccharide (54) 
(Figure 6.4) and mAb 4IVH12, no binding of the monoclonal antibody to the 
synthetic oligosaccharide fragment was observed.   
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Figure 6.4: Structure of the Ancora Hexasaccharide (54) fragment of CPS 
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It may be the case that mAb 4IVH12 either recognises a conformational epitope of 
CPS or that it is specific for the α-1,3-mannan polysaccharide (106), and as such 
does not recognise the 6-deoxy-D-manno-heptose oligosaccharide fragment.  
Access to pure α-1,3-mannan (106) oligosaccharide would prove helpful in 
determining which polysaccharide mAb 4IVH12 is specific for.  However, SPR 
experiments using the Biacore T-200 system and immobilised antibody should 
provide the required sensitivity to finally establish the level of binding of mAb 
4IVH12 to the hexasaccharide (54).  This result, in combination with the further 
characterisation of the 6dHep-TetHc sera activity to CPS will help to inform the 
decision regarding the use of monosaccharide/oligosaccharide antigens for 
vaccination purposes.       
 
6.3 D3K6D3 t-HBcAg virus-like particle 
The development of a versatile, chemically conjugatable virus-like particle carrier 
based on tandem-core technology (iQur) was also conducted as part of this 
research project.  A poly-lysine peptide sequence was inserted into the tip of the 
major immunodominant region of the tandem hepatitis B core antigen.  Initial 
expression trials demonstrated that wild-type monomeric HBcAg core particles 
would not assemble with the D3K6D3 insert, highlighting the need for the use of 
tandem core technology.  High purity VLP particles (> 90%) were produced and 
extracted from Nicotiana benthamiana and trial conjugation experiments were 
carried out using fluorescein isothiocyanate (FITC).  Successful conjugation of the 
VLPs with the FITC fluorophore was achieved and analysed by SDS-PAGE, 
agarose gel and sucrose gradient.  Conjugation of existing monosaccharide haptens 
to the D3K6D3 VLP, followed by immunisation trials will provide information 
regarding the potential use of the VLP carrier in the wider vaccine development 
program.  However, further work is needed on development of the extraction and 
purification techniques from plant material before useful quantities of VLP can be 
produced.  iQur are also investigating different expression systems; yeast, E. coli 
(LPS deficient strain Clearcoli) and Baculovirus, however much work is still needed 
before these methods are viable.  Work is currently underway (iQur) to combine the 
use of synthetic antigens (mono-/oligo-saccharide) with immunogenic B. 
pseudomallei peptides, such as LolC7, in an attempt to produce a bi-functional 
vaccine candidate. 
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6.4 Summary 
There is still a great deal of work required before the components developed as part 
of this thesis can be combined to produce a viable vaccine candidate.  However, the 
progress made in this work underpins a number of follow-up experiments which will 
be conducted as part of the ongoing research collaboration between JIC, DSTL-
Porton Down, Mologic and iQur.  Beyond, the B. pseudomallei project, the potential 
for the development of monosaccharide specific antibodies has broad potential in 
both therapeutic and diagnostic applications 8,9,10.  Carbohydrates play an important 
role in the development and prevention of diseases and much research is still 
required before the exploitation of these roles can be fully realised.    
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7 Experimental  
7.1 General Experimental Methods 
All reagents were brought from commercial suppliers and were used without further 
purification (Sigma Aldrich, Toronto Research Chemicals, Pierce, Fisher Scientific 
Ltd, Carbosynth) unless otherwise stated in the text.  Thin-layer chromatography 
(TLC) was performed using aluminium backed, pre-coated silica plates (Merck, 
silica gel 60 F254).  Components were detected by UV light or by immersion in 5% 
H2SO4 in ethanol followed by heating.  Flash chromatography was performed on an 
Isolera 4 (Biotage) flash purification system with pre-packed silica gel columns (10 
g, 25 g, 50 g and 100 g; Biotage).  Evaporation of solvents was carried out in vacuo 
at 25 – 45oC.  NMR spectra were recorded with a Bruker Avange III HD 400 MHz 
spectrometer at 400 MHz (1H) or 100.6 MHz (13C).  Assignments were made with 
the aid of homonuclear (COSY, NOESY) and heteronuclear (HSQC) two-
dimensional correlation spectroscopy.    Low-resolution mass spectrometry was 
performed on a Bruker Daltronics Ultraflex ToF/ToF mass spectrometer using a N2 
laser in 30 shot mode using a ground steel target plate and 2,5-dihydroxybenzoic 
acid matrix (DHB) in positive mode.  A total of 200 shots were collected per sample 
at 50 – 75% laser power dependant on signal intensity.  Mass data were analysed 
using Bruker Daltronics flexanalysis software.  High resolution mass spectrometry 
was performed by Dr Gerhaard Salbach using a SYNAPT G2-Si spectrometer with 
electrospray ionisation (ESI) in positive mode.  Optical rotations were recorded at 
20OC on a Perkin-Elmer 341 polarimeter.  
 
7.1.1 General deacetylation/debenzoylation procedure 
A small piece of metallic sodium was added to a solution of protected compound in 
absolute MeOH, the solution was stirred at room temperature until it was shown to 
be complete by TLC.  The reaction was neutralised with Amberlite IR-120 H+ resin, 
after which the resin was filtered off and the solvent was removed in vacuo.   
 
7.1.2 Protein conjugation 
A solution of acyl hydrazide, containing 4M HCl in dioxane (5 equiv) and t-butyl 
nitrite (1.8 equiv) in DMF (1 ml) was stirred for 15 minutes at -25oC.  After 15 
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minutes sulfamic acid (1 equiv) in DMF (100 µl) was added and the reaction mixture 
was allowed to reach 0oC.  The cold acyl azide solution was then added dropwise to 
a solution of protein (0.01 equiv) in conjugation buffer [0.08M Borax; 0.35M KHCO3; 
pH = 9.0].  The solution was stirred overnight at 4oC. 
 
After 16 hours the conjugation reaction was extensively dialysed (4 litres x 5 
changes) (Snake Skin; 10 MWCO; Fisher Scientific) against ammonium bicarbonate 
solution [200 mM, pH 8.0] and lyophilised to afford pure protein conjugate.  Protein 
conjugate were analysed using MALDI-ToF MS 7.1.3 and SDS-PAGE 7.1.4. 
 
7.1.3 MALDI-ToF MS of protein conjugates 1 2 
Glycoproteins were solubilised in a saturated solution of sinapinic acid matrix [70% 
MeCN, 0.1% TFA] at 0.4 mg/ml.  A sandwich layer technique was used for the 
preparation of the sample on to a MALDI-ToF ground steel target plate (Bruker 
Daltronics).  First saturated matrix solution (0.5 µl) was loaded onto the plate and 
left to dry on the bench, secondly the freshly prepared matrix and protein solution 
was added onto the crystallised matrix layer (0.5 µl).  After drying on the bench 
another layer of saturated matrix solution (0.2 µl) was layered on top of the spot to 
form a matrix sandwich.   
 
All protein MS analyses were conducted on a Bruker Daltronics Ultraflex ToF/ToF 
mass spectrometer using a N2 laser in 50 shot mode.  A total of 200 shots were 
collected per sample at 50 – 75% laser power dependant on signal intensity.  Mass 
data were analysed using Bruker Daltronics flexanalysis software. 
 
7.1.4 SDS-PAGE analysis of proteins3 
Loading buffer (5 µl) [SDS Running buffer; 10% (v/v) glycerol; 0.1 mg/ml 
bromophenol blue; 0.1 mg/ml β-mercaptoethanol] was added to protein (25 µl; 0.4 
mg/ml) in MQ-H2O.  After heating at 100
oC for 5 min the samples were loaded onto 
a 4-20% RunBlue precast gel (Expedion) and run in RunBlue running buffer [40 mM 
Tricine; 60 mM Tris-HCl; 0.1% SDS; 2.5 mM sodium bisulfite; pH 8.2] at 180 V for 
53 min.  Gels were removed from the case and stained for protein with Instant Blue 
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protein stain (Expedion).  LDS gels for initial VLP work were done using the same 
protocol with NuPAGE LDS gels (Life Technologies) and LDS buffer. 
 
7.1.5 Western Blot of SDS/LDS-PAGE gel 
PVDF blotting membrane cut to size (8 x 11 cm) was pre-wet in MeOH (10 ml), the 
SDS-PAGE gels were pre-soaked in Towbin blotting buffer [25 mM Tris; 192 mM 
Glycine; 20% MeOH; pH 8.6] to avoid the gel shrinking during blotting.  The gel and 
membrane were assembled in the blotting apparatus (BioRad) with pre-cooled 
Towbin buffer.  An ice block was placed in the blotting tank to keep the apparatus 
cool and the blots were run at 100 V for 1.5 hours.  Membranes were blocked 
overnight in 5% BSA in PBST and visualised using the appropriate 1
o and 2o 
antibodies. 
 
7.1.6 Polysaccharide hydrolysis with strong acid 4 
A solution of polysaccharide (20 µl of a 3 mg/ml solution in MQ-H2O) was added to 
a screw cap reaction vial containing TFA (30 µl in 150 µl of MQ-H2O).  The vial was 
sealed and heated to 100oC for 4 hours.  The reaction was concentrated in vacuo 
using a SpeedVac® evaporation centrifuge (Thermo®).  The polysaccharide was 
reconstituted in MQ-H2O (300 µl), vortexed for 30 seconds and centrifuged for 5 
mins (14,000 rcf).  The polysaccharide hydrosylate sample (10 µl, 2 µg) was then 
injected onto the Dionex® ICS-5000® HPAEC-PAD for analysis.5 
 
7.1.7 Monosaccharide analysis by HPAEC-PAD chromatography 
7.1.7.1 Assessment of gradient conditions 
A mixture (10 µl) of 6-deoxy-D-mannoheptose, L-fucose, D-galactose, D-glucose, D-
mannose and L-rhamnose (each at 10 µM concentration) was injected onto the 
Dionex® HPAEC-PAD system.  Isocratic elution with 6, 8, 10 and 12 mM NaOH 
(Fisher® HPLC grade) were run (0.25 ml/min) for 40 minutes followed by a 6 min 
wash step (100 mM NaOH) and a 15 min re-equilibration step.  Detection was 
achieved using pulsed amperometic detection (PAD). 
186 
 
 
 
Figure 7.1: Overlay of chromatograms from monosaccharide analysis of a mixed sample 1) L-
fucose 2) L-rhamnose 3)  6-deoxy-D-heptose 4) D-galactose 5) D-glucose 6) D-mannose.  Dionex 
PA-100G Column (2 x 50 mm); flow rate 0.25 ml/min; 6, 8, 10 and 12 mM NaOH isocratic elution; 
25
o
C 10 µl (2 µg) injection; pulsed amperometric detection (Au electrode). 
 
7.1.7.2 Monosaccharide analysis of polysaccharide hydrosylate 
Polysaccharide hydrosylates (10 µl) were injected onto the system and the 
monosaccharide analysis was done using an 8 mM NaOH isocratic gradient (see 
above).  Spiking experiments were done on a monosaccharide by monosaccharide 
basis.  This was due to the impact of the addition of a monosaccharide on the 
retention times of the monosaccharide mixture.  The polysaccharide hydrosylate 
samples were supplemented with monosaccharide standards (10/25 µM final 
concentration) and injected onto the column (10 µl).  
 
7.1.1 Phenol-sulphuric acid assay for carbohydrate6 
Aliquots (50 µl) of the analysed solution were added to a 96-well microtitre plate 
(Nunclon Delta Surface, Thermo Scietific) followed by the addition of concentrated 
sulphuric acid (150 µl) and 5% aqueous phenol (30 µl) to each well.  The plate was 
heated at 90oC for 5 mins in an oven and cooled to room temperature over 5 mins.  
Absorbance was read at A405 using a plate-reader to give relative concentration of 
carbohydrate. 
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7.2 Chapter 2 Experimental 
7.2.1 8-Methoxycarbonyl octanol (58)7, 8 
58
HO OMe
O
 
BH3·THF complex (1 M in THF; 100 ml) was added dropwise to a stirred solution of 
monomethyl azelate (57) (20 g; 99 mmol) in dry THF (50 ml) at -20 oC over a period 
of 30 min.  The reaction mixture was allowed to warm to room temperature and 
stirring continued for a further 4 hours.  After the reaction was shown to be complete 
(TLC Hex:EtOAc; 1:1) it was quenched using water and K2CO3 (20 g; 168 mmol) at 
0oC and extracted using Et2O (3x100 ml).   The combined organic layers were 
washed with brine and dried over MgSO4, filtered and concentrated in vacuo.  The 
resulting oil was purified using flash chromatography [Hex:EtOAc; 1:1] to afford  
methyl ester (58) as a colourless oil, (15.26 g, 82%).  1H NMR (400 MHz, CDCl3): 
3.65 (3 H, s, OMe), 3.60 (2H, t, JH7,8 = 6.5 Hz, CH2OH), 2.31 (2H, t, JH2,3 = 7.5 Hz, 
CH2OOMe), 1.90-1.25 (12H); 
13C NMR  (100 MHz, CDCl3): 176.0, 62.9, 60.0, 34.8, 
33.6, 30.7, 30.4, 30.3, 30.1, 26.9, 26.0; MALDI-ToF m/z 211.86 [M+Na]+, 227.94 
[M+K]+, calculated for C10H20O3Na 211.25 and C10H20O3K 227.36 
 
7.2.2 2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl bromide (61)9 
O
AcO
AcO
OAc
OAc
61
Br
 
Finely ground iodine (90 mg, 0.35 mmol, 2.5 mol %) was dissolved in acetic 
anhydride (2 ml) and the solution was heated until the exothermic reaction was self-
propagating.  The hot iodine/acetic anhydride complex was added to a suspension 
of D-mannose (59) (2.5 g, 13.90 mmol) in acetic anhydride (25 ml) and the mixture 
was vigorously stirred in a 25oC water bath.  After 10 min the sugar had completely 
dissolved and the reaction was shown to be complete by TLC [Hex:EtOAc, 4:1].  
The solution was diluted in 50 ml of EtOAc and quenched by the addition of solid 
NaHCO3 (5 g), it was then washed with sat. aq. NaHCO3 solution (50 ml), Na2SO3 
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(50 ml) and H2O (50 ml), dried over MgSO4 and solvents were removed in vacuo.  
The residual syrup was used without further purification (5.0 g, 12.80 mmol, 92 %). 
 
Per-O-acetylated D-mannopyranose (60) (5.0 g, 12.80 mmol) was dissolved in dry 
DCM (25 ml) and the solution was cooled to 0oC.  HBr (9 ml of 33% w/v soln 
HBr/AcOH, 38 mmol) was added dropwise and the reaction mixture was left to stir 
for 3 hours.  The solution was washed with H2O/ice (3 x 30 ml), sat. aq. NaHCO3 
solution (30 ml) and H2O (30 ml), the organic layer was dried over MgSO4 and the 
solvent was removed in vacuo, to afford bromide (61) as a white foam (4.1 g, 9.85 
mmol, 77%).  [α]D = + 110.5 (c 1.0, CHCl3), Lit
9 [α]D + 111.8 (c 1.0, CHCl3); 
1H NMR 
(400 MHz, CDCl3): 6.30 (1H, d, J1,2 = 1.5 Hz, H-1), 5.72 (1H, dd, J2,3 = 3.5 Hz, J3,4 = 
10.0 Hz, H-3), 5.45 (1H, dd, J1,2 = 1.5 Hz, J2,3, = 3.5 Hz, H-2), 5.37 (1H, t, J3,4 = J4,5 = 
10.0 Hz, H-4), 4.34 (1H, dd, J5,6 = 5.0 Hz,  J6a,ab = 12.5 Hz, H-6a), 4.24 – 4.20 (1H, m, 
H-5), 4.17 – 4.13 (1H, m, H-6b), 2.11 (3H, s, OAc), 2.09 (3H, s, OAc), 2.04 (3H, s, 
OAc), 2.01 (3H, s, OAc); 13C NMR (100 MHz, CDCl3): 170.6, 170.0, 169.8, 169.5 
(C=O), 83.4 (C-1), 73.1 (C-2), 72.6 (C-5), 67.3 (C-3), 66.0 (C-4), 60.9 (C-6), 20.9, 
20.8, 20.5 (OAc); MALDI-ToF m/z 433.89 [M+Na]+, 450.01 [M+K]+, calculated for 
C14H19BrO9Na 434.19 and C14H19BrO9K 450.30. 
 
7.2.3 8-(Methoxycarbonyl)octyl 2,3,4,6-O-acetyl-α-D-mannopyranoside 
(62)10 
O
AcO
AcO
OAc
OAc
62
O OMe
O
 
A solution of mercury bromide (330 mg; 1.30 mmol), mercury cyanide (47 mg; 0.132 
mmol), 8-methoxycarbonyl octanol (58) (205 mg; 1.10 mmol) and 4Å molecular 
sieves (250 mg) in dry DCE (4.5 ml) was stirred at room temperature for 30 mins.  
Bromide (61) (300 mg; 0.75 mmol) in dry DCE (0.5 ml) was added dropwise to the 
stirred solution and the reaction was left at room temperature for 16 hours.  After 
which, the reaction mixture was filtered and the filtrate was washed with KBr (10 
ml), H2O (3 x 10 ml), dried over MgSO4 and concentrated in vacuo.   
Chromatography [Hex:EtOAc; 5:2] was performed to isolate alkyl mannoside (62) 
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(148 mg,  0.28 mmol, 39%) as a pale yellow oil.  [α]D = +45.3 (c 1.0, CHCl3), Lit
10 
[α]D + 40.0 (c 1.02, CHCl3); 
1H NMR (400 MHz, CDCl3): 5.35 (1H, dd, J2,3 = 3.0 Hz, 
J3,4 = 10.0 Hz, H-3), 5.30 (1H, t, J3,4 = J4,5 = 10.0 Hz, H-4), 5.26 (1H, dd, J1,2 = 1.5 
Hz, J2,3 = 3.0 Hz), 4.78 (1H, d, J1,2 = 1.5 Hz), 4.30 (1H, dd, J5,6 = 5.0 Hz, J6a,6b = 12.0 
Hz, H-6a), 4.07 (1H, dd, J5,6 = 5.0 Hz, J6a,6b = 12.0 Hz, H-6b), 4.01 (1H, m, H-5), 3.65 
(3H, s, OMe), 3.62-3.54 (2H, m, OCH2-spacer), 2.30 (2H, t, J = 7.0 Hz, 
CH2COOMe), 2.10 (3H, s, OAc), 2.07 (3H, s, OAc), 2.05 (3H, s, OAc), 2.03 (3H, s, 
OAc), 1.59 - 1.47 (4H, m, 2 x CH2), 1.36 – 1.17 (8H, m, 4 x CH2); 
13C NMR (100 
MHz, CDCl3): 177.9 (COOMe), 169.9, 169.7, 169.6 (C=O),  98.6 (C-1), 72.7 (C-5), 
70.6 (C-2), 70.1 (C-3), 67.9 (CH2O), 66.7 (C-4), 60.7 (C-6), 52.0 (OMe), 33.7 
(CH2COOMe), 28.4-24.2 (4 x OAc; 6 x CH2); MALDI-ToF m/z 541.71 [M+Na]
+, 
557.81 [M+K]+, calculated for C24H38O12Na 541.54 and C24H38O12K 557.65. 
 
7.2.4 8-(Methoxycarbonyl)octyl-α-D-mannopyranoside (63)10, 11 
O
HO
HO
OH
OH
63
O OMe
O
 
 
8-Methoxycarbonyloctyl 2,3,4,6-acetyl-α-D-mannopyranoside (62) (100 mg; 1.92 
mmol) was deprotected using general deactylation procedure 7.1.1.  The solvents 
were evaporated in vacuo to afford alkyl mannoside (63) as a white amorphous 
solid (56.7mg, 0.16 mmol, 84%).  [α]D = + 49.4 (c 0.6, MeOH), Lit
11 [α]D = + 51.5 (c 
1.0, MeOH), Lit10 [α]D =  43.4 (c 0.4, MeOH); 
1H NMR (400 MHz, D2O): 4.80 (1H, dd, 
J1,2 = 1.5 Hz, H-1), 3.90 (1H, dd, J1,2 = 1.5 Hz, J2,3 = 4.0 Hz, H-2), 3.83-3.78 (2H, m, 
H-6a,b),  3.75 (1H, dd, J2,3 = 4.0 Hz, J3,4 = 9.0 Hz, H-3), 3.73 - 3.70 (2H, m, H-4, 
CH2O), 3.66 (3H, s, OMe), 3.58 - 3.62 (1H, m, H-5), 3.49 - 3.46 (1H, m, CH2O), 2.33 
(2H, t, CH2COOMe), 1.60 – 1.49 (4H, m, 2 x CH2), 1.36 - 1.19 (8H, m, 4 x CH2); 
13C 
NMR (100 MHz, D2O): 177.8 (COOMe), 99.5 (C-1, 
1JC1,H1 = 171 Hz), 72.9 (C-5), 
72.0 (C-3), 68.9 (CH2O), 67.5 (C-4), 62.1 (C-6), 53.1 (OMe), 35.1 (CH2COOMe), 
29.4 – 25.1 (6 x CH2), MALDI-ToF m/z 373.89 [M+Na]
+, 390.01 [M+K]+, calculated 
for C16H30O8Na 373.39 and C16H30O8K 389.54. 
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7.2.5 8-(Hydrazinocarbonyl)octyl-α-D-mannopyranoside (64) 
O
HO
HO
OH
OH
64
O NHNH2
O
 
 
Treatment of alkyl mannoside (63) (10 mg, 0.03 mmol) with hydrazine monohydrate 
(1 ml) in EtOH (2.5 ml) at 55oC for 6 hours afforded the hydrazide hapten (64) in 
quantitative yield.  The product (64) was cleaned up by co-evaporation of excess 
reagent with toluene (3 x 10 ml) and NMR analysis confirmed complete conversion 
by loss of the singlet at δ 3.66 ppm (OMe) in the 1H NMR spectra. 
 
7.2.6 2,3,4,6- Tetra-O-acetyl-α-D-glucopyranosyl bromide (66)12  
O
AcO
AcO
AcO
OAc
66
Br
 
Per-O-acetylated glucose (65) (10.0 g, 25.50 mmol) was dissolved in dry DCM (50 
ml) and cooled to 0oC.  HBr (18 ml of of 33% w/v soln HBr/AcOH, 76.6 mmol) was 
added drop-wise and the reaction mixture was left to stir for 3 hours.  The solution 
was washed with H2O/ice (3 x 50 ml), sat. aq. NaHCO3 solution (50 ml) and H2O (50 
ml), the organic layer was dried over MgSO4 and the solvent was removed in vacuo, 
the product was recrystallized from Et2O to afford bromide (66) (8.4 g, 20.2 mmol, 
79%).  [α]D  = +180.8 (c = 1.0, CHCl3), Lit
13 = +190.9 (c = 1.0, CHCl3); 
1H NMR (400 
MHz, CDCl3): 6.61 (1H, d, J1,2 = 4.0 Hz), 5.56 (1H, t, J2,3 = J3,4 = 9.5 Hz, H-3), 5.17 
(1H, t, J3,4 = J4,5 = 9.5 Hz, H-4), 4.84 (1H, dd, J1,2 = 4.0 Hz, J2,3 = 10.0 Hz, H-2), 4.37 
– 4.27 (2H, m, H-5, H-6a), 4.13 (1H, m. H-6b), 2.11 (3H, s, OAc), 2.10 (3H, s, OAc), 
2.06 (3H, s, OAc), 2.04 (3H, s, OAc);  13C NMR (100 MHz, CDCl3): 170.5, 169.9, 
169.8, 169.5 (C=O), 86.6 (C-1), 72.1 (C-5), 70.6 (C-2), 70.1 (C-3), 67.1 (C-4), 60.9 
(C-6), 20.7, 20.6 (4 x OAc); MALDI-ToF m/z 434.07 [M+Na]+, 450.21 [M+K]+, 
calculated for C14H19BrO9Na 434.19 and C14H19BrO9K 450.30. 
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7.2.7 8-(Methoxycarbonyl)octyl-2,3,4,6-O-acetyl-β-D-glucopyranoside (67)14 
O
AcO
AcO
OAc
OAc
67
O OMe
O
 
A solution of mercury bromide (115 mg; 0.32 mmol), mercury cyanide (830 mg; 3.28 
mmol), 8-methoxycarbonyl octanol (58) (310 mg; 1.64 mmol) and 4Å molecular 
sieves (500 mg) in dry DCE (9.5 ml) was stirred at room temperature for 30 mins.  
Bromide (66) (750 mg; 1.83 mmol) in dry DCE (0.5 ml) was added dropwise to the 
stirred solution and the reaction mixture was left at room temperature for 16 hours.  
After which, the solution was filtered and the filtrate was washed with KBr (10 ml), 
H2O (3 x 20 ml), dried over MgSO4 and concentrated in vacuo.   Chromatography 
[Hex:EtOAc; 5:2] was performed to isolate alkyl glucoside (67) (148 mg,  0.285 
mmol, 68%) as a pale yellow oil.  [α]D = -12.6 (c 1.0, CHCl3), Lit 
14 [α]D - 14.0 (c 1.0, 
CHCl3); 
1H NMR (400 MHz, CDCl3): 5.21 (1H, t, J2,3 = J3,4 = 9.5 Hz, H-3), 5.09 (1H, t, 
J3,4 = J4,5 = 9.5 Hz, H-4), 4.27 (1H, dd, J1,2 = 7.5 Hz, J2,3 = 9.5 Hz, H-2), 4.50 (1H, d, 
J1,2 = 7.5 Hz, H-1), 4.27 (1H, dd, J5,6a = 5.0 Hz, J6a,6b = 12.5 Hz, H-6a), 4.14 (1H, dd, 
J5,6b = 2.5 Hz, J6a,6b = 12.5 Hz, H-6b), 3.86 (1H, m, CH2O), 3.7 (1H, m, H-5), 3.67 
(3H, s, OMe), 3.47 (1H, m, CH2O), 2.30 (2H, t, J = 7.5 Hz, CH2COOMe), 2.09 (3H, 
s, OAc), 2.04 (3H, s, OAc), 2.03 (3H, s, OAc), 2.01 (3H, s, OAc), 1.63 – 1.49 (4H, m 
2 x CH2), 1.32 – 1.21 (8H, m, 4 x CH2); 
13C NMR (100 MHz, CDCl3): 172.5, 170.3, 
169.9, 169.3 (C=O), 100.8 (C-1), 72.9 (C-3), 71.7 (C-4), 71.3 (C-5), 70.2 (CH2O), 
68.5 (C-2), 62.0 (C-6), 51.4 (OMe), 34.0 (CH2COOMe), 29.3, 29.1, 29.0, 25.7, 24.8 
(6 x CH2), 20.7, 20.6 (4 x OAc); MALDI-ToF m/z 541.25 [M+Na]
+, 557.24 [M+K]+, 
calculated for C24H38O12Na 541.54 and C24H38O12K 557.65. 
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7.2.8 8-(Methoxycarbonyl)octyl-β-D-glucopyranoside (68)14 
O
HO
HO
OH
OH
68
O OMe
O
 
 
8-Methoxycarbonyloctyl 2,3,4,6-O-acetyl-β-D-glucopyranoside (67) (145 mg; 0.28 
mmol) was deprotected using the standard deprotection method (Section 7.1.1).  
The solvents were evaporated in vacuo to afford alkyl glucoside (68) as a colourless 
oil (91 mg, 0.26 mmol; 89%).  [α]D = -28.3 (c 1, MeOH), Lit
14 [α]D = - 24.1 (c 1.14, 
MeOH); 1H NMR (400 MHz, CD3OD): 4.15 (1H, d, J1,2 = 8.0 Hz, H-1), 3.83 – 3.74 
(2H, m, CH2O, H-6a), 3.59 – 3.54 (1H, m, H-6b), 3.57 (3H, s, OMe), 3.47 – 3.40 (1H, 
m, CH2O), 3.27 – 3.14 (3H, m, H-3, H-4, H-5), 3.06 (1H, t, J1,2 = J2,3 = 8.0 Hz, H-2), 
2.21 (2H, t, J = 7.5 Hz, CH2COOMe), 1.54 – 1.45 (4H, m,2 x CH2), 1.34 – 1.19 (8H, 
m, 4 x CH2); 
13C NMR (100 MHz, CD3OD): 176.2 (COOMe), 104.4 (C-1), 78.2 (C-3), 
77.9 (C-2), 75.1 (C-5), 71.7 (C-4), 70.9 (CH2O), 62.8 (C-6), 52.0 (OMe), 34.8 
(CH2COOMe), 30.8 – 26.0 (6 x CH2); MALDI-ToF m/z 373.02 [M+Na]
+, 389.01 
[M+K]+, calculated for C16H30O8Na 373.39 and C16H30O8K 389.54.      
 
7.2.9 8-(Hydrazinocarbonyl)octyl-β-D-glucopyranoside (69) 
O
HO
HO
OH
OH
69
O NHNH2
O
 
 
Alkyl glucoside (68) (10 mg, 0.03 mmol) was treated with hydrazine monohydrate (1 
ml) in EtOH (2.5 ml) at 55oC for 6 hours afforded the hydrazide hapten (69) in 
quantitative yield.  The product (69) was cleaned up by co-evaporation of excess 
reagent with toluene (3 x 10 ml) and NMR analysis confirmed complete conversion 
by loss of the singlet at δ 3.57 ppm (OMe) in the 1H NMR spectra. 
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7.2.10 Methyl 2,3,4-tri-O-benzyl-6-O-triphenylmethyl-α-D-mannopyranoside 
(25)15 
OBnO
BnO
OBn
OMe
OTr
25  
7.2.10.1 Tritylation method A 
Triphenylmethyl chloride (8.64 g, 31.0 mmol) and DMAP (100 mg) were added to a 
solution of methyl α-D-mannopyranoside (35) (5 g, 25.8 mmol) in pyridine (50 ml).  
The reaction was stirred at 40oC overnight.  Upon completion of the reaction 
[CHCl3:MeOH; 9:1], the solvent was removed in vacuo and the resulting residue 
was dissolved in EtOAc (150 ml). After washing with H2O (2 x 50 ml), the extracted 
organic layer was dried over MgSO4, filtered and concentrated in vacuo.  The 
resulting syrup was used without further purification, (7.71 g, 68%, crude). 
  
7.2.10.2 Tritylation method B 
Methyl α-D-mannopyranoside (35) (5 g, 25.8 mmol) and triphenylmethyl chloride 
(8.64 g, 31.0 mmol) were dissolved in a mixture of DMF (50 ml) and triethylamine 
(10 ml, 64.5 mmol) and stirred at room temperature for 16 hours.  The reaction was 
monitored by TLC [CHCl3:MeOH; 9:1] and upon completion of the reaction, the 
product was isolated as above and used in the subsequent reaction without further 
purification, (8.05 g, 72%, crude). 
 
7.2.10.3 Benzylation of monotrityl ether 
Trityl ether (24) (5 g, 11.45 mmol) was dissolved in anhydrous DMF (50 ml) and the 
solution was cooled to 0oC.  Sodium hydride (2.75 g of a 60% mineral oil 
suspension, 68.7 mmol) was added slowly and the mixture was stirred vigorously for 
30 minutes.  Benzyl bromide (6.81 ml, 57.3 mmol) was added dropwise at 0oC and 
the reaction was stirred overnight at rt.  After 16 hours the reaction was shown to be 
complete by TLC [Hex:EtOAc; 4:1].*  Upon completion, the reaction was quenched 
using MeOH (5 ml) and the solvent was removed in vacuo.  The resulting residue 
was redissolved in DCM (30 ml), washed with H2O (3 x 30 ml) and dried using 
MgSO4, then filtered and concentrated.  The resulting syrup was purified using flash 
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chromatography [Hex:EtOAc, 4:1] to afford benzylated trityl ether (25) as a white 
foam (5.34 g, 7.56 mmol, 68%). 
* If reaction is carried out on large scale (>5 grams) then compound 24 is dissolved 
in anhydrous DMF (10 mol% solution) and benzyl bromide (5 equivs.).  The reaction 
mixture is cooled to 0oC and sodium hydride 60% in mineral oil is added in 500 mg 
portions.   
[α]D = +20.4 (c 1.0 , CHCl3), Lit.
15 [α]D = +23.0 (c 4.0, CHCl3); 
1H NMR (400 MHz, 
CDCl3): 7.53-7.14 (30H, m, ArH), 4.82 (1H, d, J1,2 = 2.0 Hz, H-1), 4.31-4.82 (6H, m, 
CH2Ph), 4.04 (1H, t, J3,4 = J4,5 =10.0 Hz, H-4), 3.88 (1H, dd, J2,3 =3.5, J3,4 = 10.0 Hz, 
H-3), 3.82 (1H, dd, J1,2 = 2.0, J2,3 =  3.5 Hz, H-2), 3.80-3.76 (1H, m, H-5), 3.52 (1H, 
dd, J5,6 = 2.0, J6a,6b  11.5 Hz, H-6a), 3.37 (3H, s, OMe), 3.28 (1H, dd, J5,6 = 2.0, J6a,6b 
= 11.5 Hz, H-6b); 
13C NMR (100 MHz, CDCl3): 144.4, 138.8, 138.5, 129.6, 128.5, 
128.3, 127.9-126.9 (ArC), 98.9 (C-1), 86.4 (OCPh3), 80.4 (C-3), 75.6 (C-2), 75.2 (C-
4), 75.1 (CH2Ph), 72.9 (CH2Ph), 72.4 (CH2Ph), 71.9 (C-5), 63.3 (C-6), 54.7 (OMe); 
MALDI-ToF m/z 729.49 [M+Na]+, 745.53 [M+K]+, calculated for C47H46O6Na 729.85 
and C47H46O6K 745.96. 
 
7.2.11 Methyl 2,3,4-Tri-O-benzyl-α-D-mannopyranoside (26)16 
O
BnO
BnO
OBn
OMe
OH
26  
90% Aqueous TFA (2 ml) was added dropwise to a solution of benzyl ether (25) (5g, 
7.10 mmol) in DCM (25 ml) and the solution as stirred at room temperature for 20 
minutes.  The reaction was neutralized using NaHCO3 (decolourisation and 
effervescence).  The resulting solution was further washed with cold aqueous 10% 
NaHCO3 solution (25 ml) and H2O (25 ml), the resulting organic layer was was dried 
and concentrated.   The resulting syrup was purified using flash chromatography 
[Hex:EtOAc; 3:1] to afford product (26), (2.86 g, 6.16 mmol, 87%).  [α]D = +28.4 (c 1, 
CHCl3), Lit
16 [α]D = +34.8 (c 0.3, CHCl3); 
1H NMR (400 MHz, CDCl3): 7.46-7.29 
(15H, m, ArH), 4.96-4.82 (6H, m, CH2Ph), 4.70 (1H, d, J1,2 = 2.0 Hz, H-1), 3.96 (1H, 
t, J3,4 = J4,5 = 9.0 Hz, H-4), 3.90 (1H, dd, J2,3  = 3.5, J3,4 = 9.0 Hz, H-3), 3.84 (1H, m, 
H-2), 3.80-3.74 (3H, m, H-2, H-6a,b), 3.64-3.59 (1H, m, H-5), 3.29 (3H, s, OMe), 2.1 
(1H, bs, OH); 13C NMR (100 MHz, CDCl3): 128.3, 127.9, 12.7, 127.6 (ArC), 99.5 (C-
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1), 80.2 (C-3), 75.2 (CH2Ph), 74.9 (C-4), 74.8 (C-2), 73.0 (CH2Ph), 72.3 (CH2Ph), 
72.1 (C-5), 62.5 (C-6), 54.1 (OMe); MALDI-ToF m/z 487.12 [M+Na]+, 503.29 [M+K]+, 
calculated for C28H32O6Na 487.54 and C28H32O6K 503.65. 
 
7.2.12 Methyl 2,3,4-Tri-O-benzyl-6-deoxy-6-iodo-α-D-mannopyranoside (70)17  
O
BnO
BnO
OBn
OMe
I
70  
7.2.12.1 Method 1 
To a solution of benzyl ether (26) (3 g, 6.5 mmol) in anhydrous toluene (30 ml) were 
added; finely ground triplenylphosphine (2.4 g, 9.1 mmol), imidazole (883 mg, 13.0 
mmol) and iodine (6.6 g; 26.0 mmol).  The reaction mixture was heated under reflux 
conditions for 4 hours and the reaction progress was monitored by TLC [Tol:EtOAc; 
4:1].  The cooled reaction mixture was transferred to a separating funnel and 
washed with 10% Na2S2O3 solution (50 ml); Sat. aq. NaHCO3 solution (50 ml) and 
H2O (50 ml) successively and dried over MgSO4.  The volatiles were removed in 
vacuo and the resulting syrup was purified using two rounds of flash 
chromatography [Hex:EtOAc; 3:1] to afford iodide (70) as a pale orange oil (2.72 g, 
4.75 mmol, 73%). [α]D = +28.4 (c 1.0, CHCl3), Lit
17 [α]D = +26.0 (c 1.39, CHCl3); 
1H 
NMR (400 MHz, CDCl3):  7.37-7.28 (15H, m, ArH), 4.79 (1H, d, J1,2 = 1.5 Hz, H-1), 
4.98-4.58 (6H, m, 3 x CH2Ph), 3.93 (1H, dd, J2,3 = 3.0, J 3,4 = 9.5 Hz, H-3), 3.81-3.84 
(2H, m, H-2, H-4), 3.55 (1H, m, H-5), 3.61 (1H, m, H-6a), 3.41 (3H, s, OMe), 3.37 
(1H, m, H-6b); 
13C NMR (100 MHz CDCl3): 139.1, 139.0, 128.8, 128.6, 128.3, 128.2 
(ArC), 98.71 (C-1), 76.2 (CH2Ph), 74.3 (CH2Ph), 71.9 (CH2Ph), 71.6 (C-3), 71.4 (C-
2, C-4), 70.9 (C-5), 54.1 (OMe), 6.8 (C-6); MALDI-ToF m/z 597.57 [M+Na]+, 613.42 
[M+K]+, calculated for C28H31IO5Na 597.44 and C28H31IO5K 613.54.
 
 
7.2.12.2 Method 2 – Iodination using Sp-PPh3 
To a solution of benzyl ether (26) (100 mg, 0.22 mmol) in anhydrous toluene (5 ml) 
were added; Sp-PPh3 (230 mg, 0.48 mmol, 2.0 mmol/g loading), imidiazole (33 mg, 
0.48 mmol) and iodine (156 mg, 0.62 mmol).  The reaction mixture was heated 
under reflux for 4 hours and monitored by TLC [Tol:EtOAc; 4:1].  Upon completion 
of the reaction, the Sp-PPh3 was filtered off and the solvents removed in vacuo.  
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The residual syrup was washed with 10% Na2S2O3 (20 ml), Sat. aq. NaHCO3 
solution (20 ml) and H2O (20 ml) successively and dried over MgSO4 and 
concentrated in vacuo.  The resulting syrup was purified using flash 
chromatography [Hex:EtOAc; 3:1] to afford iodide (70) as a pale orange oil (123 mg, 
0.21 mmol, 97%).  All characterisation data was in accordance with the literature 
and results obtained for compound (70) as synthesised by method 7.2.12.1.17 
 
7.2.13 Methyl 2,3,4-tri-O-benzyl-6-deoxy-α-D-manno-
heptopyranosylurononitrile (34)18 
O
BnO
BnO
OBn
OMe
CN
34  
Iodide (70) (250 mg, 0.44 mmol) was dissolved in anhydrous DMF (0.5 ml) in a 
microwave reaction vial (Biotage 0.5 – 2 ml).  Sodium cyanide (55 mg, 1.1 mmol), 
was added to the reaction mixture and the vial was sealed using a rubber septum 
and cap.  The vial was placed in the microwave reactor (Biotage Initiator) and was 
heated at 70oC for two 1.5 hour time periods, at which point the reaction was 
complete, TLC [Hex: EtOAc, 3:1].  Upon completion of the reaction, the solvent was 
removed in vacuo and the resulting syrup was dissolved in DCM (10 ml) and 
washed successively with H2O (20 ml), 1 M HCl (10 ml), sat. aq. NaHCO3 solution 
(10 ml) and H2O (10 ml), the organic phase was dried over MgSO4 and 
concentrated in vacuo.  The resulting oil was passed through a 5 cm bed of silica 
gel [Hex:EtOAc, 3:1] to remove impurities and the solvent was removed in vacuo to 
afford nitrile (34) (185 mg, 0.39 mmol, 89%).  [α]D = + 47.7 (c 1, CHCl3), Lit
18 [α]D = 
+47.0 (c 1.35, CHCl3); νmax (thinfilm): 2278 cm
-1; 1H NMR (400 MHz, CDCl3): 7.38-
7.24 (15H, m, ArH), 4.71 (1H, d, J1,2 = 1.5 Hz, H-1), 4.84-4.74 (2H, m, CH2Ph), 4.68 
(2H, d, J = 10.5 Hz, CH2Ph), 4.61 (2H, m, CH2Ph), 3.81 (1H, dd, J2,3 = 3.0, J3,4 = 9.0 
Hz, H-3), 3.80 (1H, dd, J1,2 = 1.5, J2,3 = 3.0 Hz, H-2), 3.77-3.74 (2H, m, H-4, H-5), 
3.34 (3H, s, OMe), 2.73 (1H, dd, J5,6 = 3.0, J6a,6b 15.0 Hz, H-6a), 2.49 (1H, m, H-6b); 
13C NMR (100 MHz, CDCl3): 139.9, 138.7, 128.9, 128.7, 128.2 (ArC), 99.3 (C-1), 
75.1 (CH2Ph), 73.3 (CH2Ph), 72.5 (CH2Ph), 71.6 (CH2Ph), 71.4 (C-3), 70.8 (C-2), 
70.4 (C-4), 68.0 (C-5), 53.5 (OMe), 20.2 (C-6); MALDI-ToF m/z 496.47 [M+Na]+, 
512.32 [M+K]+, calculated for C29H31NO5Na 496.55 and C29H31NO5K 512.66. 
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7.2.14 Methyl 2,3,4-tri-O-benzyl-6-deoxy-α-D-manno-heptopyranoside (30)18 
O
BnO
BnO
OBn
OMe
30
HO
 
 
7.2.14.1 Reduction of (34) with DIBAL-H 
DIBAL-H (1 M in hexane, 0.91 ml, 0.91 mmol) was added dropwise to a solution of 
nitrile (34) (361 mg, 0.83 mmol) at -15oC; after 30 minutes further DIBAL-H (0.26 ml, 
0.26 mmol) was added and the reaction was terminated after 15 min by the addition 
of MeOH (0.75 ml) followed by aqueous 2 M HCl (0.75 ml).  The mixture was stirred 
for 45 minutes and filtered and extracted with diethyl ether (5 ml).  The organic 
layers were washed with 2M HCl (5 ml), sat. aq. NaHCO3 solution (5 ml) and H2O (5 
ml), dried and concentrated in vacuo.   Sodium borohydride (15 mg) was added to 
the resulting syrup dissolved in MeOH (5 ml) and the mixture was stirred for 30 min.  
Upon completion, TLC [Hex:EtOAc; 3:1], the reaction was quenched by the addition 
of acetone (5 ml) and concentrated in vacuo, the residual syrup was concentrated 
again (x3) with hot MeOH (5 ml) to remove borate impurities.  The residue was 
dissolved in EtOAc (5 ml) and washed with 2 M HCl (5 ml); sat. aq. NaHCO3 
solution (5ml) and H2O (5ml), dried over MgSO4 and concentrated in vacuo to a 
syrup that was purified using flash chromatography [Hex:EtOAc; 2:1] to afford 
alcohol (30) as an oil, (220 mg, 0.46 mmol, 56%).  [α]D = +30.3 (c 1.0 CHCl3), Lit
18 
[α]D, + 31.0 (c 1.8, CHCl3); νmax (thinfilm) 3468 cm
-1 (broad); 
1H NMR (400 MHz, 
CDCl3): 7.47–7.23 (15H, m, ArH), 4.99-4.59 (6H, m, 3 x CH2Ph), 4.66 (d, J1,2 = 2.0 
Hz, H-1), 3.89 (1H, dd, J2,3 = 3.5, J3,4 = 8.5 Hz, H-3), 3.79 (1H, dd, J1,2 = 2.0, J2,3 3.5 
Hz, H-2), 3.75-3.70 (4H, m, H-4, H-5, H-7a,b), 3.31 (3H, s, OMe), 2.15-2.06 (1H, m, 
H-6a), 1.89-1.80 (1H, m, H-6b); 
13C NMR (100 MHz, CDCl3): 138.7, 138.1, 128.4, 
128.0, 127.8, 127.7 (ArC) 99.1, (C-1), 80.1 (C-3), 78.3 & 71.4 (C-4 & C-5), 75.3 
(CH2Ph), 74.6 (C-2), 72.1 (CH2Ph), 61.2 (C-7), 54.8 (OMe), 33.8 (C-6); MALDI-ToF 
m/z 501.87 [M+Na]+, 517.89 [M+K]+; calculated for C29H34O6Na 501.56 and 
C29H34O6K 517.67. 
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7.2.15 Benzyl α-D-mannopyranoside (76)19, 20 
 
 
Acetyl chloride (20 ml, 0.28 mmol) was added drop-wise to a solution of D-mannose 
(59) (20 g, 110 mmol) in benzyl alcohol (100 ml) at 50oC under inert atmosphere.  
The solution was heated at 50oC for 1.5 hours and then stirred at room temperature 
for a further 15 hours.   The product mixture was poured into ice/H2O (500 ml) and 
extracted (3x) with EtOAc (100 ml), the organic layer was washed (3x) with H2O 
(100 ml), dried and concentrated in vacuo.  The resulting oil was recrystallized from 
Hex-EtOAc to afford benzyl-α-D-mannopyranoside (76) as a white solid (28.5 g,  
96%):  [α]D = +84.3 (c 1, MeOH), Lit  = 85.1 (c 1, MeOH); 
1H (400 MHz, D2O): 7.40-
7.28 (5H, m, ArH), 4.85 (1H, d, J1,2 = 2.0 Hz, H-1), 4.67 (2H, ABq, JHa,Hb = 12.0 Hz, 
CH2PH), 3.87 (1H, dd, J5,6 = 2.0 Hz, J6a,6b = 12.0 Hz, H-6a), 3.84 (1H, dd, J1,2 = 2.0 
Hz, J2,3 = 4.0 Hz, H-2), 3.77-3.71 (2H, m, H-3, H-6b), 3.65 (1H, t, J3,4 = J4,5 = 9.0 Hz, 
H-4), 3.62 (1H, m, H-5); 13C NMR (100 MHz, D2O): 129.4, 129.2, 128.8 (ArC), 100.7 
(C-1), 74.9 (C-4), 72.7 (C-3), 72.2 (C-2), 69.9 (CH2Ph), 68.7 (C-5), 63.0 (C-6); 
MALDI-ToF m/z 293.13 [M+Na]+, 309.11 [M+K]+, calculated for C13H18O6Na 293.27 
and C13H18O6K 309.38. 
 
7.2.16 Benzyl 6-deoxy-6-iodo-α-D-mannopyranoside (77)19 
 
To a solution of benzyl α-D-mannopyranoside (76) (2.0 g, 7.5 mmol) in dry THF (20 
ml) was added triphenylphosphine (2.9 g, 11.3 mmol), imidazole (1.0 g, 15 mmol) 
and iodine (2.8 g, 11.3 mmol).  The reaction was stirred under reflux conditions for 4 
hours before the solvent was removed in vacuo.  The resulting syrup was diluted 
with EtOAc (20 ml) and washed with 10% Na2SO3 solution (20 ml) and H2O (20 ml), 
dried over MgSO4 and concentrated.  The resulting oil was purified using flash 
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chromatography [DCM:MeOH; 10:1] to yield (77) as a white foam (2.4 g, 6.45 mmol, 
86%).  αD = + 63.6 (c 1.0, CHCl3);  
1H NMR (400 MHz, CDCl3): 7.35-7.27 (5H, m, 
ArH), 4.93 (1H, d, J1,2 = 1.5  Hz, H-1), 4.67 (2H, ABq, JHa,Hb = 11.5 Hz, CH2Ph), 3.59-
3.50 (4H, m, H-2, H-3, H-4, H-6a), 3.84-3.80 (1H, m, H-6b), 3.32 (1H, dd, J4,5 = 10.0 
Hz, J5,6 = 7.0 Hz, H-5); 
13C NMR (100 MHz, CDCl3): 128.6, 128.4, 128.2 (ArC), 99.7 
(C-1), 71.9, 71.6, 71.4 (C-2, C-3, C-4), 70.9 (C-5), 69.3 (CH2Ph), 6.9 (C-6); MALDI-
ToF m/z 402.97 [M+Na]+, 419.01 [M+K]+, calculated for C13H17IO5Na 403.16 and 
C13H17IO5K 419.27. 
 
7.2.17 Benzyl 6-dexoy-α-D-manno-heptopyranosylurononitrile (78) 
 
 
To a stirred solution of iodide (77) (100 mg, 0.26 mmol) in 50:50 MeCN:H2O (5 ml) 
was added KCN (50 mg, 0.78 mmol).  The reaction mixture was left to stir for 16 
hours at room temperature.  The solvent was removed in vacuo and the aqueous 
solution was washed with EtOAc (3 x 10 ml); the combined organic layers were then 
washed with 1M HCl (10 ml) and H2O (10 ml), dried over MgSO4 and concentrated.  
Nitrile (78) (70 mg) was afforded in quantitative yield after being passed through a 3 
cm bed of silica gel [DCM:MeOH; 10:1].  αD = + 79.5 (c 0.5, CHCl3);   
1H NMR (400 
MHz, CDCl3): 7.35 – 7.26 (5H, m, ArH), 4.86 (1H, d, J1,2 = 1.5 Hz, H-1), 4.60 CH2Ph 
(2H, ABq, JHa,Hb = 12.0 Hz, CH2Ph) 3.94, (1H, dd, J1,2 = 1.5 Hz, J2,3 = 3.0 Hz, H-2), 
3.80 (1H, dd, J2,3 = 3.0 Hz, J3,4 = 9.0 Hz, H-3), 3.75 (1H, m, H-5), 3.64 (1H, t, J3,4 = 
J4,5 = 9.0 Hz, H-4), 2.75 – 2.65 (2H, m, H6a,b); 
13C NMR (100 MHz, CDCl3): 128.6, 
128.2, 128.1 (ArC), 99.3 (C-1), 71.5 (C-3), 70.8 (C-2), 70.0 (C-4), 69.7 (CH2Ph), 
97.6 (C-5), 20.7 (C-6); MALDI-ToF m/z 302.16 [M+Na]+, 318.17 [M+K]+, calculated 
for C14H17NO5Na 302.28 and C14H17NO5K 318.39. 
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7.2.18 1,7-Di-O-acetyl-2,3,4-tri-O-benzyl-6-deoxy-α-D-manno-
heptopyranoside18 (85) 
 
 
Benzylated 6-deoxy-heptose (30) (200 mg, 0.42 mmol) was dissolved in 
Ac2O:AcOH (1:1, 10 mL) at 0
oC and catalytic  H2SO4 was added dropwise, eliciting a 
colour change.  The reaction was stirred for 30 minutes and then neutralised using 
solid NaHCO3, the resulting suspension was added to a conical flask containing 
H2O and ice (25 mL) and left stirring overnight.  The product was extracted using 
DCM (15 mL) and washed with 1 M HCl (10 mL), sat. aq. NaHCO3 solution (10 mL) 
and H2O (10 mL), dried and concentrated in vacuo.  The resulting syrup was purified 
using flash chromatography [Hex:EtOAc; 2:1] to afford protected di-acetate (85) 
(115 mg, 0.21 mmol, 65%). [α]D = 37.4 (c 1.0  , CHCl3); 
1H NMR (400 MHz, CDCl3) 
7.42-7.37 (15H, m, ArH), 6.11 (1H, d, J 1,2 = 2.0 Hz, H-1), 4.79-4.63 (4H, m, 2 x 
CH2Ph), 4.58 (2H, s, CH2Ph), 4.18-4.09 (1H, m, H-7a), 4.108-4.09 (1H, m, H-7b), 
3.82 (1H, dd, J2,3 = 3.0, J3,4 = 9.0 Hz, H-3), 3.77-3.75 (3H, m, H-2, H-4 & H-5), 2.23-
2.15 (1H, m, H-6a), 2.02 (3H, s, OAc), 2.00 (3H, s, OAc), 1.91-1.83 (1H, m, H-6b); 
13C NMR (100 MHz, CDCl3): 170.8 (C=O), 168.7 (C=O), 138.1, 138.0, 128.5, 128.4, 
128.2 (ArC), 91.7 (C-1), 79.4 (C-3), 77.8, 72.2 & 70.9 (C-2, C-4, C-5), 75.5 (CH2PH), 
73.5 (CH2Ph), 72.6 (CH2Ph), 60.9 (C-7), 30.7 (C-6), 21.1 (2 x OAc); MALDI-ToF m/z 
572.05 [M+Na]+, 588.10 [M+K]+, calculated for C32H36O8Na 571.61 and C32H36O8K 
587.72. 
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7.2.19 6-deoxy-D-manno-heptopyranose (32)21, 22 
O
HO
HO
OH
OH
32
HO
 
Protected 6-deoxy-heptose (85) (354 mg, 0.65 mmol) was dissolved in EtOAc:EtOH 
[3:2, 5 ml] at room temperature and catalytic 10% Pd/C was added.  The solution 
was degassed under vacuum and H2 was added using a gas bladder, this was 
repeated 3 times to ensure saturation with H2.  The reaction was heated to 40
oC 
and left stirring overnight.  The catalyst was removed via filtration and the solvents 
were removed in vacuo.  The product (157 mg, 0.56 mmol, 87%) was used without 
further purification.  The crude triol (86) (157 mg, 0.56 mmol) was deactylated using 
the standard deprotection 7.1.1 to afford 6-deoxy-manno-heptose (32) as a white 
amorphous solid as an anomeric mixture in the α:β ratio 2.5:1 (101 mg, 0.52 mmol, 
87%). 1H NMR (400 MHz, CD3OD): 5.00 (1H, d, J1,2 = 2.0 Hz, H-1α), 4.71 (1H, d, J1,2 
= 1.0 Hz, H-1β), 3.89-3.66 (5H, m, H-2, H-3, H-5, H-7a+b), 3.45 (1H, t, J3,4 = J4,5 = 9.5 
Hz, H-4), 2.18-2.04 (1H, m, H-6a), 1.74-1.66 (1H, m, H-6b); 
13C NMR (100 MHz, 
CD3OD) 95.9 (C-1), 73.2 (C-2), 72.8 (C-4), 72.2 (C-3), 70.6 (C-5), 59.8 (C-7), 35.8 
(C-6); HR ESI-MS m/z 217.0688 [M+Na]+, calculated for C7H14O6Na 217.0692 
 
7.2.20 1,2,3,4,7-Penta-O-benzoyl-6-deoxy-D-manno-heptopyranoside (87) 
  
To a stirred solution of 6-deoxy-heptose (32) (100 mg, 0.52 mmol) in anhydrous 
pyridine (2 ml) benzoyl chloride (0.315 ml, 3.64 mmol) was added dropwise at 0oC 
and the reaction mixture was allowed to reach room temperature and left stirring 
overnight.  After careful addition of H2O (1 ml), the solvent was removed in vacuo 
and the residue was dissolved in DCM (5 ml), washed with 1M HCl (5 ml), NaHCO3 
aq. sat. solution (5 ml) and H2O (5 ml), dried over MgSO4 and concentrated in 
vacuo.  The product was purified using flash chromatography [Hex:EtOAc; 5:2] to 
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afford protected 6-deoxy-heptose (87) as a colourless oil (315 mg, 0.44 mmol, 84%, 
α/β ratio 2:1). 1H NMR (400 MHz, CDCl3): 8.13-7.28 (25H, m, ArH), 6.57 (d, J1,2 = 
2.0 Hz, H-1α), 6.36 (d, J1,2 = 1.5 Hz, H-1β), 6.01 (1H, dd, J1,2 = 2.5, J2,3 = 10.0 Hz, H-
2), 5.90-5.85 (2H, m, H-3 & H-4), 4.54-4.48 (2H, m, H-5 & H-7a), 4.22-4.19 (1H, m, 
H-7b), 2.21-2.16 (2H, m, H-6a+b); 
13C NMR (100 MHz, CDCl3): 168.1, 167.8 (C=O), 
134.2, 130.4, 129.7, 128.0, 127.8 (ArC), 91.2 (C-1), 69.8 (C-3), 69.7 (C-4), 69.4 (C-
2, C-5), 60.2 (C-7) 30.7 (C-6); HR ESI-MS [M+Na]+  737.1944, calculated for 
C45H48O12Na 737.1999. 
 
7.2.21 8-(methoxycarbonyl)octyl 2,3,4,7-tetra-O-benzoyl-α-D-manno-
heptopyranoside (89) 
 
To a solution of benzoylated 6-deoxy-heptose (87) (200 mg, 0.30 mmol) in absolute 
DCM (4 ml) was added HBr/AcOH (4 ml of a 33% w/v soln in AcOH, 1.64 mmol HBr) 
and the reaction mixture was stirred at 0oC for 3 hours.  Upon completion of the 
reaction TLC [Hex:EtOAc; 5:1] the mixture was poured into ice water (10 ml) and 
extracted twice with DCM (2 x 10 ml).  The crude bromide (88) (147 mg, 73%) was 
used without further purification. MALDI-Tof m/z [M+Na]+ 673.04, [M+K]+ 689.09 
calculated for C33H29BrO9Na 672.47, C33H29BrO9K 688.58
 
 
A solution of mercury bromide (10 mg, 0.03 mmol), mercury cyanide (70 mg, 0.26 
mmol), 8-methoxycarbonyl octanol (58) (45 mg, 0.24 mmol) and 4Å molecular 
sieves (75 mg) in dry DCE (2.5 ml) was stirred at room temperature for 30 minutes.  
Bromide (88) (150 mg, 0.22 mmol) in dry DCE (0.5 ml) was added dropwise and the 
reaction was left at room temperature and monitored by TLC [Hex:EtOAc, 5:3].  
After 48 hours, the reaction was shown to be complete, the solution was filtered and 
solvent was removed in vacuo.  The resulting syrup was diluted with EtOAc (5 ml) 
and washed with KBr (5 ml), H2O (3 x 5 ml) and dried over MgSO4.  Flash 
chromatography [Hex:EtOAc; 5:2] afforded the protected alkyl 6-deoxy-manno-
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heptopyranoside (89) (160 mg, 0.20 mmol,  59%) as a colourless oil.  [α]D = +21.9 (c 
1, CHCl3); 
1H NMR (400 MHz, CDCl3): 8.11-7.33 (20H, m, ArH), 5.89 (1H, dd, J2,3 = 
3.5, J 3,4 = 10.0 Hz, H-3), 5.76 (1H, at, J3,4 = J4,5 = 10.0 Hz, H-4), 5.66 (1H, dd, J1,2 = 
2.0, J2,3 3.5 Hz, H-2), 5.02 (1H, d, J1,2 = 2.0 Hz, H-1), 4.55-4.49 (2H, m, H-7ab), 4.34-
4.28 (1H, m, H-5), 3.75-3.69 (1H, m, Spacer-CH2O), 3.67 (3H, s, OMe), 3.50-3.43 
(1H, m, Spacer-CH2O), 2.35 (2H, t, J = 7.7 Hz, CH2COOMe), 2.25-2.18, (1H, m, H-
6a), 2.17-2.09 (1H, m, H-6b), 1.67-1.52 (4H, m, 2 x CH2), 1.35-1.19 (8H, m, 4 x CH2); 
13C NMR (100 MHz, CDCl3): 168.3 (CH2COOMe), 167.9 (C=O), 133.3, 132.8, 130.0, 
129.8, 128.4, 128.1 (ArC), 97.4 (C-1, 1JC1,H1 = 172.6 Hz), 70.7 (C-2), 70.5 (C-4), 
69.5 (C-3), 68.3 (Spacer-CH2O), 66.9 (C-5), 60.7 (C-7), 51.4 (OMe), 34.3 
(CH2COOMe), 30.7 (C-6), 29.4, 26.4, 25.0 (CH2); HR ESI-MS m/z   803.3028 
[M+H]+, calculated for C45H48O12 803.3043. 
 
 
7.2.22 8-(Methoxycarbonyl)octyl-α-D-6-deoxy-manno-heptopyranoside (90) 
 
 
Protected alkyl mannoside (89) (100 mg, 0.13 mmol) was debenzoylated using the 
standard deprotection procedure outlined in general methods 7.1.1.  The resulting 
oil was passed through a bed of silica gel [CHCl3:MeOH, 9:1] to afford alkyl 6-
deoxy-mannoheptoside (90) as an amorphous white solid (36 mg, 0.10 mmol, 77%).  
[α]D = + 2.2 (c = 1.0, MeOH); 
1H NMR (400 MHz, CD3OD): 4.57 (1H, d, J = 1.5 Hz, 
H-1), 3.70-3.59 (5H, m, H-2, H-3, H-7a, Spacer-CH2O), 3.55 (3H, s, OMe), 3.49 (1H, 
at, J3,4 = J4,5 = 8.5 Hz, H-4), 3.36-3.26 (2H, m, H-5, H-7b),  2.22 (2H, t, J = 7.5 Hz, 
CH2OOMe), 2.04-1.97 (1H, m, H-6a), 1.61-1.57 (1H, M, H-6b), 1.52-1.45 (4H, m, 
2xCH2), 1.27-1.20 (8H, m, 4xCH2); 
13C NMR (100 MHz, CD3OD): 101.5 (C-1), 72.7 
(C-3), 72.4 (C-5), 72.3 (C-2), 70.9 (C-4), 68.5 (Spacer-CH2O), 60.1 (C-7), 52.03 
(OMe), 35.6 (C-6), 34.8 (CH2COOMe), 30.6, 30.4, 30.3, 30.1, 27.3, 26.0 (6xCH2); 
HR ESI-MS m/z 387.1987 [M+Na]+, calculated for C17H32O8Na 387.1995. 
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7.2.23 8-(Hydrazinocarbonyl)octyl-α-D-6-deoxy-manno-heptopyranoside (91) 
 
Alkyl mannoside (90) (20 mg, 0.05 mmol) was treated with hydrazine monohydrate 
(1 ml) in EtOH (2.5 ml) at 55oC for 6 hours to afford the hydrazide hapten (92) in 
quantative yield.  The product (91) was cleaned up by co-evaporation of excess 
reagent with toluene (3 x 10 ml) and 1H NMR analysis confirmed complete 
conversion by loss of the singlet at δ 3.55 ppm (OMe) in the 1H NMR spectra. 
 
7.2.24 Expression of Tet-Hc Fragment in E. coli 
4 x 1 litre of Luria-Bertani (LB) broth containing kanamycin (50 µg ml-1) were 
inoculated with 1 ml of an overnight culture of E. Coli BL21 cells transformed with 
pSK1-Tet-Hc.  At an OD650 = 0.8 (approx.), expression of CRM mutant Tet-Hc 
protein was induced by the addition of IPTG to a final concentration of 1 mM.  The 
cells were transferred to a 16oC incubator; after 16 h the cells were harvested by 
centrifugation (7,500 rcf) for 7 min; and frozen at -80 oC until required.  To purify the 
His-tagged proteins, cell pellets were thawed and resuspended in lysis buffer [50 ml 
of 20 mM HEPES, 150 mM NaCl, pH 7.5, 1 x complete protease inhibitor tablet 
(Roche), 0.1 mg/ml lysosyme, 0.02 mg/mL DNase].  Cells were lysed using a cell 
disrupter (Constant Systems, UK, one shot mode, 25 kpsi) and the cell debris was 
removed by centrifugation (30,000 rcf) for 20 min. 
 
The protein was purified using an ÄKTA Xpress FPLC system (GE Healthcare); the 
supernatant was passed through a HiTrap Ni-IMAC column [5 ml, GE Healthcare), 
washed with wash buffer (50 mM Tris-HCl pH 8.0, 0.5M NaCl, 30 mM imidazole 
(BioUltra)] until UV absorption was stable with 5 mAU over 3 mins, then eluted using 
elution buffer [50 mM Tris-HCl pH 8.0, 0.5 M NaCl, 0.5 M imidazole].  The protein 
was further purified by GPC on a Superdex S75 XK26/60 column using elution 
buffer [50 mM HEPES, 100 mM NaC, pH 7.5] at a flow rate of 3.2 ml/min.  The peak 
over 100 mAU with a slope steeper than 100 mAU/min was collected automatically.  
Further purification was achieved using a Superdex 200 (GE Healthcare) gel 
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filtration column; using GF buffer [20 mM HEPES, 150 mM NaCl, pH 7.5] at a flow 
rate of 3.2 ml/min.  The protein containing peak was collected automatically and the 
resulting solution was dialysed (Snake Skin; 10 MWCO; Fisher Scientific) into 
ammonium bicarbonate buffer [100 mM pH 8.0] and lyophilized to give TetHc at a 
concentration of 55 mg/ml of cell culture.  
 
The quality of the protein was analysed on coomassie stained (Instant Blue 
Expedeon) SDS-PAGE (Section 2.3.1, Figure 2.4) (RunBlue 4-20% SDS Gel, 
Expedeon) and MALDI-TOF (Section 2.3.1, Figure 2.5) MS 53.8 kDa, calculated 
51.7 kDa for TetHc fragment. 
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7.2.25 Mannose (TetHc) Conjugate (92) 
 
 
Hydrazide (64) (5 mg) was conjugated to Tet-Hc carrier protein (8 mg) according to 
general method 7.1.2.    The prepared antigen (92) (9 mg) was analysed using 
MALDI-TOF (61.3 kDa) and SDS-PAGE gel which gave an estimate of 23 D-
mannose hapten molecules per protein.  [(61.3 kDa - 53.6 kDa)/334 = 23]  Western 
blot analysis of the glycoprotein was done according to standard procedure 7.1.3, 
the blot membrane was visualised using Alexa 633 labelled Con A (1 in 5,000) and 
imaged using a FLA7000 phosphoimager (Fuji). 
 
7.2.26 Mannose (BSA) Conjugate (93) 
 
 
Hydrazide (64) (6 mg) was conjugated to BSA carrier protein (10 mg) according to 
general method 7.1.3.     The prepared antigen (93) (9 mg) was analysed using 
MALDI-TOF (73.4 kDa) and SDS-PAGE gel analysis which gave an estimate of 20 
hapten molecules per protein.  [(73.4 kDa – 66.5 kDa)/334 = 20]   
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7.2.27 Mannoheptose (TetHc) Conjugate (94) 
 
 
Hydrazide (91) (5 mg) was conjugated to TetHc carrier protein (9 mg) according to 
general method 7.1.3.  The prepared antigen (94) (8 mg) was analysed using 
MALDI-TOF [61.1 kD]; SDS-PAGE gel analysis, which gave an estimate of 22 
hapten molecules per protein.  [(61.5 – 53.6)/348 = 23] 
 
7.2.28 Mannoheptose (BSA) Conjugate (95) 
 
Hydrazide (91) (5 mg) was conjugated to BSA carrier protein (9 mg) according to 
general method 7.1.3.  The prepared antigen (95) (11 mg) was analysed using 
MALDI-TOF [73.2 kD]; SDS-PAGE gel analysis, which gave an estimate of 18 
hapten molecules per protein. [(73.2 kDa – 66.5 kDa)/348 = 19]  
 
7.2.29 Glucose (TetHc) Conjugate (96) 
 
Hydrazide (69) (13 mg) was conjugated to TetHc carrier protein (20 mg) according 
to general method 7.1.3.  The prepared antigen (96) (19 mg) was analysed using 
208 
 
 
MALDI-TOF [ca. 61.8 kD]; SDS-PAGE gel analysis, which gave an estimate of 24 
hapten molecules per protein.  [(62.2 kDa – 53.6 kDa)/334 = 25] 
 
7.2.30 Glucose-BSA Glycoconjugate (97) 
 
 
Hydrazide (69) (8 mg) was conjugated to BSA carrier protein (15 mg) according to 
general method 7.1.3.  The prepared antigen (77) (13 mg) was analysed using 
MALDI-TOF [ca. 73.4 kDa]; SDS-PAGE gel analysis, which gave an estimate of 20 
hapten molecules per protein.  [(73.4 kDa – 66.5 kDa)/334 = 21 
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7.3 Chapter 3 Experimental  
7.3.1 B. thailandensis E555 ΔwbiI capsular polysaccharide (104) extraction 
and purification 
A 10 ml starter culture of Burkholderia thailandensis E555 (wbiI pKNOCK KmR 
mutant) was incubated overnight at 37oC in LB-Lennox (LB-L; 1 litre containing 10 g 
tryptone, 5g yeast extract and 5g NaCl in 1 litre).  LB-L media (4 x 1 litre) in 2 litre 
baffled flasks was inoculated with the starter culture and the flasks were placed in a 
shaking incubator for 16 hours at 37oC.  The cells were pelleted (10 minutes at 
7,500 rcf) and resuspended in MQ-H2O (100 ml).  The cell suspension was added to 
90% aqueous phenol (100 ml) and heated to 80oC with gentle stirring.  After 30 
minutes the slurry was allowed to cool and extensively dialysed against MQ-H2O 
(Spectra/Por® 6-8K MWCO dialysis tubing, flat width 100mm).  After 8 changes of 
MQ-H2O (5 litre) the insoluble material was collected by centrifugation (10 minutes 
at 7,5000 rcf) and the supernatant was lyophilised.  The crude preparation (780 mg) 
was solubilised in 10 mM Tris-HCl [1 mM MgCl2; 1 mM CaCl2; pH 7.5] to an 
approximate concentration of 30 mg/ml.  Both RNAse and DNAse (50 µg/ml) were 
added and the solution was incubated at 37oC for 3 hours with gentle shaking.   
After which, Proteinase K (50 µg/ml) was added and the mixture was incubated 
overnight in a heating block at 60oC.  Centrifugation of the mixture (10 minutes @ 
8,000 rcf) afforded three layers, insoluble material which was discarded, the 
supernatant and a white waxy substance.  Both the supernatant and the white layer 
were combined and underwent ultracentrifugation (3 x 2 hrs at 100,00 rcf), with the 
supernatant being replaced with MQ-H2O each time.  After ultracentrifugation, the 
white sediment was collected and lyophilised to afford a white powder (635 mg).  1H 
NMR (400 MHz, D2O) diagnostic peaks only: 2.03 (1H, m, H-6a), 1.99 (3H, s, OAc), 
1.59 (1H, m, H-6b). 
 
7.3.1.1 Removal of lipid contaminants 
The crude CPS preparation was solubilised in aqueous acetic acid (2% AcOH) at an 
approximate concentration of 5 mg/ml) and heated at 100oC for 4 hours in a sealed 
glass reaction vial.  After cooling the mixture was clarified using centrifugation (40 
min, @ 8,000 rcf) and the supernatant was lyophilised to afford a white powder (365 
mg).   
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The hydrosylate (30 mg) was solubilised in MQ-H2O (2 ml) and loaded onto a 
Sephadex G-50 gel permeation chromatography column (GPC) (XK26/40 
Phenomenex) and eluted using MQ-H2O (0.25 ml/min).  Fractions (4 ml) were 
collected and assayed using a high-throughput phenol-sulphuric acid method as 
described in Section 7.1.8.  The carbohydrate containing fractions were pooled and 
lyophilised to afford Bth-CPS (5 mg).  1H NMR (400 MHz, D2O): 5.17 (H-2), 4.80 (H-
1), 3.86 (H-3), 3.63 (H-7a,b), 3.65 (H-4, H-5), 2.03 (H-6a), 2.00 (OAc), 1.58 (H-6b); 
13C NMR (100 MHz, D2O): 173.4 (C=O), 96.0 (C-1), 78.7 (C-3), 72.5 (C-5), 69.3 (C-
2), 68.8 (C-4), 57.7 (C-7), 33.4 (C-6) 20.1 (OAc). 
 
7.3.2 Partial acid hydrolysis of Bth-CPS4 
A solution of Bth-CPS (104) (1 mg) in 0.75 M H2SO4 (2 ml) was heated at 85
oC for 1 
h in a sealed screw cap glass reaction vial.  After cooling the reaction was 
neutralised by the addition BaCO3 (30 mg) in MQ-H2O (2 ml).  The insoluble BaSO4 
was removed by centrifugation (5 min at 14,000 rcf) and the solution was clarified 
using a 0.45 µm filter and lyophilised. 
 
7.3.3 APTS labelling of oligosaccharides23 
The partially hydrolysed oligosaccharide fragments of CPS isolated from B. 
thailandensis E555 ΔwbiI were labelled with APTS (105) for analysis by capillary 
electrophoresis. The crude oligosaccharide preparation (1 mg) was dissolved in 
AcOH (5 µl, 30%), NaBH3CN (0.5 mg, 8 µmol) and APTS (0.5 mg, 1 µmol) were 
added to the reaction, which was incubated at 37oC for 18 hours.  The sample was 
loaded onto a 30% mono:bis (38:2) acrylamide Tris-borate [100 mM, pH 8.2] gel 
and labelled oligosaccharides were separated by electrophoresis (400 V, Tris-
borate 100 mM, pH 8.2), (Figure 7.2). 
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Figure 7.2: Fluorescence image of Tris-borate gel of APTS labelled oligosaccharides of CPS 
 
The bands highlighted by the two red boxes were excised from the gel and the 
APTS labelled oligosaccharides extracted into MQ-H2O (1 ml) by means of a bead 
mill (Thermo®, Fast Prep FP 120).  The gel impurities were removed by 
centrifugation (10 min at 14,000 rcf) and residual borate buffer was removed 
through co-evaporation with methanol (x3) at elevated temperature to afford APTS 
labelled oligosaccharides. 
 
7.3.4 Capillary electrophoresis23  
APTS labelled oligosaccharides were injected (0.5 psi, 20 s) onto an N-CHO 
capillary (Beckman Coulter) in a PA800 Proteome Lab® System (Beckman 
Coulter®).  Seperation in running buffer [25 mM LiOAc, 0.4% polyethylene oxide, pH 
4.75] was achieved at 30 kV for 20 min.  Laser-induced fluorescence (LIF) 
(excitation 488 nm, detection 520 nm) was used for the detection of the APTS 
labelled oligosaccharides. 
 
7.3.5 Deactylation of APTS labelled oligosaccharides24 
The partially acetylated APTS labelled oligosaccharides (above) were fully 
deactylated by means of hydrazine monohydrate, the protocol was adapted from 
Takasu et al.24  To the crude oligosaccharide preparation (100 µl) was added 
hydrazine monohydrate (100 µl) in methanol (500 µl).  The reaction mixture was 
heated to 40oC for 3 hours, after cooling the hydrazine was quenched by addition of 
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acetone (500 µl) and the solvents were removed (x3) by SpeedVac® evaporative 
centrifugation (Thermo®).  The samples were then re-submitted for CE analysis 
using protocol 7.3.4.  
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7.4 Chapter 4 Experimental 
7.4.1 Antibody Generation 
Each Tet-Hc antigen sample (2.5 mg) was submitted to Ig-innovations for antibody 
generation in sheep.  Initial immunisations were done with an emulsion comprised 
of antigen (0.5 mg), Freund’s Complete Adjuvant and saline.  Each animal was 
injected at 6 sites.  Re-immunisations with an emulsion of antigen (0.25 mg), 
Freund’s Incomplete Adjuvant and saline were administered at weeks 4, 8, 12, 16, 
20, 24 & 28.  Blood samples were taken at weeks 0, 6, 10, 14, 18.   
 
Coagulation of the blood samples was induced and the blood was incubated at 
37oC for 40 minutes.  At which point the clot was collected by centrifugation and the 
isolated sera was stored at -20oC for use in immunological assessments. 
 
7.4.2 ELISA protocols 
All reagents including anti-sheep IgG (whole molecule)-alkaline phosphatase and 
anti-mouse IgG (whole molecule)-alkaline phosphatase secondary antibodies were 
ordered from Sigma Chemical.  Costar high binging polystyrene 96 well plates were 
used for all ELISAs with BSA glycoconjugate antigens.  (Pierce) Thermo Scientific 
streptavidin coated 96-well plates coated with SuperBlock were used for all ELISAs 
with biotin-CPS (124).  Absorbance readings were done on a FLUOstar Omega 
(BMG labtech) plate reader in absorbance mode at a wavelength of 405nm.  All 
dilutions were made in PBST unless otherwise stated.  Each sample was run in 
triplicate, with the average result and standard error used for data analysis.  For 
details of the individual ELISAs please refer to the appropriate section in the results 
and discussion Section 4.2.  Controls with no 1o or 2o secondary antibody and 
analyte were performed for each experiment and were within the experimental error 
for each ELISA experiment 
 
7.4.2.1 Standard ELISA general protocol 
- The plate was coated with target antigen(s) at 50 µg/ml (100 µl each well) 
and incubated for 2 h at room temperature. 
- The plate was washed 3 times with PBST (PBS with 0.1% Tween 20). 
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- The plate was blocked with 5% w/v BSA in PBST (200 µl each well) and 
incubated for 1 h at room temperature 
- Serial dilutions of combined sample serum* (1 in 100, 1 in 200, 1 in 400, 1 in 
800, 1 in 1600, 1 in 3200, 1 in 6400, 1 in 12800 & 1 in 25600) were prepared 
in PBST. 
- The plate was washed 3 times with PBST 
- Serum serial dilutions were loaded onto the plate (100 µl each well) in 
triplicate and incubated at 37oC for 1 h. 
- The plate was washed 3 times with PBST 
- Secondary antibody (anti-sheep IgG-alkaline phosphatase) in PBST at 1 in 
30,000 dilution was loaded (100 µl each well) and incubated at 37oC for 1 h. 
- The plate was washed 3 times with PBST  
- Phosphatase substrate (5 mg/ml) in alkaline phosphatase buffer [100 mM 
Tris-HCl, 100 mM NaCl, 50 mM MgCl2, 1% Tween 20] was loaded (100 µl 
each well) into each well and incubated at 37oC for 25 min. 
- Plates were read on plate reader (405nm) 
 
* An ELISA was run on individual sheep sera samples and was shown to be 
analogous to that of the combined sera results (Appendix 8.5) and as such all 
ELISAs were run on the combined sera.   
 
7.4.2.2 Competition ELISA general protocol 
- The plate was coated with target antigen(s) at 50 µg/ml (100 µl each well) 
and incubated for 2 h at room temperature. 
- The plate was washed 3 times with PBST  
- The plate was blocked with 5% w/v BSA in PBST (200 µl each well) and 
incubated for 1 h at room temperature. 
- Serial dilutions of the target analyte in PBST were prepared, mixed 50:50 
with 1 in 800 dilution of target serum in PBST and incubated at 37
oC for 30 
min.   
- The plate was washed 3 times with PBST 
- Serum:analyte mix was loaded onto plate (100 µl each well) and incubated 
at 37oC for 1 h 
- The plate was washed 3 times with PBST 
- Secondary antibody (anti-sheep IgG-alkaline phosphatase) in PBST at 1 in 
30,000 dilution was loaded (100 µl each well) and incubated at 37oC for 1 h. 
- The plate was washed 3 times with PBST 
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- Phosphatase substrate (5 mg/ml) in alkaline phosphatase buffer [100 mM 
Tris-HCl, 100 mM NaCl, 50 mM MgCl2, 1% Tween 20] was loaded (100 µl 
each well) into each well and incubated at 37oC for 25 min. 
-  Plates were read on plate reader (405nm) 
 
7.4.2.3 Biotin CPS ELISA on streptavidin plate general protocol 
- Streptavidin 96 well plates (Pierce) were coated with biotin labelled CPS 
(124) at 2 µg/ml in PBST (100 µl) and incubated at room temperature for 30 
min. 
- Serial dilutions of antibody in PBST were loaded onto the plate (100 µl) and 
incubated at 37oC for 1 h.  For competition ELISAs the analyte:mAb 
dilutions were pre-incubated as previously described.  
- The plate was washed 3 times with PBST 
- Secondary antibody (anti-sheep IgG-alkaline phosphatase) in PBST at 1 in 
30,000 dilution was loaded (100 µl each well) and incubated at 37oC for 1 
h. 
- The plate was washed 3 times with PBST 
- Phosphatase substrate (5 mg/ml) in alkaline phosphatase buffer [100 mM 
Tris-HCl, 100 mM NaCl, 50 mM MgCl2, 1% Tween 20] was loaded (100 µl 
each well) into each well and incubated at 37oC for 25 min. 
- Plates were read on plate reader (405nm) 
 
7.4.3 Slot-blot analysis of polyclonal sera 
Slot-blot analysis was conducted using a Hoefer PR600 24-slot-blot apparatus with 
PVDF blotting membrane cut to 3.8 x 11 cm (Immobilon, Millipore).  A biometra mini 
vacuum pump was used as the vacuum source. 
- The blotting membrane was soaked in MeOH for 1 min, then transferred 
to blotting buffer (PBST) for 2 min. 
-The blot apparatus was assembled with the pre-wet membrane and the 
target antigen (50µg/ml) was loaded into the slots (150 µl). 
- Vacuum (350 mBar) was applied for two minutes to load the antigen onto 
the membrane.   
- After the samples were loaded the vacuum was released and 1 ml of 
PBST was loaded into each slot.   
- Vacuum was reapplied (750 mBar) and a further 1 ml of PBST was added 
to wash the membrane. 
-The blot was removed and blocked in 5% BSA for 2 h at room 
temperature. 
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- The blot was washed in PBST 3 x 5 min  
- The blots were incubated with respective sample serum (Glc-TetHc & 
Glc-BSA; 1 in 1600 dilution) for 1 h at 37oC. 
- The blot was washed in PBST 3 x 5 min  
- Incubation with the anti-sheep IgG-alkaline phosphatase secondary 
antibody was done at 37oC for 1 h. 
- The blot was washed in PBST 3 x 5 min  
- Visualisation of the blot was achieved using the insoluble BCIP/NBT 
substrate reagent system (Promega) for 45 min at 37oC.  An image of the 
blot was taken and the picture was analysed using ImageJ gel analysis 
software25.  
 
7.4.4 Synthesis of 6-deoxy-6-fluoro glucose hapten 
7.4.4.1 8-(Methoxycarbonyl)octyl-6-deoxy-6-fluoro-β-D-glucopyranoside (107) 
  
8-(Methoxycarbonyl)octyl-β-D-glucopyranoside (68) (36 mg; 0.11 mmol) was 
suspended in anhydrous DCM (2.5 mL) and cooled to -40oC.  DAST (84 µl, 0.66 
mmol) was added drop-wise and the reaction mixture was allowed to warm to room 
temperature and left stirring for 1 hour.  Upon completion, TLC [DCM:MeOH, 9:1], 
the solution was cooled to -10oC and the reaction was quenched with MeOH (5 mL) 
and then the solvents were removed in vacuo.  6-Deoxy-6-fluoro glycoside (107) 
was isolated using flash chromatography [DCM:MeOH, 13:1] (rf 0.45) (14 mg, 0.04 
mmol, 36%).  [α]D = - 1.81 (c 1, MeOH); 
1H decoupled 19F NMR (CD3OD): φ -235.4 
(s); 1H NMR (400 MHz, CD3OD): 4.74-4.67 (1H, m, H-6a), 4.62-4.55 (1H, m, H-6b), 
4.28 (1H, d, J1,2 = 8.0 Hz, H-1), 3.96-3.86 (1H, m, CH2a), 3.67 (3H, s, OMe), 3.57-
3.34 (5H, m, H-2, H-3, H-4, H-5 & CH2b), 2.30 (2H, t, J = 7.5 Hz, CH2COOMe), 1.68-
1.55 (4H, m, 2 x CH2), 1.38 – 1.24 (8H, m, 4 x CH2); 
13C NMR (100MHz, CD3OD): 
176.9 (C=O), 102.5 (C-1), 82.2 (d, J6,F = 170 Hz, C-6), 76.4 (C-3), 74.5 (d, J5,F = 16 
Hz, C-5), 73.5 (C-2), 70.3 (CH2O),  69.1 (d, J4,F = 7.6 Hz, C-4), 51.5 (OMe), 34.1 
(CH2COOMe), 29.5 – 24.9 (6 x CH2); MALDI-ToF m/z 374.31 [M+Na]
+, 390.32 
[M+K]+, calculated for C16H29FO7Na 375.18 and C16H29FO7K 391.15 
 
217 
 
 
7.4.4.2 8-(Hydrazinocarbonyl)octyl-6-deoxy-6-fluoro-β-D-glucopyranoside 
(111) 
 
6-Deoxy-6-fluoro glucoside (107) (5 mg, 0.015 mmol) was treated with hydrazine 
monohydrate (0.5 ml) in EtOH (1 ml) at 55oC for 6 hours to afford 6-deoxy-6-fluoro 
hydrazide hapten (111) in quatative yield.  The product was cleaned up by co-
evaporation with toluene (3 x 5 ml) and NMR analysis showed successful 
conversion to the hydrazide by loss of the singlet at δ 3.67 ppm (OMe) in the 1H 
NMR spectrum. 
 
7.4.4.3 6-Deoxy-6-fluoro Conjugate (6D6FGlc-TetHc) (112) 
 
Hydrazide (111) (5 mg) was conjugated to TetHc carrier protein (8 mg) according to 
general method 7.1.2.  The prepared antigen (112) (5 mg) was analysed using 
MALDI-Tof MS 61.5 kDa and SDS-PAGE gel electrophoresis to give an estimate of 
23 hapten molecules per protein. [(61.5 – 53.9)/336 = 23] 
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7.4.4.4 8-(methoxycarbonyl)octyl 2,4-di-O-acetyl-3,6-di-deoxy-3,6-di-fluoro-β-
D-allopyranoside  (109) 
  
 
8-Methoxycarbonyloctyl-β-D-glucopyranoside (107) (36 mg; 0.11 mmol) was 
suspended in anhydrous DCM (2.5 mL) and cooled to -40oC.  DAST (84 µl, 0.66 
mmol) was added drop-wise and the reaction was allowed to warm to room 
temperature and left stirring for 1 hour.  Upon completion, TLC [DCM:MeOH, 9:1], 
the solution was cooled to -10oC and quenched using MeOH (5 mL) and then the 
solvents were removed in vacuo.  3,6-di-deoxy-3,6-di-fluoro glycoside (108) was 
isolated using flash chromatography [DCM:MeOH, 13:1] (rf 0.4).  
 
The difluoride was acetylated with Ac2O (1 mL) and catalytic DMAP in anhydrous 
pyridine (5 mL).  The reaction was left stirring overnight (ca. 16 h) and the solvents 
were removed in vacuo. The resulting residue was diluted in DCM (5 mL) and 
washed with 1m HCl (5 mL), sat. aq. NaHCO3 solution (5 mL) and H2O (5 mL), dried 
and concentrated in vacuo.  Flash chromatography was performed [Hex:EtOAc, 5:3] 
to afford acetylated difluoride (109) as a pale yellow oil (11 mg, 0.03 mmol,21%).  1H 
decoupled 19F NMR φ -215.6 (F-3),-235.4 (s, F-6); 1H NMR (400 MHz, CDCl3): 5.13 
(1H, dt, J2,3 = J3,4 = 3.5 Hz, J3,3F = 55.5 Hz, H-3), 4.89 (1H, ddd, J3,4 = 3.5 Hz, J4,5 = 
10.0 Hz, J4,3F = 27.0 Hz, H-4), 4.81 (1H, d, J1,2 = 7.5 Hz, H-1), 4.84-4.74 (1H, m, H-
2), 4.59 (1H, ddd, J5-6a = 3.0 Hz, J6a,6b = 10.0 Hz, J6a,6F = 22.0 Hz, H-6a), 4.48 (1H, 
ddd, J5-6b = 3.0 Hz, J6a,6b = 10.0 Hz, J6b,6F = 22.0 Hz, H-6b), 4.14-4.02 (1H, ddq, J5,6a/b 
= 3.0 Hz, J4,5 = 10.0 Hz, J5,6F = 24.0 Hz, H-5), 3.93-3.86 (1H, m, CH2O), 3.67 (3H, s, 
OMe), 3.54-3.47 (1H, m, CH2O), 2.30 (1H, t, J = 7.5 Hz, CH2COOMe), 2.13 (6H,s, 2 
x OAc), 1.67-1.55 (4H, m, 2 x CH2), 1.33-1.26 (8H, m, 4 x CH2); 
13C NMR (100 MHz, 
CDCl3): 176.3 (C=O), 98.3 (C-1), 88.1 (J3,3F = 181.5, C-3), 81.6 (d, J6,6F = 179.0 Hz, 
C-6), 70.4 (d, J5,6F = 4.0 Hz, C-5), 70.2 (CH2O), 70.0 (d, J2,3F = 17.0 Hz, C-2), 67.7 
(dd, J4,6F = 8.0 Hz, J3F,4 = 17.0 Hz, C-4), 51.5 (OMe), 34.1 (CH2COOMe), 29.7 – 24.9 
(6 x CH2), 20.7 (2 x OAc); MALDI-ToF m/z 442.05 [M+Na]
+, calculated for 
C20H32FO8Na 442.20. 
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7.4.5 Synthesis of Short Linker Haptens 
7.4.5.1    Methyl 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosylthio)propanoate 
(113)26 
 
Per-O-acetylated D-glucose (65) (1.0 g, 2.56 mmol) was dissolved in dry DCM (20 
ml), methyl 3-mercaptopropanoate (1.2 ml, 10.3 mmol) and BF3.OEt2 (475 µL, 3.9 
mmol) were added at 0oC.  The reaction mixture was allowed to warm to room 
temperature and left stirring overnight until the reaction was shown to be complete, 
TLC [Hex:EtOAc, 2:1].  The solution was washed with sat. aq. NaCHO3 solution (3 x 
20ml) and H2O (20 ml) and then dried over MgSO4 and concentrated in vacuo.  The 
resulting syrup was isolated by flash chromatography [Hex: EtOAc, 3:1], the 
fractions were collated and solvents removed in vacuo to afford thioglycoside (113) 
as a white foam (450 mg, 1.00 mmol, 39%).  [α]D = - 53.1 (c 1.0, CHCl3), Lit
26 [α]D = - 
32.0 (c 0.26, CHCl3); 
1H NMR (400 MHz, CDCl3): 5.24 (1H, m H-2), 5.13-5.01 (2H, 
m, H-3, H-4), 4.56 (1H, d, J1,2 = 10.0 Hz, H-1), 4.25-4.22 (1H, m, H-6a), 4.20-4.10 
(1H, m, H-6b), 3.78 -3.69 (4H, m, H-5, OMe), 2.99 (1H, dt, J = 4.0 Hz, J = 11.5 Hz, 
CH2a), 2.89 (1H, dt, J = 2.0, J = 12.0 Hz, CH2b), 2.69 (2H, t, J = 7.0 Hz, SCH2), 2.09 
(3H, s, OAc), 2.06 (3H, s, OAc), 2.03 (3H, s, OAc), 2.01 (3H, s, OAc);  13C NMR 
(100 MHz, CDCl3): 172.0, 170.5, 170.0, 169.3 (C=O), 83.8 (C-1), 75.8 (C-5), 73.7 
(C-2), 69.7, 69.4 (C-3 & C-4), 61.9 (C-6), 51.7 (OMe), 35.3 (SCH2), 25.3 (CH2), 
20.6, 20.5 (4 x OAc); MALDI-ToF m/z 472.95 [M+Na]+, 488.99 [M+K]+, calculated for 
C18H26O11SNa 473.12 and C18H26O11SK 489.08. 
 
7.4.5.2 Methyl 3-(β-D-glucopyranosylthio)propanoate (114)26 
 
Protected thioglycoside (113) (450 mg, 1.00 mmol) underwent Zemplén deactylation 
as described in general procedure 7.1.1 to afford deprotected thioglycoside (114) as 
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colourless oil (240 mg, 0.85 mmol, 92%).  [α]D = -52.3  (c 1.0, MeOH), Lit
26 [α]D = - 
74.0 (c 0.19, H2O); 
1H NMR (400 MHz, CD3OD): 4.42 (1H, d, J1,2 = 10.0 Hz, H-1), 
3.87 (1H, dd, J5,6 = 2.5 Hz, J6a,6b = 11.5 Hz, H-6a), 3.70 (3H, s, OMe), 3.69-3.65 (1H, 
m, H-6b), 3.44-3.31 (3H, m, H-3, H-4 & H-5), 3.21 (1H, pt, J1,2 = J2,3 = 10.0 Hz), 3.05-
2.97 (1H, quintet, CH2a), 2.95 – 2.87 (1H, m, CH2b), 2.74 (2H, t, J = 7.0 Hz, SCH2); 
13C NMR (100MHz, CD3OD): 173.7 (C=O), 87.8 (C-1), 82.0, 79.5, 79.2, (C-3, C-4 & 
C-5), 71.5 (C-2), 63.0 (C-6), 52.3 (OMe), 36.3 (SCH2), 29.1 (CH2); MALDI-ToF m/z 
305.37 [M+Na]+, 321.22 [M+K]+, calculated for C10H18O7SNa 305.07 and 
C10H18O7SK 321.04 
 
7.4.5.3 β-D-(Glucopyranosylthio)propanoic acid hydrazide (115) 
 
 
(114) (10 mg, 0.03 mmol) was treated with hydrazine monohydrate (1 ml) in EtOH 
(2.5 ml) at 55oC for 6 hours afforded the hydrazide (115) in quantative yield.  The 
product was cleaned up by co-evaporation with toluene (3 x 10 ml) and NMR 
analysis showed successful conversion by loss of the singlet at δ 3.70 ppm (OMe) 
in the 1H NMR spectra. 
 
 
7.4.5.4 Methyl 3-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosylthio)propanoate 
(116) 
 
Peracetylated D-mannose (60) (670 mg, 1.71 mmol) was dissolved in dry DCM (20 
ml), methyl 3-mercaptopropanoate (840 µl, 6.93 mmol) and BF3.OEt2 (270 µL, 2.57 
mmol) were added at 0oC.  The reaction was allowed to warm to room temperature 
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and left stirring overnight (ca. 16h) until the reaction was shown to be complete, 
TLC [Hex:EtOAc, 2:1].  The solution was washed with sat. aq. NaCHO3 solution (3 x 
20ml) and H2O (20 ml) and then dried over MgSO4 and concentrated in vacuo.  The 
resulting syrup was isolated by flash chromatography [Hex: EtOAc, 3:1], the 
fractions were collated and solvents removed in vacuo to afford thiomannoside 
(116) as a colourless oil (350 mg, 0.77 mmol, 51%).  [α]D = +48.4 (c 1.0, CHCl3); 
1H 
NMR (400 MHz, CDCl3): 5.33 (1H, d, J1,2 = 1.5 Hz, H-1), 5.31 (1H, dd, J1,2 = 1.5 Hz, 
J2,3 = 3.0 Hz, H-2), 5.29 (1H, t, J3,4 = J4,5 = 9.5 Hz), 5.21 (1H, dd, J2,3 = 3.0 Hz, J3,4 = 
9.5 Hz, H-3), 4.40-4.36 (1H, m, H-5), 4.30 (1H, dd, J5,6a = 6.0 Hz, J6a,6b = 12.0 Hz, H-
6a), 4.13 (1H, dd, J5,6b = 2.0 Hz, J6a,6b = 12.0 Hz, H-6b), 3.71 (3H, s, OMe),  2.94-
2.86 (2H, m, CH2),  2.71 (2H, t, J = 7.0, SCH2), 2.17 (3H, s, OAc), 2.11 (3H, s, OAc), 
2.06 (3H, s, OAc), 1.99 (3H, s, OAc);  13C NMR (100 MHz, CDCl3): 172.4, 170.5, 
169.3 (C=O), 82.8 (C-1), 70.7 (C-2), 69.3 (C-5), 69.8 (C-3), 68.6 (C-4), 62.2 (C-6), 
51.6 (OMe), 34.6 (SCH2), 26.4 (CH2), 20.6, 20.4, 20.3 (4 x OAc);  MALDI-ToF m/z 
473.58 [M+Na]+, 489.51 [M+K]+, calculated for C18H26O11SNa 473.12 and 
C18H26O11SK 489.08.   
 
7.4.5.5 Methyl 3-(α-D-mannopyranosylthio)propanoate (117) 
 
Protected thiomannoside (116) (350 mg, 0.77 mmol) underwent Zemplén 
deactylation as described in general procedure 7.4.1 to afford deprotected 
thiomannoside (117) as colourless oil (1.95 mg, 0.96mmol, 96%).  [α]D = +61.3 (c 
0.8, MeOH);  1H NMR (400 MHz, CD3OD): 5.30 (1H, d, J1,2 = 1.5 Hz, H-1), 3.91-
3.89 (2H, m, H-2, H-3 ), 3.85 (1H, dd, J5,6a = 3.0 Hz, J6a,6b = 12.0 Hz, H-6a), 3.75-
3.72 (2H, m, H-6b), 3.70 (3H, s, OMe),  3.66-3.62 (2H, m, H-4, H-5), 2.95-2.83 (2H, 
m, CH2), 2.73 (2H, t, J = 7.0 Hz, SCH2); 
13C NMR (100MHz, CD3OD): 172.8 (C=O), 
86.7 (C-1), 75.0 (C-2), 73.6 (C-4), 73.2 (C-3), 73.1 (C-5), 63.1 (C-6), 52.3 (OMe), 
35.6 (SCH2), 27.2 (CH2); MALDI-ToF m/z 305.75 [M+Na]
+, 321.72 [M+K]+, 
calculated for C10H18O7SNa 305.07 and C10H18O7SK 321.04 
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7.4.5.6 α-D-(Mannopyranosylthio)propanoic acid hydrazide (118) 
 
117 (10 mg, 0.03 mmol) was treated with hydrazine monohydrate (1 ml) in EtOH 
(2.5 ml) at 55oC for 6 hours afforded the hydrazide (118) in quantative yield.  The 
product was cleaned up by co-evaporation with toluene (3 x 10 ml) and NMR 
analysis showed successful conversion by loss of the singlet at δ 3.70 ppm (OMe) 
in the 1H NMR spectra. 
 
7.4.5.7 Methyl 3-(α-D-mannoheptopyranosylthio)propanoate (121) 
 
Protected thiomannoheptoside (120) was provided by G. Pergolizzi (Field Lab) (450 
mg, 0.97 mmol) underwent Zemplén deactylation as described in general procedure 
7.1.1 to afford deprotected thiomannoside (121) as colourless oil (260 mg, 0.89, 
92%).  [α]D = +170.0 (c 1.0, CHCl3);  
1H NMR (400MHz, CD3OD): 5.19 (1H, d, J1,2 = 
1.5 Hz, H-1), 3.96 (1H, dd, J1,2 = 1.5 Hz, J2,3 = 3.0 Hz, H-2), 3.91 (1H, td, J5,6 = 3.0 
Hz, J4,5 = 10.0 Hz, H-5), 3.72-3.64 (3H, m, H-3, H-7ab), 3.65 (3H, s, OMe), 3.46 (1H, 
t, J3,4 = J4,5 = 10.0 Hz, H-4), 2.86-2.82 (2H, m, CH2), 2.69 (2H, t, J = 7.0 Hz, SCH2), 
2.04-2.01 (1H, m, H-6a), 1.66-1.63 (1H, m. H-6b); 
13C NMR (100MHz, MeOD): 175.1 
(C=O), 84.70 (C-1, JH1-C1 = 170.32 Hz), 71.99 (C-2), 71.6 (C-3), 70.7 (C-4), 69.9 (C-
5), 58.2 (C-7), 52.3 (OMe), 34.8 (SCH2), 33.2 (C-6), 25.6 (CH2); MALDI-ToF m/z 
296.38 [M+Na]+, 315.81 [M+K]+, calculated for C11H20O7SNa 316.08 and 
C11H20O7SK 335.06  
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7.4.5.8 α-D-Mannoheptopyranosylthio)propanoic acid hydrazide (122) 
 
(121) (10 mg, 0.03 mmol) was treated with hydrazine monohydrate (1 ml) in EtOH 
(2.5 ml) at 55oC for 6 hours afforded the hydrazide (122) in quantative yield.  The 
product was cleaned up by co-evaporation with toluene (3 x 10 ml) and NMR 
analysis showed successful conversion by loss of the singlet at δ 3.65 ppm (OMe) 
in the 1H NMR spectra. 
 
7.4.6 Conjugation CPS to cBSA27 
Sodium meta-periodate (6 mg, 0.3 mmol) and CPS (5 mg) was dissolved in PBS (1 
ml) and the reaction mixture was left at room temperature for 1 hour.  Excess 
sodium meta-periodate was removed using a PD-10 desalting column (GE 
Healthcare), equilibrated with PBS.  The oxidised CPS was added to a solution of 
cBSA (Pierce) at 5mg/ml (1 ml) in PBS.  20 µl of NaBH3CN [1 M in 10 mM NaOH] 
was added to the solution and it was left for four days at room temperature in the 
dark.  20 µl of NaBH4 [1 M NaBH4 in 10 mM NaOH] was added, after agitation the 
reaction was left for 40 min.  The solution was diluted in MQ-H2O and extensively 
dialysed (Snakeskin 10,000 MWCO, Pierce) against MQ-H2O (x 5) and lyophilised 
to afford crude conjugate (9 mg). 
 
The crude preparation was run on an SDS-PAGE gel according to general protocol 
7.1.4.  Following SDS-PAGE analysis the CPS-cBSA conjugate was purified on an 
AKTA Xpress FPLC purification system.  The conjugate solution (500 µl at 12 
mg/ml) was injected onto a Superdex S200 HR (GE Healthcare) XK 26/60 column 
(Phenomonex) and eluted using elution buffer [50 mM HEPES, 150 mM NaCl, pH 
7.5] at 1ml/min.  All fractions (1 ml) were collected and analysed for carbohydrate 
using the phenol:sulphuric acid assay (7.3.5).  A selection of carbohydrate active 
fractions (A4, A8, A12, A15, B12, B8, B4 & C7 were analysed by SDS-PAGE gel 
(7.1.4) and western blot (7.1.5). 
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7.4.7 The biotinylation of Bth-CPS 
Bth-CPS (104) (2 mg) was dissolved in coupling buffer (1 ml) [0.1 M sodium 
acetate, pH 5.5] and cooled to 0oC, sodium meta-periodate solution (1 ml) [20 mM in 
coupling buffer] was added and the soltuion was left in the dark at 4oC.  After 30 min 
glycerol, to a final concentration of 15 mM and the reaction mixture was left for 10 
min at 4oC to quench the NaIO4.  A PD-10 column pre-equilibrated with coupling 
buffer was used to remove the impurities.  The oxidised Bth-CPS (104) was 
collected and treated with EZ-link Hydrazide-PEG4-Biotin (Pierce, Thermo Fisher), 
in DMSO, to a final solution of 5 mM and was left stirring at room temperature for 2 
hours.  Again the impurities were removed through the use of a PD-10 desalting 
column.  The resulting solution was lyophilized to afford a white solid (124) (ca. 2 
mg).   
Biotinylated Bth-CPS (124) (2 mg) was dissolved in MQ-H2O (20 mL of PBST) and 
spotted (3x10 µl) onto a streptavidin labelled microscope slide (Xenopore®) and left 
for 10 mins.  The excess liquid was pipetted off and the slide was washed with PBST 
(x3), after which the slide was soaked in primary anti-CPS-antibody (1 in 3200 
dilution in PBST) for 1 hour at 37
oC.  After extensive washing with PBST (x3) the 
slide was then soaked in the secondary antibody (Alexa 566 labelled anti-mouse 
antibody, Invitrogen, 1 in 30,000 dilution in PBST) for another hour at 37
oC.  The 
slide was washed thoroughly with PBS (x5) before it was imaged on a fluorescence 
scanner (FLA-7000, Fuji). 
 
7.4.8 Octet analysis 
All Octet analysis was conducted using an Octet Red (ForteBio) system using Dip 
and Read Streptavidin coated Biosensors (ForteBio; 18-5019).  The Biosensors 
were first dipped into 1 x Kinetics buffer (ForteBio) in PBS for 5 min prior to the 
experiment.  An equilibration step of 60 seconds was run (baseline), after which the 
streptavidin biosensors were dipped into 200 µl of biotinylated CPS at 10 µg/ml 
(loading step) for 400 seconds.  A second baseline stabilisation step was done in 
fresh Kinetics buffer (60 seconds) before the biosensors were dipped into the target 
antibody solution (mAb 4IVH12 and Hep-TetHc sera 0 & 18W) at decreasing nM 
concentrations (see Section 4.5.1 and 4.5.2).  The association step was carried out 
for 900 seconds before the biosensors were moved to Kinetics buffer for 1200 
seconds to allow dissociation of the antibody to occur (Figure 7.3).  Analysis of the 
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binding curves was carried out using Octet analysis software (ForteBio) using a 1:1 
binding mode. 
 
Figure 7.3;  Schematic representation of the octet experiment for mAb 4IVH12.  Workflow: A) 
Initial baseline for biosensor stabilisation (60 seconds); B) loading of biotinylated CPS (400 
Seconds); C) baseline stabilisation (60 seconds); D) binding of antibodies to immobilised CPS 
(900 Seconds); E) dissociation of antibodies (1200 seconds).  Image adapted from ForteBio 
Octet Brochure
28
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7.5  Chapter 5 Experimental  
7.5.1 General methods 
7.5.1.1 Nucleic Acid Agarose Gels 
0.8% agarose solution in TBE buffer [100 mM Tris-HCl; 90 mM boric acid; 10 mM 
EDTA] was poured into gel mould supplemented with 50 μl of ethidium bromide and 
left to set at 4oC.  Samples (5 µl) were loaded in DNA loading buffer (5 µl; New 
England Biolabs) and gels were run at 90 V for 60 mins.   
 
7.5.1.2 VLP Agarose Gels 
1.2 % agarose solution in TBE buffer [100 mM Tris-HCl; 90 mM boric acid; 10 mM 
EDTA] was poured into gel mould and left to set at 4oC.  Samples (20 µl) were 
loaded in DNA loading buffer (5 µl; New England Biolabs) and gels were run at 60 V 
for 120 mins. 
 
7.5.1.3 Coomassie staining of agarose gels 
Agarose gels were transferred to coomassie staining solution [1 g Coomassie R250; 
100 ml AcOH; 400 ml MeOH; 500 ml MQ-H2O] and incubated overnight.  The stain 
solution was poured off and the gel was rinsed (x2) with MQ-H2O.  The excess stain 
was removed using de-stain solution [20% MeOH; 10% AcOH; 70% MQ-H2O] (5 x 2 
hours washes) and finally with MQ-H2O (2 x 1 hour washes). 
 
7.5.1.4 Silver staining of agarose gels  
Silver staining of agarose gels was done according to the method described by 
Prieto and co-workers in 1997.29  After electrophoresis the gels was immersed 10% 
AcOH solution for 10 minutes at room temperature.  The gels were washed with 
MQ-H2O (x2) to remove excess fix solution and the gel was stained using 20 mM 
AgNO3 at 40
oC for 20 minutes.  The gel was extensively washed with MQ-H2O (x 
10) and developing solution [3% NaOH, 1 ml/l of 37% formaldehyde] until bands 
were visible. 
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7.5.1.5 Ethidium bromide staining of agarose gels  
Gels were submerged in ethidium bromide stain (10 mg/ml) for 30 minutes and then 
washed with MQ-H2O (x1) and visualised with a Syngene G:Box transilluminator.   
 
7.5.1.6 Enhanced chemiluminescence of western blot 
Enhanced chemiluminescence was carried out using ECL-Plus Western Blotting 
Detection Kit as per manufacturer’s instructions.  Blots were visualised using an 
ImageQuant LAS 500 scanner (GE Healthcare) or by UV film detection with the 
assistance of Aadil El-Turabi (iQur) 
 
7.5.1.7 Transmission Electron Microscopy 
All TEM was performed with the assistance of H. Peyret (Lomonossoff Lab, JIC) on 
a FEI Tecnai20 microscope, at 200 kV and imaged with an AMT digital camera.  
VLP particles were deposited onto TEM grids (Pd/Cu with plastic/carbon coating) 
and stained with 2% uranyl acetate30 and imaged using TEM 
 
7.5.2 Cloning of t-HBcAg D3K6D3 and wt-HBcAg D3K6D3 
7.5.2.1 Restriction Digest 
The optimised pEAQ-HT-t-HBcAg-EL and pEAQ-HT-t-HBcAg plasmids were kindly 
donated by the Lomonossoff group (JIC).  Restriction digests of the plasmids were 
carried out using SalI and AseI (New England Biolabs) as per the manufacturer’s 
instructions. 
Reaction (37oC for 60 mins): 
- 9µl MQ-H2O 
- 4 µl of buffer (NEB buffer 3) [100 mM NaCl; 50 mm Tris-HCl; 10 mM 
MgCl2; 1 mM DTT; pH 7.9 
- 0.2 µl BSA (x 100) 
- 1 µl Ase I 
- 1 µl Sal I 
- 5 µl of plasmid (1 µg) in elution buffer (Qiagen Mini-prep kit) [10 mM Tris-
HCl; pH 8.5] 
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Restriction digest samples were run on a 0.8% agarose gel (TBE buffer) pre-loaded 
with 50 µl of ethidium bromide and run at 90V for 60 mins (Figure 7.4). 
 
Figure 7.4: Restriction digest of pEAQ-HT-wt/t-HBcAg D3K6D3 plasmids on agarose gel (0.8%).  
Lanes: A) Ladder (Hyperladder 1; Bioline) B) pEAQ-HT-wt-HBcAg restriction digest reaction; C) 
pEAQ-HT-t-HBcAg restriction digest reaction; D) native pEAQ-HT-wt-HBcAg plasmid.  Lanes B 
and C demonstrate the successful restriction digest of the two plasmids (11 kbp), which run 
slower than the un-cut native plasmid (lane D). 
 
Plasmids were excised form the gel with Qiaquick gel extraction kit (Qiagen) as per 
the manufacturer’s instructions.   
 
7.5.2.2 Ligation reaction 
The phosphorylated primers (5 ng/ml) (Figure 7.5) were annealed at 86oC for 10 
mins and left to cool to room temperature. 
 
 
Figure 7.5: Primers for the production D3K6D3 HBc-Ag plasmids.  Primers were ordered from 
Sigma Chemical 
 
The concentration of the plasmids were analysed by Nanodrop (Thermo) pEAQ-HT-
wt-HBcAg (22.0 ng/μl) and pEAQ-HT-t-HBcAg (10.7 ng/µl).  Ligation reactions were 
carried out with a 3:1 ratio of insert to plasmid backbone to ensure completion of the 
reaction. 
Reaction (16oC overnight) 
- 8 μl of plasmid backbone 
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- X μl of insert (0.23 μl for pEAQ-HT-t-HBcAg or 0.49 μl of pEAQ-HT-wt-
HBcAg) 
- 2 μl of 10 x T4 DNA ligase reaction buffer (NEB) [50 mM Tris-HCl; 10 
mM MgCl2; 1 mM ATP; 10 mM DTT; pH 7.5
oC] 
- 1 μl of T4 DNA polymerase enzyme 
- 9 – X μl of MQ-H2O  
A control reaction was carried out with no insert in order to assess the levels of self-
ligation. 
 
7.5.2.3 Transformation of plasmids into E. coli 
The ligation reactions were transformed into chemically competent E. coli cells (One 
shot Top10 E. coli cells; Invitrogen) by heat shock. 
Reaction 
- 1 μl of ligated plasmid  
- 25  μl of SOC media 
The samples were cooled on ice for 30 mins and then subjected to heat shock 
treatment 42oC for 30 seconds before recovery on ice (10 mins).  200 μl of LB was 
added to the cells which were immediately plated out onto agar for Kanamycin 
resistance and incubated at 37oC overnight.  Individual colonies were grown up in 
LB (10 ml) with kanamycin and single successful cultures were stored at -80oC in 
40% (v/v) glycerol for long term storage. 
 
7.5.2.4 Colony PCR of plasmids 
Successful single colonies (7 from each plasmid) were picked and subjected to 
colony PCR and reactions (5 μl) were run on a 0.8% agarose gel to demonstrate 
successful cloning of the D3K6D3 encoding plasmids (Figure 7.6) 
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Reactions 
 - 10 μl of GoTaq green 
- 0.5 μl of C1 primer (specific for the CPMV UTR region of the pEAQ 
cassette) 
- 0.5 μl of C3 primer (specific for the CPMV UTR region of the pEAQ 
cassette) 
 - 9 μl of nuclease free H2O 
 - Colony prick 
PCR Cycle 
 - 95oC 2 mins (denature) 
 - [95oC 30 seconds (denature); 63oC 45 seconds (anneal); 72o 130  
seconds (extension)] x 29 
 - 72o 300 seconds (final extension) 
 - 4oC rest 
 
Figure 7.6: Agarose gel (0.8%) of colony PCR reactions.  Lanes: A) pEAQ-HT-t-HBcAg D3K6D3 
samples; B) -ve control; C) pEAQ-HT-wt-HBc-Ag D3K6D3 samples; D) re-ligation control pEAQ-
HT-wt-HBcAg; E) Ladder (Hyperladder 1; Bioline.  The pEAQ-HT-t-HBcAg D3K6D3 samples gave 
rise to bands around 2000 bp corresponding to 1835 bp and the pEAQ-Ht-wt-HBcAg D3K6D3 
plasmid gave rise to bands around 1000 bp corresponding to 1288 bp, indicating successful 
cloning of the D3K6D3 constructs. 
 
Selected colonies (highlighted with red circles) were grown up in LB media (10 mL) 
overnight at 37oC to select for kanamycin resistance.  The plasmids were extracted 
with a Miniprep kit (Qiagen) and sent to Genome Enterprise Limited for sequencing. 
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7.5.3 Transformation of D3K6D3 plasmids into Agrobactrium tumifaciens 
Agrobacterium tumifaciens LBA4404 cells (50 μl, OD600 = 0.6) were transformed the 
plasmid  pEAQ-HT-wt-HBAg D3K6D3 and pEAQ-HT-t-HBcAg D3K6D3 (50 μg) by 
electroporation (2.5 kV, 1 second).  The cells were transferred into SOC media (200 
µl) to recover for 2.5 hours at 28oC.  Cells (150 µl) were then plated on agarose 
containing 50 µl/ml kanamycin and rifampicin and incubated at 27oC for 3 days.  
Colony PCR was performed as before (section 7.5.1.4) (3 samples for each 
construct) and reactions (5 µl) were run on at 0.8% agarose gel (Figure 7.7).   
 
 
Figure 7.7: Agarose gel of colony PCR of A. tumifaciens transformation.  Lanes: A) Ladder 
(Hyperladder 1; Bioline; B) pEAQ-HT-wt-HBcAg D3K6D3; C) pEAQ-HT-t-HBcAg D3K6D3.  The 
pEAQ-HT-t-HBcAg D3K6D3 samples gave rise to bands around 2000 bp corresponding to 1835 
bp and the pEAQ-Ht-wt-HBcAg D3K6D3 plasmid gave rise to bands around 1000 bp 
corresponding to 1288 bp, indicating successful cloning of the D3K6D3 constructs. 
 
7.5.4 Trial expression of wt/t-HBcAg D3K6D3 constructs in planta 
Each sample colony were grown in LB media (10 ml; 50 µg/ml 
kanamycin/rifampicin) at 270C over the weekend.  The cell cultures were diluted with 
fresh LB media to achieve an OD600 = 0.4 and centrifuged for 5 mins @ 4,000 rcf.  
The cells were re-suspended in the appropriate volume of MMA buffer [10 mM MES 
pH 5.6; 1 mM MgCl2; 10 µM acetosyringone] to make an OD600 of 0.4.  Each culture 
was used to infiltrate the leaves of two plants (3 weeks old).  The leaves were 
nicked with a sterile needle and the infiltration solution is injected into the 
intracellular space.  Plants were grown in glasshouses maintained at 25oC with 
supplemental lighting to provide 16 hours of daylight and were watered daily.  The 
leaves were harvested 6 days post infiltration. 
 
 
232 
 
 
7.5.5 Large scale expression of t-HBcAg D3K6D3 in planta 
Cultures of the pEAQ-HT-t-HBcAg D3K6D3 Agrobacterium strains were grown in LB 
media (100 ml; 50 µg/ml kanamycin/rifampicin) at 270C over the weekend.  The cell 
cultures were diluted with fresh LB media to achieve an OD600 = 0.4 and centrifuged 
for 5 mins @ 4,000 rcf.  The cells were re-suspended in the appropriate volume of 
MMA buffer [10 mM MES pH 5.6; 1 mM MgCl2; 10 µM acetosyringone] to make an 
OD600 of 0.4.  The surface of young plant leaves (3 weeks old) were nicked with a 
sterile needle and the infiltration solution is injected into the intracellular space.  
Plants were grown in glasshouses maintained at 25oC with supplemental lighting to 
provide 16 hours of daylight and were watered daily.  The leaves were harvested 6 
days post infiltration. 
 
7.5.6 Purification of VLPs from plants 
The fresh plant material was weighed and added to extraction buffer (3 ml per gram 
of plant material) and homogenised in a blender.  During the initial plant expression 
two extraction buffers were assessed for the extraction of the D3K6D3 VLPs.  It was 
shown that the phosphate buffer gave rise to better virus like particles and was used 
exclusively for subsequent expressions. 
HBex Buffer [10 mM Tris-HCl; 120 mM NaCl; 1 mM EDTA; 0.75 M sodium 
deoxycholate; 1 mM DTT; Roche cOmplete protease inhibitor tablet (EDTA free) as 
per manufacturer’s instructions] 
 
Phosphate Buffer [100 mM sodium phosphate; Roche cOmplete protease inhibitor 
tablet (EDTA free) as per manufacturer’s instructions] 
 
The homogenised cells were filtered through Miracloth (Merck Millipore) to remove 
plant debris before centrifugation at 9,000 rcf for 10 mins at 4oC before being 
decanted and centrifuged at 3,000 rcf for 5 mins at 4oC.  The supernatant was then 
purified using a sucrose gradient*, solutions of 20, 30, 40 50 and 60% sucrose (w/v) 
were made up using the appropriate buffer.  Gradients were made by underlying 
solutions of increasing density in ultracentrifuge tubes (Thinwall, Ultra-Clear, 38.5 
ml, Beckmann Coulter) before loading the supernatant on top.  The gradients were 
centrifuged in a SureSpin 630i swing arm rotor (28,000 rpm, ca. 240,000 rcf) for 2.5 
hours at 4oC.  The sucrose layers were collected and dialysed (Snake Skin, 10,000 
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MWCO, Thermo Scientific) against PBS and analysed by western blot (section 
7.1.5). 
 
* For large scale preps (20+ plants) an initial sucrose cushion was carried out 
(25% and 70% (w/v) sucrose).  The 70-25% sucrose interface and 25% layer 
were shown to contain VLP by Western blot and were subsequently dialysed 
(Snake Skin, 10 MWCO, Thermo Scientific) against PBS before further 
purification by sucrose gradient. 
 
The VLP active fractions were combined and extensively dialysed (5 x 1L) against 
ammonium bicarbonate buffer [20 mM, pH 7.4] and concentrated to 10% original 
volume using Speed-Vac (Thermo Scientific) and analysed using TEM. 
 
7.5.7 Conjugation of t-HBcAg D3K6D3 VLP to FITC 
t-HBcAg D3K6D3 (ca. 500 µg) in AmBic buffer (1.2 ml of 0.4 mg/ml solution) was 
extensively dialysed (Snake Skin, 10 MWCO, Thermo Scientific)  against Borax 
conjugation buffer [0.08 M, pH 9.0].  After dialysis potassium hydrogen carbonate 
(70 mg) was added to the solution (2 ml) give a final concentration of 350 mM.  
FITC (100 μg) was added and the conjugation reaction was allowed to stir at 4oC 
overnight.  The conjugate was extensively dialysed against AmBic [20 mM; pH 7.4] 
(Snake Skin, 10,000 MWCO, Thermo Scientific) before being concentrated on 
Speed-Vac (Thermo Scientific).  The VLP sample was analysed by SDS-PAGE, 
western blot, agarose gel. 
 
7.5.8 SEC purification of VLPs 
VLPs were purified using an AKTA prime system at room temperature.  The VLP 
solution (6 ml) was clarified with a 0.2 µm filter before being loaded onto Sepharose 
CL4B XK 26/40 column and eluted with PBS at a flow rate of 2 ml/min.  Fractions (1 
– 18, 2 ml; 19 – 27, 10 ml) were collected and analysed by SDS-PAGE, western 
blot, agarose gels (1.2%) and TEM. 
 
7.5.9 Second conjugation of t-HBcAg D3K6D3 VLP with FITC 
Conjugation of FITC to the t-HBCAg D3K6D3 VLPs was achieved as previously 
stated, section 7.5.6.  Free FITC was removed from the conjugated VLP using spin 
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filtration (x5) (Sartorius Vivaspin; 10,000 MWCO) with PBS as the eluent.  FITC-
labelled VLPs were suspended in PBS (5 ml) and added to a sucrose gradient (20, 
30, 40, 50 & 60%) (section 7.5.5) (Thinwall, Ultra-Clear, 13 ml, Beckmann Coulter) 
and centrifuged in a T684 swing arm rotor (40,000 rpm; ca. 270,000 rcf) for 2.5 
hours at 4oC.  After centrifugation the sucrose gradient was visualised with blue light 
excitation (470 nm, Safe Imager) and the UV active layer was collected and 
dialysed (Piecre Float-A-Lyzer; 1000 KD MWCO) into AmBic [20 mM. pH 7.4].  The 
sample was then analysed by SDS-PAGE and agarose gel (1.2%).  
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8 Appendix 
8.1 Glycoconjugate MALDIs 
 
Figure 8.1: Overlay of MALDI-ToF spectra for native TetHc and Hep-TetHc (94) glycoconjugates 
 
Figure 8.2: Overlay of MALDI-ToF spectra for native BSA and Hep-BSA (95) glycconjugates 
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Figure 8.3: Overlay of MALDI-ToF spectra for native TetHc and Glc-TetHc (96) glycoconjugates 
 
Figure 8.4: Overlay of MALDI-ToF spectra for native BSA and Glc-BSA (97) glycoconjugates 
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8.2 NMR overlay of crude B. thailandensis CPS prep and 
authentic B. pseudomallei sample 
 
Figure 8.5: Crude B. thailandensis CPS prep and authentic B. pseudomallei sample 
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8.3 13C NMR of B. thailandensis CPS prep  
 
Figure 8.6: B. thailandensis CPS prep 13C NMR (21,000 scans) 
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8.4 NMR integration of H-1 and H-2 of CPS preparations from B. 
pseudomallei and B. thailandensis 
 
Figure 8.7: NMR Integration of H-1 protons of CPS and mannan polysaccharides for A) B. 
pseudomallei extract 1: CPS (82%) and mannan (18%), B) B. pseudomallei extract 2: CPA (72%) 
and manna (28%) and C) B. thailandensis extract: CPS (73%) and mannan (27%) 
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8.5 ELISA of separate sera samples CF1497 and CF1498 
 
 
 
Figure 8.8: (Top) Average of ELISA data for separate sera samples from single sheep bleeds 
(CF1497 & CF1498); (Bottom) Data from combined sheep sera as used throughout the thesis.  
The data for the separate sera has larger error as a result of reduced activity in CF1498.  Based 
on this result the data from the combined sheep sera was shown to be suitable  
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0.800
0.900
1.000
1
 in
 1
0
0
1
 in
 2
0
0
1
 in
 4
0
0
1
 in
 8
0
0
1
 in
 1
6
0
0
1
 in
 3
2
0
0
1
 in
 6
4
0
0
1
 in
 1
2
8
0
0
1
 in
 2
5
6
0
0
A
4
0
5
 
Sera Dilution 
0 W Average 6 W Average
10 W Average 10 W BSA Average
14 W Average 18 W Average
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
1
 i
n
 1
0
0
1
 i
n
 2
0
0
1
 i
n
 4
0
0
1
 i
n
 8
0
0
1
 i
n
 1
6
0
0
1
 i
n
 3
2
0
0
1
 i
n
 6
4
0
0
1
 i
n
 1
2
8
0
0
1
 i
n
 2
5
6
0
0
A
4
0
5
 
Sera Dilution 
0 W 6 W 10 W
14 W 18 W 10 W (BSA)
 242 
 
8.6 MALDI-ToF of 6D6FGlc-TetHc glycoconjugate (112) 
 
Figure 8.9:  Overlay of MALDI-ToF spectra for native TetHc and 6D6FGlc-TetHc (112) 
glycoconjugates 
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8.7 13C NMR data for 8-(methoxycarbonyl)octyl 6-deoxy-6-fluoro-
β-D-glucopyranose (107) and 8-(methoxycarbonyl)octyl 2,4-di-
O-acetly-β-D-allopyranoside (109)   
 
Figure 8.10: 
13
C NMR data for 6-deoxy—6-fluoro-D-glucoside (107), with zoomed in region for δ 
68-78 ppm.  Diagnostic carbon peaks labelled indicating the carbon-fluorine coupling of the C-
4, C-5 and C-6 carbons. 
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Figure 8.11: 13C NMR data for 3,6-dideoxy—3,6-difluoro-D-alloside (109), with zoomed in region 
for δ 66-72 ppm.  Diagnostic carbon peaks labelled indicating the carbon-fluorine coupling of 
the C-2, C-3, C-4, C-5 and C-6 carbons.  
 
The coupling patterns of the two NMR spectra above help to confirm the location of 
the fluorine groups on the carbohydrate ring.  The double spiting pattern of C-4 
indicates and single coupling of C-2 to fluorine place the two fluorine atoms at the 3-
OH and 6-OH positions.   
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8.8 pEAQ-HT wtHBcAg Plasmid 
 
Figure 8.12: Plasmid map of the pEAQ-HT-t-HBcAg-EL expression system with the specific 
restriction sites (SalI and AseI) highlighted.  (Plasmid is the same for wt-HBcAg-El apart from 
protein sequence) 
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Region Use 
CaMV 35S promoter Strong promoter region enhancing transcription.  It is widely 
used in plant transformations.1, 2 
5’-UTR Modified 5’-UTR from CPMV RNA-2, used to promote gene 
expression.3 
tHBcAg-EL Sequence for the desired protein, in this case the tandem 
core HBc VLP. 
3’-UTR 3’-UTR form CPMV RNA-2, used to promote gene 
expression 
NOS terminator Signals end of transcription region. 2 
P19 Supressor of RNA silencing from Carnation Italian ringspot 
virus. 4, 5 
NPT(II) Neomycin phosphotransferase (II) encodes for kanamycin 
resistance. 6-8 
LB/RB Borders for genomic data 
ORiV and TfrA Control plasmid replication in bacteria9 
Table 8.1: Table identifying the regions of the pEAQ-HT plasmid 
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